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Jessica J. Pellman 
 
REGULATION OF NEURONAL CALCIUM HOMEOSTASIS IN HUNTINGTON’S 
DISEASE 
 
Huntington’s Disease (HD) is an inherited, autosomal dominant, 
neurodegenerative disorder. There is no cure for HD and the existing therapies 
only alleviate HD symptoms without eliminating the cause of this neuropathology. 
HD is linked to a mutation in the huntingtin gene, which results in an elongation 
of the poly-glutamine stretch in the huntingtin protein (Htt). A major hypothesis is 
that mutant Htt (mHtt) leads to aberrant Ca2+ homeostasis in affected neurons. 
This may be caused by increased Ca2+ influx into the cell via the N-methyl-D-
aspartate (NMDA)-subtype of glutamate receptors. The contribution of two major 
Ca2+ removal mechanisms, mitochondria and plasmalemmal Na+/Ca2+ 
exchangers (NCX), in neuronal injury in HD remains unclear.  
We investigated Ca2+ uptake capacity in isolated synaptic (neuronal) and 
nonsynaptic mitochondria from the YAC128 mouse model of HD. We found that 
both Htt and mHtt bind to brain mitochondria and the amount of mitochondria-
bound mHtt correlates with increased mitochondrial Ca2+ uptake capacity. 
Mitochondrial Ca2+ accumulation was not impaired in striatal neurons from 
YAC128 mice. We also found that expression of the NCX1 isoform is increased 
with age in striatum from YAC128 mice compared to striatum from wild-type 
mice. Interestingly, mHtt and Htt bind to the NCX3 isoform but not to NCX1. 
NCX3 expression remains unchanged.  
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To further investigate Ca2+ homeostasis modulation, we examined the role 
of collapsin response mediator protein 2 (CRMP2) in wild-type neurons. CRMP2 
is viewed as an axon guidance protein, but has been found to be involved in Ca2+ 
signaling. We found that CRMP2 interacts with NMDA receptors (NMDAR) and 
disrupting this interaction decreases NMDAR activity. CRMP2 also interacts with 
and regulates NCX3, resulting in NCX3 internalization and decreased activity. 
Augmented mitochondrial Ca2+ uptake capacity and an increased 
expression of NCX1 in the presence of mHtt suggest a compensatory reaction in 
response to increased Ca2+ influx into the cell. The role of NCX warrants further 
investigation in HD. The novel interactions of CRMP2 with NMDAR and NCX3 
provide additional insight into the complexity of Ca2+ homeostasis regulation in 
neurons and may also be important in HD neuropathology. 
 
Nickolay Brustovetsky, Ph.D., Chair 
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I. INTRODUCTION 
A. Huntington’s Disease 
 George Huntington, a 22-year old physician working in Long Island, New 
York, first described the disease that bears his name in 1872 (Harper, 2002). In 
his report, entitled “On Chorea,” Huntington noted that the disease was 
hereditary and manifested in adulthood (Huntington, 1872). Indeed, the hallmark 
symptom of Huntington’s Disease (HD) is chorea, a movement disorder 
characterized by abrupt, irregular, and spontaneous movements. In addition to 
chorea, HD patients also experience personality changes, anxiety, and 
depression. These symptoms can precede the motor symptoms. A decline in 
cognitive abilities such as abstract thinking and planning is also associated with 
HD. In later stages, memory function also can decline (Govert & Schneider, 
2013). Patients with advanced HD may lose the ability to walk, talk, swallow, and 
care for themselves. Complications from HD can be life-threatening and the most 
common cause of death in HD patients is aspiration pneumonia, most likely due 
to difficulty swallowing (Haines & Conneally, 1986; Bates et al., 2002; Heemskerk 
& Roos, 2012). 
Huntington’s Disease is an autosomal dominant neurodegenerative 
disorder affecting approximately 1 in 10,000 people, with many more people at 
risk of developing the disease, but not yet diagnosed (Shannon et al., 2009; 
Roze et al., 2010). HD is found throughout the world but is most common in 
populations with European heritage (Warby et al., 2011). Symptoms typically 
present in midlife, with an average age of onset of thirty-eight years. There is a 
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large patient to patient variation, however, and symptoms of HD may begin at 
any age (Bates et al., 2002; Govert & Schneider, 2013; Kumar et al., 2015). Less 
than 10% of people with HD develop symptoms prior to age 21. Onset of HD at a 
younger age is called Juvenile HD and differs from adult-onset HD (Nance & 
Myers, 2001).  
 Because HD is a genetic disorder and symptoms occur later in life, there 
is a potential for pre-symptomatic therapy. However, there is currently no cure for 
HD because the mechanisms of the pathology are not clear, and the existing 
therapies only decrease HD symptoms without eliminating the cause of this 
neuropathology. Risk-benefit must be evaluated regarding the current therapies 
to alleviate symptoms, as the standard therapeutics lose efficacy and have a high 
incidence of side effects (Anderson, 2011). Thus, understanding of the molecular 
mechanisms underlying HD is crucial for development of new therapies aimed at 
treating and curing HD. 
 The pathology of HD is localized to the brain. Atrophy of the striatum 
(caudate nucleus and putamen) followed by eventual atrophy of cortical 
structures has been shown to be consistent with the primary symptoms of HD 
(Vonsattel & DiFiglia, 1998; Bates et al., 2002; Walker & Raymond, 2004; Li et 
al., 2014). Striatal volume decreases prior to HD diagnosis and symptoms, but 
this decrease is not significant until around 10 years before onset of symptoms 
(Aylward et al., 2004). The trigger of striatal atrophy and neuronal loss is not yet 
known. The striatum is primarily composed of medium spiny neurons (95% of 
striatal neurons) (Han et al., 2010). Medium spiny neurons are gamma-
3 
aminobutyric acid (GABA)ergic and are the most vulnerable and first affected in 
HD (Reiner et al., 1988; Vonsattel & DiFiglia, 1998; Walker & Raymond, 2004; 
Ehrlich, 2012; Li et al., 2014). The mechanisms underlying increased vulnerability 
of striatal neurons are not understood.  
  In 1993, the Huntington’s Disease Collaborative Research Group found 
that HD is causally linked to a mutation in IT15, now known as the huntingtin 
gene (HTT). HTT is located on chromosome 4 at position 16.3 (MacDonald et al., 
1993). In healthy individuals HTT contains a stretch of 16-20 CAG repeats 
encoding a poly-glutamine (polyQ) stretch near the NH2 terminus in the 
huntingtin protein (Htt). A mutation causing an expansion in the HTT CAG repeat 
domain to greater than 35 repeats is diagnosed as HD (Myers, 2004; Paulson & 
Albin, 2011). Individuals with Htt containing intermediate polyQ repeat lengths of 
~27-35 may not develop symptoms but are at risk of passing HD to their children 
(Ashizawa et al., 1994). Genetic anticipation, i.e. further expanse in the polyQ 
repeat from generation to generation, has been shown to occur in HD (Harper & 
Jones, 2002). Greater number of repeats increases the severity of the disease 
and is correlated with earlier onset of the disease (Harper & Jones, 2002; Roze 
et al., 2010; Zuccato et al., 2010) 
 
a. Huntingtin Protein Function  
 HTT encodes the huntingtin protein, a large (348 kDa) cytoplasmic protein 
with a polyQ stretch of variable length near the N-terminus. In the wild-type (WT) 
Htt protein, this stretch is less than 35 glutamines long (MacDonald et al., 1993; 
La Spada et al., 2011). Htt is ubiquitously expressed in various tissues, with 
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highest expression found in neurons of the central nervous system (CNS). 
Expression of Htt, however, is not different between medium spiny neurons, and 
other neuronal types. Furthermore, the expression level of Htt does not correlate 
with vulnerability to HD (Trottier et al., 1995; Fusco et al., 1999). 
 Htt is essential in development because the Htt knock-out is embryonic 
lethal (DiFiglia et al., 1995). Subsequent studies found that the addition of human 
mutant Htt (mHtt) can compensate for endogenous Htt knock-out to rescue the 
embryonic lethality in mice, meaning that mHtt is a functional protein (Leavitt et 
al., 2001). Furthermore, use of a Cre/loxP site specific strategy to conditionally 
inactivate Htt in mice resulted in a clasping phenotype similar to HD models, as 
well as cortical atrophy (Reddy et al., 1999; Dragatsis et al., 2000). These data 
show that Htt is essential, not only in development, but also in neuronal health 
later in life. Most importantly, these studies suggest that the expanded polyQ 
stretch of mHtt does not result in a complete loss of function. 
 Htt is involved in many processes and functions in adults. A few include, 
regulation of brain derived neurotropic factor (BDNF) production (Zuccato et al., 
2001; Gauthier et al., 2004), vesicle transport (Brandstaetter et al., 2014), 
endocytosis (Velier et al., 1998), transcriptional regulation (Li & Li, 2004), anti-
apoptotic function (Rigamonti et al., 2000), and N-type voltage-gated Ca2+ 
channel modulation (Swayne et al., 2005). Introduction of mHtt can result in 
irregular gene transcription (Sugars & Rubinsztein, 2003), defective autophagy 
(Martinez-Vicente et al., 2010), abnormal mitochondrial biogenesis (Shirendeb et 
al., 2012), mitochondrial dynamics (Costa et al., 2010; Song et al., 2011; 
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Shirendeb et al., 2011) mitochondrial trafficking (Trushina et al., 2004; Shirendeb 
et al., 2012), and mitochondrial Ca2+ handling defects (Beal et al., 1993; Panov et 
al., 2002).  
 Htt also interacts with over 100 proteins involved in various pathways, 
including pre- and post-synaptic signaling, cytoskeletal organization, calcium 
signaling, and mitochondrial function (Shirasaki et al., 2012). Some Htt-protein 
interactions are dependent on the length of the polyQ stretch, meaning that some 
proteins interact more strongly with mHtt than Htt. The converse has also been 
observed (Harjes & Wanker, 2003; Li & Li, 2004). It is unknown if the polyQ 
stretch mutation results in a loss-of-function of Htt or a gain-of-function of mHtt. 
Some groups report that both gain- and loss-of-function are involved in HD 
pathology (Zuccato et al., 2010). 
Protein interactions with Htt and mHtt have been reported to be important 
in Ca2+ channel modulation. Two examples of note are postsynaptic density 
protein 95 (PSD-95) and CaV2.2. PSD-95 is a scaffold protein that binds to 
signaling proteins including the N-methyl-D-aspartate (NMDA) subtype of 
glutamate receptors.  The polyQ expansion in mHtt increases interaction 
between NMDA receptors and PSD-95 leading to increased Ca2+ influx and 
neuronal damage (Sun et al., 2001; Harjes & Wanker, 2003; Fan et al., 2009). Htt 
interacts with CaV2.2, an N-type voltage gated Ca2+ channel, and enhancing Ca2+ 
influx (Swayne et al., 2005). These findings suggest that both Htt and mHtt are 
involved in Ca2+ signaling. 
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b. Models of HD 
 Prior to the identification of the mutation linked to HD, chemical models of 
HD were used to study the disease. For these models, excitotoxic chemicals 
such as quinolinic acid or kainic acid were injected into the striatum of rats. The 
models produced lesions similar to the striatal atrophy seen in HD (McGeer & 
McGeer, 1976; Beal et al., 1986). Mitochondrial toxins such as 3-nitropropionic 
acid and malonic acid also have been shown to produce striatal lesions and HD-
like behavior in rats (Borlongan et al., 1995; Brouillet et al., 1999). Although these 
models produce similar behavioral results, they do not correctly recapitulate HD 
pathology due to the lack of genetic alterations. While these models provide 
some insight into potential causes of HD pathology, the mechanisms responsible 
for similar behavior and lesions may be distinct from the mechanism or 
mechanisms actually responsible for HD pathology. Therefore, chemical models 
of HD should be used with caution. 
 Rodent models of HD have been developed based on the expanded 
polyQ stretch mutation found in mHtt in human HD patients (Ramaswamy et al., 
2007; Pouladi et al., 2013). These models are summarized in Table 1. There are 
three main categories of genetic HD models, expressing expanded polyQ in (1) 
truncated N-terminal mutant human Htt protein; (2) full-length mutant human Htt 
protein; and (3) full-length mouse Htt protein.  
 HD mouse models expressing a portion of N-terminal mHtt with expanded 
polyQ, most notably the mouse line R6/2, result in a more severe phenotype than 
full-length mHtt models (Ramaswamy et al., 2007). Furthermore, the R6/2 also 
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presents other complications, such as diabetes (Bjorkqvist et al., 2005). It is 
important to note that both truncated and full-length transgenic models maintain 
endogenous Htt in addition to expressing human mutant Htt. This does not 
accurately represent the genetics in human HD patients, who typically have one 
normal copy of HTT and one mutant copy. To address this limitation, we use a 
control transgenic mouse model in these studies. YAC18 mice express full length 
human Htt containing 18 glutamines in the polyQ region (Hodgson et al., 1999; 
Hodgson et al., 1996). The use of this mouse model controls for the presence of 
both human and mouse Htt. This control does not, however, address if mouse Htt 
alters the effect of human mHtt.   
Knock-in models of HD are the most genetically faithful but phenotypes 
are very mild and in some models (e.g. HdhQ92 and HdhQ111) striatal atrophy 
does not occur (Wheeler et al., 1999; Wheeler et al., 2000). For these reasons it 
is important to acknowledge that animal models are a useful tool in the study of 
HD but may not recapitulate the human disease in its entirety. Rodent HD 
models have both limitations and advantages; therefore a carefully selected HD 
model has to be used to investigate certain aspects of the disease.   
 In the studies described in this thesis, we used isolated mitochondria and 
primary neurons from the striata of the YAC128 mouse model of HD. This mouse 
model makes use of a yeast artificial chromosome (YAC) to express the entire 
human HD gene with a 128 CAG repeat expansion under the control of the 
human HTT promoter (Slow et al., 2003). Full-length mHtt transgenics, such as 
the YAC model, show an extended development of the HD phenotype and are 
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better suited for the study of early changes (Fan & Raymond, 2007). YAC128 
was the most recently developed of the YAC models. YAC46 and YAC72, with 
46 and 72 CAG repeats, respectively, were previously developed by the same 
group (Hodgson et al., 1999). Increased CAG repeats were added to decrease 
the time until HD-related phenotypes could be observed. In YAC128, motor 
phenotypes are visible by 12 weeks and striatal volume is significantly decreased 
(15%) by 9 months (Bates et al., 2002; Slow et al., 2003; Ramaswamy et al., 
2007). HD symptoms are seen in humans across a range of striatal atrophy 
classifications, from no visible atrophy to 95% in very severe cases (Vonsattel et 
al., 1985; Douaud et al., 2006). We chose to use this transgenic model because 
it develops striatal atrophy, unlike knock-in models, and the animals have a 
longer life with less severe phenotypes than transgenic models with truncated 
mHtt. 
 In addition to animal models of HD, conditionally immortalized, mutant 
STHdhQ111/Q111 striatal neuronal progenitor cells have been used in HD research 
This cell line is derived from knock-in mice with 111 CAG repeats in the 
endogenous HTT gene. The cells stain positive for neuronal markers and 
recapitulate some phenotypes seen in HdhQ111 knock-in mouse striatum. These 
cells may be useful in the study of some aspects of HD (Trettel et al., 2000). 
  
Table 1. Genetic Rodent HD Models 
Rodent Model  Construct Notable Features 
Transgenic truncated N-terminal fragment models 
 
 
Transgenic R6/2 mice 
(Mangiarini et al., 1996) 
N-terminal fragment (67 aa) of human 
HTT with 115-150 or 195 CAG 
repeats 
Neuronal atrophy by 3 months (Stack et al., 2005)  
Death at 10-13 weeks (Mangiarini et al., 1996) 
Diabetes (Bjorkqvist et al., 2005) 
Augmented Ca2+ uptake capacity in brain 
nonsynaptic mitochondria (Oliveira et al., 2007) 
Transgenic N171-82Q 
mice (Schilling et al., 1999) 
N-terminal fragment (171, 118, or 586 
aa) of human HTT with 82 CAG repeats
Neuronal atrophy by 16 weeks (McBride et al., 
2006) 
Transgenic D9-N171-98Q 
mice, also known as DE5 
mice (Brown et al., 2008)  
N-terminal fragment of human HTT with 
98 CAG repeats expressed only in 
medium spiny neurons of the striatum 
No striatal atrophy (Kim et al., 2011) 
Motor abnormalities (Brown et al., 2008) 
Transgenic Short Stop 
mice (Slow et al., 2005) 
N-terminal fragment (171 aa) of human 
HTT with 128 CAG repeats 
Presence of mHtt aggregates 
No behavioral dysfunction or neuronal loss (Slow 
et al., 2005) 
Transgenic HD rats (von et 
al., 2003) 
 
Express 727 amino acids of the HTT51Q 
gene, corresponding to 22% of the full-
length gene 
Reduced mitochondrial membrane potential 
stability in response to Ca2+, decreased Ca2+ 
uptake capacity, increased propensity to PTP 
induction (Gellerich et al., 2008) 
Transgenic full-length models 
 
 
Transgenic BACHD mice 
(Gray et al., 2008) 
Full-length human HTT gene with 97 
mixed CAA-CAG repeats 
Striatal atrophy by 12 months 
Symptoms by 6 months (Gray et al., 2008) 
Transgenic YAC46 or 
YAC72 mice (Hodgson et 
al., 1999) 
Full-length human HTT gene with 46 or 
72 CAG repeats 
Decreased Ca2+ uptake capacity (Panov et al., 
2002) 
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Rodent Model  Construct Notable Features 
Transgenic YAC128 mice 
(Slow et al., 2003) 
Full-length human HTT gene with 128 
CAG repeats 
Striatal atrophy by 9 months (Slow et al., 2003) 
Augmented mitochondrial depolarization in 
response to Ca2+ in medium spiny neurons, 
increased susceptibility to PTP induction 
(Fernandes et al., 2007) 
Augmented Ca2+ uptake capacity in brain 
nonsynaptic mitochondria (Oliveira et al., 2007) 
 
Transgenic BACHD rats 
(Yu-Taeger et al., 2012) 
Full-length human HTT gene with 97 
mixed CAA/CAG repeats 
Early onset motor deficits 
mHtt aggregates (Yu-Taeger et al., 2012) 
Knock-in full-length models 
Knock-in HdhQ50, Q92, 
and Q111 mice (Wheeler 
et al., 1999) 
Mouse HTT gene with inserted 50, 92, 
or 111 CAG repeats in exon 1 
No striatal degeneration (Wheeler et al., 1999) 
No cognitive phenotypes (Wheeler et al., 2000) 
Gait abnormalities at 24 months in Q111 (Wheeler 
et al., 2000) 
No increase in sensitivity to Ca2+-induced damage 
in striatal and cortical nonsynaptic mitochondria 
(Brustovetsky et al., 2005) 
Knock-in Hdh150Q and 
Hdhq200 mice (Lin et al., 
2001; Yu et al., 2003)  
Mouse HTT gene with inserted 150 and 
200 CAG repeats in exon 1 in a single 
allele (Hdh150/+) or both alleles 
(Hdh150/150) 
No cognitive symptoms 
Liver mitochondria from Hdh150/150 mice have 
increased propensity to Ca2+-induced PTP (Choo 
et al., 2004). 
No change in Ca2+ uptake capacity in brain 
nonsynaptic mitochondria  (Oliveira et al., 2007) 
           10 
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c. Proposed Mechanisms of Neurodegeneration in Huntington’s Disease 
 Because Htt has multiple functions and interactions, several mechanisms 
have been postulated to cause neurodegeneration in HD. Furthermore, the 
possibility of both gain- and loss-of-function of mHtt suggests that it is likely that 
many pathways may be involved in HD pathology. My research is focused on 
Ca2+ homeostasis but other mechanisms likely participate in neuronal loss and 
symptom onset in HD. I will briefly describe some of the leading pathways linked 
to neurodegeneration in HD.  
 Transcriptional dysregulation has been detected in postmortem HD brains 
(Arzberger et al., 1997) as well as mouse models of HD (Luthi-Carter et al., 2000; 
Luthi-Carter et al., 2003). The polyQ stretch of mHtt may lead to this 
dysregulation by recruiting other polyQ containing proteins, such as transcription 
factors, and preventing their normal function (Cha, 2007). PolyQ proteins have 
been shown to interact with transcription factors and mHtt has increased nuclear 
localization compared to Htt, which is found mostly in the cytosol (Kegel et al., 
2002). Increased nuclear localization along with the polyQ tract, suggests that 
mHtt may be interacting with transcription factors in HD (Sugars & Rubinsztein, 
2003). Altered transcription could lead to dysregulation of many molecular 
functions and, ultimately neurodegeneration. 
 One, of many, consequences of altered transcription by mHtt could be 
loss of BDNF, a growth factor. In HD, decreased BDNF has been observed and 
is linked to neurodegeneration (Cha, 2007). BDNF is produced in the cortex and 
transported to medium spiny neurons. Studies have shown that medium spiny 
 12 
neurons depend on BDNF from the cortex, and that BDNF is decreased nearly 
50% in HD. (Zuccato & Cattaneo, 2007; Zuccato & Cattaneo, 2009). Further 
studies have shown that experimentally decreasing BDNF in the cortex leads to 
neuronal loss in the striatum (Zuccato et al., 2010). In support of this, 
experimental application of BDNF is neuroprotective in the presence of mHtt 
(Kells et al., 2004). Studies are ongoing to study delivery of BDNF as a potential 
therapeutic in HD. 
 Both Htt and mHtt are subject to cleavage by caspases, specifically 
caspase-2, caspase-3, caspase-6, and caspase-7 (Wellington et al., 2000; 
Wellington et al., 2002). The toxic fragment hypothesis proposes that the 
cleavage of mHtt produces toxic fragments containing expanded polyQ sections. 
These fragments can, in turn, lead to additional amplification of caspase activity 
and, subsequently, more fragments. Fragment aggregation is dependent upon 
polyQ and fragment length (Chen et al., 2002) and accumulation of these 
fragments may lead to further caspase activity and eventual cell death (Goldberg 
et al., 1996; Zuccato et al., 2010). In support of the toxic fragment hypothesis, in 
studies where caspase-6 was inhibited, reducing mHtt cleavage, the phenotype 
of HD mice improved (Graham et al., 2006).  Fragments of mHtt can also be 
produced by calpains, calcium-dependent proteases (Bizat et al., 2003; Gafni et 
al., 2004). Calpain activation and increased levels of calpains have been 
detected in HD patients (Gafni et al., 2004). Calpains are activated by alterations 
in calcium homeostasis, due to excitotoxicity or mitochondrial dysfunction. 
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 Ca2+ signaling has been demonstrated to be altered in neurons from 
mouse models of HD (Tang et al., 2003; Bezprozvanny & Hayden, 2004). Mutant 
Htt-induced excitotoxicity has been reported in striatal neurons from mice 
expressing full-length human mHtt (YAC lines), but not in transgenic mice 
bearing an NH2-terminal portion of the protein (R6/2 and N171–82Q lines) that 
have shown striatal resistance to excitotoxicity. The resistance to excitotoxicity in 
the truncated models may represent an adaptive measure in response to mHtt 
expression to generate compensatory mechanisms that reduce some of the toxic 
effects of the mHtt fragment with expanded polyQ stretch (Fan & Raymond, 
2007). 
 Elevated cytosolic Ca2+ has been proposed as a mechanism responsible 
for increased neuronal cell death in HD (Tang et al., 2005). In support of this 
hypothesis, aberrant functioning of mechanisms responsible for the increase in 
intracellular Ca2+ (from extracellular and intracellular sources) has been 
implicated in HD neuropathology (Chen et al., 1999a; Milnerwood et al., 2010; 
Bezprozvanny, 2011). However, Ca2+ influx mechanisms in the cell are 
counterbalanced by mechanisms that extrude or sequester Ca2+ to remove 
excessive Ca2+ from the cytosol (Guerini et al., 2005). These mechanisms have 
not been previously investigated (Na+/Ca2+ exchanger activity) in HD or previous 
studies have resulted in varied and conflicting results (mitochondrial Ca2+ uptake 
capacity in HD). These mechanisms will be the focus of this dissertation. 
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B. Calcium Dysregulation 
 In non-pathological situations, the concentration of cytosolic Ca2+ in 
neurons is under tight control. The basal cytosolic concentration of Ca2+ is 
maintained at approximately 100 nM and can increase to  between 1 and 100μM 
when neurons are stimulated, while the extracellular Ca2+ concentration is 
approximately 2 mM (Nicholls, 1986). Increased cytosolic Ca2+ is rapidly removed 
by extrusion or by mechanisms that sequester the cation, in an attempt to return 
to resting (or basal) Ca2+ concentrations (Nicholls, 1986; Gleichmann & Mattson, 
2010). Ca2+ dysregulation can occur when there is an imbalance between Ca2+ 
influx and removal of the cation from the cytosol. Ca2+ dysregulation can be 
divided into phases (as shown in Figure 1); beginning with (1) the entry of Ca2+, 
predominantly through NMDA receptors (additional explanation in the next 
section). During (2) the latent period, it is thought that cytosolic Ca2+ levels are 
lowered by mechanisms such as Na+/Ca2+ exchanger (NCX) operation in the 
forward mode and mitochondrial Ca2+ uptake (Guerini et al., 2005). In (3) the last 
phase, a second irreversible increase in cytosolic Ca2+ occurs and this 
constitutes delayed Ca2+ dysregulation (DCD), sometimes also called delayed 
Ca2+ deregulation (Nicholls & Budd, 1998).  
We believe that “dysregulation” is a more appropriate term because there 
is still some remaining control over intracellular Ca2+ concentrations. During the 
last phase of Ca2+ dysregulation, the cytosolic Ca2+ concentration is much 
greater than basal Ca2+ concentration, but does not reach the levels of 
extracellular Ca2+ concentrations. This suggests an impairment (dys-) not a 
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removal (de-) of regulation. The phases of DCD are shown in an example trace 
in Figure 1. 
 DCD is a hallmark of glutamate excitotoxicity (Manev et al., 1989; Thayer 
& Miller, 1990; Tymianski et al., 1993a; Budd & Nicholls, 1996). Glutamate is a 
major neurotransmitter in the body and glutamate-induced excitotoxicity is a key 
factor contributing to neuronal loss in many neurodegenerative diseases, 
including Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and HD. 
Excitotoxicity also plays a role in damage and neuronal death in stroke and 
traumatic brain injury (Mattson, 2003; Salinska et al., 2005). Persistent elevation 
of extracellular glutamate ultimately results in a sustained elevation in cytosolic 
Ca2+ concentration and activation of Ca2+-dependent degradation enzymes 
such as phospholipases, DNAases, and proteinases (calpains). A causal link has 
been established between sustained elevation of cytosolic Ca2+ and cell death 
(Manev et al., 1989; Choi & Hartley, 1993). 
 Prolonged increase in cytosolic Ca2+ initiates multiple damaging 
pathways, both directly and indirectly influenced by elevated Ca2+. Increased 
free cytosolic Ca2+ activates degradation enzymes such as calpains, Ca2+-
dependent proteases (Goll et al., 2003). This results in the degradation of 
proteins, including cytoskeleton proteins, membrane receptors, and metabolic 
enzymes (Chan & Mattson, 1999; Nixon, 2003). The activation of calpains also 
may lead to the activation of caspases, initiating the apoptotic pathway 
(Waterhouse et al., 1998; Lankiewicz et al., 2000; Smith et al., 2008). Ca2+-
dependent phospholipases, such phospholipase A2, are activated as well.  
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Figure 1. Example of delayed Ca2+ dysregulation phases 
Neurons were loaded with Ca2+-sensitive dye Fura-2FF-AM to monitor changes 
in cytosolic Ca2+ concentration ([Ca2+]c) over time. The data are mean±SEM. At 
90 seconds (the first solid line) glutamate plus glycine was applied. In (1) Ca2+ 
influx occurs, likely through NMDA receptors. Next, in (2), is the latent period 
where Ca2+ removal mechanisms work to lower intracellular Ca2+ to the basal 
level. Finally, in (3), delayed Ca2+ dysregulation occurs as Ca2+ influx 
overwhelms Ca2+ removal mechanisms.  
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These enzymes degrade important membrane phospholipids, disrupting 
organelle membranes (Bonventre, 1997). The activation of these degradation 
enzymes ultimately results in neuronal death. 
 Mitochondria play an important role in regulation of Ca2+ homeostasis in 
neurons by taking up elevated Ca2+ from the cytosol. However, excessive Ca2+ 
uptake by mitochondria during DCD can result in mitochondrial permeability 
transition, a condition characterized by dramatically increased permeability of the 
inner mitochondrial membrane, leading to inhibition of oxidative phosphorylation, 
inhibition of Ca2+ uptake, and release of different mitochondrial apoptogenic 
proteins such as cytochrome c, Smac/DIABLO, Apoptosis Inducing Factor (AIF), 
and Omi/HtrA2 (Fan et al., 2001; Hagberg, 2004; Orrenius et al., 2015). 
Cytochrome c initiates the apoptotic pathway by activating pro-apoptotic proteins, 
subsequently leading to eventual neuronal death (Slee et al., 1999; Brustovetsky 
et al., 2002; Goldstein et al., 2005).  
 
a. Glutamate Receptors 
 Glutamate receptors (GluR) are transmembrane receptors expressed 
primarily in the CNS. Glutamate, the major excitatory neurotransmitter in the 
brain, binds to GluRs and mediates fast synaptic transmission (Dingledine et al., 
1999; Glasgow et al., 2015). There are two classes of glutamate receptors, 
metabotropic GluR (mGluR) and ionotropic GluR (iGluR). mGluR are G-protein 
coupled receptors, whereas iGluR are ion channels (Gregory et al., 2013). It is 
important to note that mGluR appear to have a minimal role in the onset of 
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glutamate-induced delayed Ca2+ dysregulation (Tymianski et al., 1993a; Kritis et 
al., 2015). On the other hand, iGluR activation by glutamate binding to the 
receptor allows the flow of cations into cells, quickly raising intracellular Ca2+ and 
Na+ concentrations (Sattler & Tymianski, 2000). Because iGluR activation can so 
quickly alter ion concentrations and thus contribute to DCD, this research is 
focused on the iGluR class of GluR. 
 There are three subtypes of iGluR; they are named for chemical 
compounds that bind to the receptor more selectively than glutamate. These 
subtypes are N-methyl-D-aspartate (NMDA) receptors, α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors, and kainate receptors 
(Dingledine et al., 1999; Kohr, 2006). Activation of iGluRs causes the ion channel 
to open, allowing ions to flow freely down their respective electrochemical 
gradients. Since glutamate is the major excitatory neurotransmitter, iGluRs play 
an important role in neuronal synaptic transmission (McEntee & Crook, 1993; 
Okubo et al., 2010).  
 Under normal conditions, glutamate is released from glutamatergic nerve 
terminals and binds to post-synaptic glutamate receptors. Glutamate activates 
iGluRs, leading to depolarization of the plasma membrane and cation influx into 
neurons (McEntee & Crook, 1993).  It has been hypothesized that continuous 
presence of glutamate results in prolonged iGluR activation. This allows an 
uninterrupted influx of Ca2+ into the cytosol leading to Ca2+ dysregulation 
(Tymianski et al., 1993a).  
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i. NMDA Subtype of Ionotropic Glutamate Receptors  
 The NMDA receptor (NMDAR) is an iGluR, which can be specifically 
activated by NMDA, an exogenous molecule. When NMDAR is activated, the ion 
channel opens, allowing Na+ and Ca2+ to flow into the cell. NMDAR are 3-4 times 
more permeable to Ca2+ than AMPA or Kainate receptors (MacDermott et al., 
1986; Traynelis et al., 2010). Ca2+ influx, along with plasma membrane 
depolarization, occurs as a result of the activation of NMDARs (McEntee & 
Crook, 1993; Okubo et al., 2010). NMDARs are expressed in neurons in both the 
central and peripheral nervous systems, with high expression in the 
hippocampus, cortex, and striatum (Monyer et al., 1994). Interestingly, these 
regions of the brain also correspond to those regions most susceptible to a 
prolonged elevation in glutamate (Nicholls, 2004), suggesting a link between 
NMDA receptor density and excitotoxic neuronal death. Supporting this, NMDAR 
antagonists have been shown to be neuroprotective in ischemia-induced 
excitotoxicity and animal models of traumatic brain injury (Faden et al., 1989; 
Steinberg et al., 1989)   .  
 NMDARs are heterotetramers composed of four transmembrane subunits 
(Kohr, 2006). Seven subunits, classified into three families, have been described. 
These families are NR1, NR2 and NR3 (also called GluN1, GluN2, and GluN3) 
(Paoletti & Neyton, 2007). NMDARs are typically made up of two NR1 (or GluN1) 
subunits and either two NR2 (or GluN2) subunits or a mixture of NR2 and NR3 
(GluN2 and GluN3) subunits (Masu et al., 1993; Glasgow et al., 2015).  These 
four subunits multimerize to form the functional pore that allows passage of 
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cations in response to extracellular ligand binding (Dingledine et al., 1999). The 
composition of subunits can result in great variation of the properties of the 
receptors (Groc et al., 2006; Paoletti & Neyton, 2007). 
 There are eight isoforms of the NR1 subunit, the only member of the NR1 
family, derived from alternative splicing. These subunits have overlapping 
expression in neurons and are expressed from the embryonic stage through 
adulthood (Kohr, 2006). The alternative splicing yields functional isoforms with 
slight modifications in the N-terminal (N1) and C-terminal (C1, C2) domains of 
the subunit protein (Janssens & Lesage, 2001). 
 The NR2 family consists of four members, NR2A, NR2B, NR2C, and 
NR2D. Unlike NR1, NR2 subunits are not ubiquitously expressed and expression 
varies. Only NR2B and NR2D subunits are expressed embryonically with NR2D 
expression dropping to low levels after birth (Paoletti & Neyton, 2007). NR2A 
expression begins shortly after birth and is abundantly expressed throughout the 
CNS. As the neurons mature, NR2A expression increases, and eventually the 
NR2A subunits outnumber the NR2B subunits (Liu et al., 2004; Brewer et al., 
2007).  NR2C expression begins later in development and is restricted to the 
cerebellum and olfactory bulb (Dehorter et al., 2012). NR2A and NR2B are seen 
as the predominant subunits and appear to have greater importance in 
excitotoxicity due to localization and expression (Nicholls, 2004). NR2B are more 
highly expressed in striatal medium spiny neurons compared with other NR2 
subtypes and other parts of the brain (Li et al., 2003). Importantly, NR2B subunits 
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are linked to cell death compared with NR2A (Zhou & Baudry, 2006; Liu et al., 
2007). 
 The NR3 family of subunits contains two members, NR3A and NR3B. 
These subunits also show variable expression patterns. NR3A expression peaks 
shortly after birth then declines (Kehoe et al., 2013). NR3B subunit expression on 
the other hand, slowly increases throughout development. NR3B subunit 
expression in adulthood is primarily in motor neurons (Paoletti & Neyton, 2007). 
 A distinguishing feature of NMDARs is the requirement of a co-agonist for 
activation (McBain & Mayer, 1994). The NR1 subunit binds a co-agonist, glycine 
or D-serine, and the NR2 subunit binds the excitatory neurotransmitter, normally 
glutamate (Lester et al., 1990). Interestingly, NMDAR composed of only NR1 and 
NR3 subunits have been shown to be activated by glycine alone. This subunit 
combination has, to date, only been identified in vivo in the myelin surrounding 
the optic nerve (Balasuriya et al., 2014). 
 Another feature unique to NMDAR is that the receptor is both ligand-gated 
and voltage-dependent. The voltage-dependence of NMDAR is due to an 
endogenous Mg2+ block that prevents ion flow through the channel when the 
plasma membrane is at resting potential (Nowak et al., 1984). When the plasma 
membrane is depolarized, Mg2+ is expelled from the ion channel, and can be 
activated if the correct ligands are present (Spandou et al., 2007). 
 Based on the unique properties of NMDAR, they are thought to play an 
important role in glutamate-induced DCD. It is hypothesized that prolonged 
glutamate exposure results in plasma membrane depolarization, causing removal 
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of the endogenous blocker, Mg2+. Then, once both co-agonists, glutamate and 
glycine, bind to NMDAR, the receptor becomes continuously activated (Nowak et 
al., 1984; Planells-Cases et al., 2006). Activation of NMDAR allows massive Ca2+ 
influx, overwhelming the homeostatic Ca2+ extrusion and accumulation 
mechanisms, leading to DCD (Nicholls & Budd, 1998; Tymianski et al., 1993b).  
 
ii. NMDAR Activity in HD Models 
 Activation of NMDARs can increase susceptibility to excitotoxicity resulting 
in intracellular Ca2+ overload. Some of the first indications that this could be a 
mechanism for HD pathology came from chemically induced rodent models. 
Injection of excitatory iGluR agonists into the striata of rats caused 
neurodegeneration and behavioral abnormalities resembling HD. This approach 
was used to generate an early model for HD (Coyle & Schwarcz, 1976). While 
this early model was limited in utility to study HD, it did provide potential clues 
regarding a possible mechanism of HD pathology. 
 Since activation of NMDARs could induce excitotoxicity in animal models, 
these receptors became an attractive target to better understand the pathology of 
HD. NMDA-evoked currents in striatal slices from both symptomatic and pre-
symptomatic R6/2 mice were found to be enhanced compared to WT (Cepeda et 
al., 2001). These results were also supported by experiments in cultured striatal 
neurons from R6/2 mice (Andre et al., 2006). 
  In experiments using medium spiny neurons from YAC72 mice, Zeron 
and colleagues found enhanced cell death subsequent to exposure to 3mM 
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NMDA compared with neurons from WT animals (Zeron et al., 2002). They also 
showed enhanced current in dissociated YAC72 medium spiny neurons in 
response to 1mM NMDA. Interestingly, this laboratory later showed no difference 
in current in medium spiny neurons from YAC128 mice compared with neurons 
from WT animals (Fernandes et al., 2007). 
 Increased function of NMDAR in the presence of mHtt was first shown 
using transiently transfected NMDAR subunits and full-length human Htt with 
either 15 polyQ (normal, Htt-15Q) or 138 polyQ (expanded, mHtt-138Q) (Chen et 
al., 1999b). Co-expression of the NR1/NR2B-type of NMDARs with mHtt-138Q 
led to larger NMDAR-mediated currents than with Htt-15Q. Importantly, cells 
transfected with NR1/NR2A-type NMDARs had similar currents when co-
expressed with either Htt-15Q or mHtt-138Q (Chen et al., 1999b). Further 
evidence suggesting the importance of NR2B in increased NMDAR sensitivity in 
HD models is a correlation between decreased mRNA levels of NR2A and no 
change in NR1 or NR2B in neurons with larger NMDAR currents than in medium 
spiny neurons from WT littermates (Ali & Levine, 2006). These data, together 
with the high expression of NR2B in the striatum as compared to other parts of 
the forebrain (Landwehrmeyer et al., 1995; Li et al., 2003), suggest that the 
NR2B subunit may be a key mediator of the excitotoxic damage elicited by mHtt 
expression. 
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iii. NMDAR Agonists and Antagonists  
 NMDARs are endogenously activated by glutamate as well as L-aspartate 
(Dingledine et al., 1999). They are additionally activated by NMDA (for which 
NMDARs are named), an exogenous molecule, which does not activate other 
iGlurRs. NMDARs are endogenously blocked at resting membrane potentials by 
Mg2+, but the block can be removed with plasma membrane depolarization 
(Nowak et al., 1984). 
 Several NMDAR inhibitors have been developed as laboratory research 
tools and potential therapeutics. In my research, I used D-(-)-2-Amino-5-
phosphonopentanoic acid (AP-5). AP-5 is a competitive antagonist that acts by 
reversibly binding to the glutamate site on the NR2 subunit and competing with 
glutamate binding (Morris et al., 1986; Clements & Westbrook, 1994). AP-5 
inhibition is reversible with a short half-life. These qualities make AP-5 a useful 
tool in studying NMDAR because it can be applied and washed off.  
 Another inhibitor of NMDAR used in my research is (+)-5-methyl-10,11-
dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801). MK-801 
inhibits NMDARs by binding to and irreversibly blocking the open pore of the 
NMDAR (Foster & Wong, 1987; Huettner & Bean, 1988). However, our 
laboratory recently showed that MK-801 also inhibits the activity of NCX 
operating in the reverse mode (full description in following sections) (Brittain et 
al., 2012b). For this reason, MK-801 is only used in these studies as an inhibitor 
of reverse NCX in experiments independent of NMDAR agonists. There are 
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numerous additional NMDAR antagonists act as competitive, uncompetitive, and 
non-competitive antagonists that were not used in this research. 
 
iv. NMDAR Regulation 
 Along with the modulation of NMDAR by mHtt described above, other 
proteins have been shown to interact with, and regulate the activity of NMDARs. 
One of these interactions is with PSD-95, a scaffold protein that has been shown 
to also be regulated by mHtt (Fan et al., 2009). In WT neurons, PSD-95 
expression has been shown to enhance NMDAR opening rate. Futhermore, 
PSD-95 increases NMDAR membrane localization by promoting membrane 
insertion and inhibiting internalization (Lin et al., 2006).  
 In collaboration with Dr. Khanna’s laboratory, we recently showed that 
NMDAR may be regulated by collapsin response mediator protein 2 (CRMP2). 
We showed that a peptide derived from CRMP2 decreased NMDA-induced Ca2+ 
influx into cultured neurons, diminished ion current, and decreased surface 
expression of NMDAR in dendritic spines (Brittain et al., 2011a). Interaction 
between NR1 and NR2 subunits with CRMP2 has also been shown (Al-Hallaq et 
al., 2007). These results suggest that CRMP2 may be involved in modulating 
NMDAR activity in healthy and possibly HD patients, but the mechanism is not 
yet understood and involvement in HD pathology is not yet established. 
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b. Collapsin Response Mediator Protein 2  
 CRMP2 is a 62 kDa phosphoprotein in the CNS (Charrier et al., 2003). 
Due to many groups identifying CRMP2 in parallel, it has also been known by the 
names CRMP-62 (named for its molecular weight), Dihydropyrimidinase-like 
protein-2 (DPYSL2), Dihydropyrimidinase Related Protein 2 (DRP-2), Turned On 
After Division 64-kDa (TOAD-64), and Unc-33 LIke Phosphoprotein 2 (ULIP-2) 
(Hensley et al., 2011; Charrier et al., 2003). There are five members of the 
CRMP family of proteins. All of the CRMP genes are highly homologous and are 
evolutionarily conserved (about 95% between mouse and human) (Byk et al., 
1998; Ricard et al., 2001).   
 CRMP2 is the most studied member of the CRMP family and is 
traditionally regarded as a regulator of axon guidance and neurite outgrowth 
(Schmidt & Strittmatter, 2007; Hensley et al., 2011). CRMP2 is the most 
abundantly expressed member of the CRMP family and is maintained at high 
levels in adults, unlike other CRMPs that are maintained at low levels in adult 
CNS (Wang & Strittmatter, 1997). Due to alternative splicing in the N-terminus 
there are two CRMP2 isoforms, a short form and a long form. The isoforms are 
identical from residues 1-572, the long form has an additional 112 amino acids in 
the N-terminus (Quinn et al., 2003). 
 CRMP2 forms homotetramers and heterotetramers with other members of 
the CRMP family (Wang & Strittmatter, 1997). CRMP2 interacts with many 
diverse proteins including cytoskeletal proteins tubulin and actin (Fukata et al., 
2002; Arimura et al., 2005), NMDARs (Al-Hallaq et al., 2007), and N-type Ca2+ 
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channel CaV2.2 (Brittain et al., 2009). Recent research on the diverse and 
unique interactions of CRMP2 showed its involvement in many more processes 
than originally thought (Brittain et al., 2011a; Wilson et al., 2012). 
 
i. Molecular Tools for the Study of CRMP2 
 A 15-amino acid peptide, CBD3, from the Ca2+ channel binding domain of 
CRMP2 has been shown to disrupt the interaction between CRMP2 and CaV2.2 
(Brittain et al., 2009). The peptide cannot cross the plasma membrane, so the tat 
cell penetrating motif of the HIV-1 protein was added to facilitate peptide entry 
into neurons (Tat-CBD3) (Brittain et al., 2011a). In addition to disrupting the 
interaction between CRMP2 and CaV2.2, tat-CBD3 has previously been shown 
to decrease NMDAR activity. The mechanism leading to this decrease is not yet 
understood, but we hypothesize that tat-CBD3 disrupts an interaction between 
NMDAR and CRMP2. We use this peptide as a tool to understand the interaction 
of CRMP2 with potential interacting partners. 
 
ii. Potential Involvement of CRMP2 in HD Pathology 
 At the time of writing this dissertation, only one paper has discussed 
CRMP2 in relation to HD. Lim and colleagues recently studied glycogen synthase 
kinase-3β (GSK3β), a regulator of CRMP2 phosphorylation, in HD models and 
postmortem human brain tissue. This group showed an increase in GSK3β 
phosphorylation and corresponding decrease in CRMP2 phosphorylation in 
cortical tissue from the R6/1 mouse model of HD. Interestingly, they saw 
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increased phosphorylated GSK3β in the striatum but no change in 
phosphorylated CRMP2. This group did not assess total CRMP2 expression in 
HD models or investigate interaction between mHtt and CRMP2 (Lim et al., 
2014). 
  
C. Mitochondria 
 Normal Ca2+ signaling utilizes fine tuning of cytosolic Ca2+ concentrations 
by different mechanisms (Carafoli, 1988; Erecinska & Silver, 1996). Prolonged 
glutamate exposure leading to high levels of Ca2+ requires high capacity 
mechanisms of Ca2+ clearance (Brini et al., 2002; White & Reynolds, 1995). Two 
major mechanisms of Ca2+ removal and uptake are via mitochondria and 
plasmalemmal Na+/Ca2+ exchanger. Each of these mechanisms, however, can 
be overwhelmed and contribute to glutamate-induced elevation in cytosolic Ca2+ 
concentrations (Kiedrowski et al., 1994; Kiedrowski, 1999; Chalmers & Nicholls, 
2003).  
   Accumulation of Ca2+ in mitochondria is a major mechanism contributing 
to clearance of elevated cytosolic Ca2+ (Kiedrowski & Costa, 1995). A Ca2+ 
channel called the Ca2+ uniporter in the inner mitochondrial membrane allows 
Ca2+ influx into mitochondria (Baughman et al., 2011; De et al., 2011) and Ca2+ 
accumulation in the mitochondrial matrix (Bernardi, 1999). The influx is driven by 
a large negative membrane potential inside of mitochondria. The magnitude of 
mitochondrial Ca2+ uptake capacity is limited by mitochondrial sensitivity to the 
detrimental effect of Ca2+ manifested in induction of the mitochondrial 
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permeability transition pore (PTP) (Chalmers & Nicholls, 2003). The Ca2+ 
accumulated by mitochondria can be released via mitochondrial Na+/Ca2+ 
exchangers or due to induction of the PTP (Carafoli & Lehninger, 1971). 
 The affinity of the uniporter to Ca2+ is low, and under physiological 
conditions, the concentration of Ca2+ within mitochondria is relatively low (0.2-
10µM) (McCormack et al., 1990). Mitochondria can accumulate much larger 
amounts of Ca2+ in response to high cytosolic Ca2+ concentration (Thor et al., 
1984). Therefore, mitochondrial Ca2+ uptake has been regarded as a safety 
mechanism in situations of temporary intracellular Ca2+ overload. 
 
i. Permeability Transition Pore 
 A large Ca2+ load in mitochondria induces mitochondrial damage through 
induction of the PTP that, in turn causes mitochondrial depolarization (Bernardi, 
1999).  During PTP induction, the inner mitochondrial membrane becomes 
permeable to solutes up to 1500 Da (Green & Kroemer, 2004). PTP opening is 
followed by mitochondrial swelling and eventual rupture of the mitochondrial 
membrane. This limits the ability of mitochondria to accumulate Ca2+, produce 
ATP, and retain pro-apoptotic proteins like cytochrome c (Rasola & Bernardi, 
2011). These factors significantly decrease the cell’s ability to maintain calcium 
homeostasis and often lead to neuronal death (Bernardi & Petronilli, 1996).  
 The molecular structure and composition of the PTP remains elusive 
although many proteins have been hypothesized to be part of the PTP complex. 
The level of expression of Cyclophilin D (CyD), a mitochondrial matrix protein, 
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correlates with PTP induction in brain mitochondria (Brustovetsky et al., 2003)  
and is the only protein shown by pharmacological and knock-out studies to 
sensitize the PTP to Ca2+ (Baines et al., 2005; Malouitre et al., 2010). Brain 
mitochondria isolated from homozygous CyD knockout mice (Ppif-/- mice) were 
much less susceptible to opening of PTP (Baines et al., 2005). These data 
support that CyD is an important component of the PTP (Javadov & Kuznetsov, 
2013). 
 
ii. Permeability Transition Pore Modulation 
 The PTP is Ca2+ dependent but opening can be facilitated by other factors 
such as ATP depletion, low pH, and reactive oxygen species (ROS) (Bernardi, 
1999; Crompton, 1999). Cyclosporine A (CsA) is an inhibitor of PTP 
(Broekemeier et al., 1989). CsA inhibits the PTP by binding to mitochondrial CyD 
(Halestrap & Davidson, 1990). In experiments with isolated mitochondria, CsA 
makes mitochondria resistant to Ca2+ and suppresses the PTP activation 
(Kushnareva et al., 2005). ADP can also be used as an inhibitor of the PTP and 
can act synergistically with CsA (Novgorodov et al., 1992; Chalmers & Nicholls, 
2003). 
 
iii. Mitochondrial Ca2+ Uptake in HD Models 
 One of the major hypotheses for neurodegeneration in HD posits that mHtt 
leads to aberrant Ca2+ handling in affected neurons (Bezprozvanny & Hayden, 
2004). As it was discussed in previous sections, this could be due to augmented 
 31 
activity of NMDA-subtype of glutamate receptors (Zhang et al., 2008). Defects in 
mitochondrial Ca2+ handling have also been suggested as a potential mechanism 
leading to DCD and excitotoxic neuronal death (Panov et al., 2002).    
In early studies, investigators found decreased Ca2+ uptake capacity in 
brain mitochondria from YAC72 mice and a rat HD model (Panov et al., 2002; 
Gellerich et al., 2008) and in mitochondria of a conditionally immortalized striatal 
progenitor cell line STHQ111/Q111 expressing mHtt with 111 glutamines (Milakovic 
et al., 2006; Lim et al., 2008). The facilitated induction of the PTP in mitochondria 
associated with mHtt was proposed to explain Ca2+ handling defects in 
mitochondria from HD animal and cell models (Milakovic et al., 2006; Gellerich et 
al., 2008).  Indeed, increased propensity to Ca2+-stimulated PTP induction was 
found in mitochondria in neurons from HD mice and immortalized striatal cells 
(Choo et al., 2004; Fernandes et al., 2007; Lim et al., 2008; Quintanilla et al., 
2013a).   
 Previous studies in our laboratory did not confirm an increase in likelihood 
of PTP induction in striatal and cortical mitochondria isolated from HD mice 
compared with mitochondria from WT mice (Brustovetsky et al., 2005).  Another 
group demonstrated increased Ca2+ uptake capacity in brain nonsynaptic 
mitochondria isolated from R6/2 and YAC128 mice compared to mitochondria 
from WT littermates (Oliveira et al., 2007).  In experiments with cultured cortical 
neurons expressing N-terminal or full-length mHtt, investigators failed to find a 
significant effect of mHtt on mitochondrial Ca2+ accumulation following exposure 
of neurons to excitotoxic glutamate (Chang et al., 2006).  Thus, the question 
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whether mHtt increases sensitivity of brain mitochondria and, particularly, 
neuronal mitochondria to Ca2+-induced damage remains open.  
 Since the discovery of the Htt mutation, numerous studies have been 
conducted to elucidate the mHtt effect on mitochondrial Ca2+ handling.  However, 
after much investigation, the question whether mHtt impairs mitochondrial 
functions remains controversial. Some investigators report mHtt-induced defects 
in mitochondrial Ca2+ uptake and increased susceptibility to PTP induction, 
whereas others do not find evidence for the deleterious alterations associated 
with mHtt.  The reason for this is not clear, but it could be related to the use of 
different HD models and variations in methodological approaches.   
 Studies have demonstrated mHtt-induced defects in mitochondrial Ca2+ 
uptake (defects in mitochondrial Ca2+ handling) and reduction in Ca2+ uptake 
capacity by mitochondria isolated from cells and tissues expressing mHtt (Panov 
et al., 2002).  Mitochondria from lymphoblasts of patients with HD as well as 
brain nonsynaptic mitochondria from YAC72 mice had a diminished membrane 
potential and were depolarized at smaller Ca2+ loads compared with 
mitochondria from healthy YAC18 mice.  These defects persisted even in the 
presence of inhibitors (Panov et al., 2002). Based on the fact that ADP and CsA 
failed to eliminate the difference between mitochondria from mutant and WT 
animals, PTP involvement could be excluded.  Intriguingly, the effect of mHtt on 
mitochondrial Ca2+ uptake capacity appeared to be elusive, and in the next study 
Panov et al. found that “the defect in Ca2+ handling in brain mitochondria was 
consistently observed only if brain mitochondria were isolated without BSA” 
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(Panov et al., 2003).  The authors proposed that BSA could replace mHtt in its 
binding sites on mitochondria, but did not provide experimental evidence 
supporting this hypothesis.     
 In addition to isolated mitochondria, neurons in culture were used to study 
detrimental effects of mHtt on Ca2+ signaling and mitochondrial Ca2+ handling.  
Fernandes et al. reported that Ca2+ influx into cells mediated by the NMDA-
subtype of ionotropic glutamate receptors resulted in augmented mitochondrial 
depolarization in medium spiny neurons from YAC128 mice (Fernandes et al., 
2007).  This effect was paralleled by reduced clearance of elevated cytosolic 
Ca2+ following NMDA withdrawal.  Suppression of the PTP resulted in a decrease 
in cytosolic Ca2+ and diminished mitochondrial depolarization induced by NMDA 
in neurons from YAC128 mice, but not from WT mice.  Based on these 
observations, the authors concluded that mitochondria in medium spiny neurons 
from YAC128 mice have increased susceptibility to PTP induction by Ca2+ 
(Fernandes et al., 2007).   
 Despite reported defects in mitochondrial Ca2+ handling, some 
investigators did not find evidence for mHtt-induced mitochondrial Ca2+ handling 
deficiency and increased propensity to PTP induction in the presence of mHtt.  A 
previous study by our laboratory did not find an increased susceptibility to Ca2+-
induced PTP induction in striatal nonsynaptic mitochondria from HD mice (Q50, 
Q92, Q111 and R6/2) compared with mitochondria from WT animals 
(Brustovetsky et al., 2005).  In these studies, our laboratory found increased 
resistance to Ca2+ in striatal mitochondria isolated from HD mice.  In line with 
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these findings, Oliveira et al. demonstrated that nonsynaptic mitochondria from 
R6/2 and YAC128 mice had augmented Ca2+ uptake capacity compared with 
mitochondria from WT mice, whereas mitochondria from Hdh150/+ and Hdh150/150 
mice had similar Ca2+ uptake capacity compared with mitochondria from WT 
animals (Oliveira et al., 2007).  The reason for the increased Ca2+ uptake 
capacity is not clear, but it may reflect compensatory adaptation to augmented 
Ca2+ influx via activated NMDA receptors (Bezprozvanny & Hayden, 2004).  Both 
the previous findings by our laboratory (Brustovetsky et al., 2005) and the study 
by Oliveira et al. (Oliveira et al., 2007) suggested that the lack of mHtt-induced 
impairment of mitochondrial Ca2+ handling argues against facilitated PTP 
induction in the presence of mHtt, and consequently does not support 
involvement of the PTP in HD pathogenesis.   
 Furthermore, it was demonstrated that crossing R6/2 mice with cyclophilin 
D-knockout mice (cyclophilin D sensitizes the PTP to Ca2+ (Tanveer et al., 1996; 
Basso et al., 2005)) augmented neuronal mitochondrial Ca2+ uptake capacity 
without any improvement in either behavioral or neuropathological characteristics 
(Perry et al., 2010).  The authors reasoned that increased Ca2+ capacity of 
neuronal mitochondria is not advantageous for R6/2 mice. Altogether, these 
results cast doubt on the ability of mHtt to increase susceptibility to PTP induction 
and decrease mitochondrial Ca2+ uptake capacity as well as  the role of 
mitochondrial Ca2+ handling defects in HD pathogenesis.   
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d. Plasmalemmal Sodium Calcium Exchangers 
 In neurons, the plasmalemmal Na+/Ca2+ exchanger (NCX) has the highest 
transport capacity for Ca2+ extrusion and therefore plays a key role in the 
maintenance of Ca2+ homeostasis (Yu & Choi, 1997; Carafoli et al., 2001; DiPolo 
& Beauge, 2006). There is also a mitochondrial Na+/Ca2+ exchanger involved in 
the regulation of mitochondrial Ca2+ homeostasis and oxidative phosphorylation 
that will not be further discussed in this dissertation. There has been little 
research on the role of mitochondrial Na+/Ca2+ exchanger in Ca2+ in HD, and 
future studies may help better understand both the mitochondrial Na+/Ca2+ 
exchanger and Ca2+ regulation. All instances of the abbreviation NCX will be in 
reference to the plasmalemmal NCX. NCX is a nine transmembrane antiporter. 
This antiporter is driven by the electrochemical gradient of sodium to exchange 
one Ca2+ ion from the cytosol for three external Na+ ions (Blaustein & Lederer, 
1999; Blaustein et al., 2002).  
 There are three major isoforms of NCX in the brain: NCX1, NCX2, and 
NCX3 (Sakaue et al., 2000; Kiedrowski et al., 2004). All three isoforms are 
functionally similar but have differing expression. All of the isoforms are 
expressed in both the striatum and cortex (Canitano et al., 2002; Papa et al., 
2003). In cultured cortical neurons, NCX1 is a dominant isoform (Sakaue et al., 
2000; Kiedrowski et al., 2004). NCX2 is predominantly expressed in glial cells 
(Thurneysen et al., 2002a; Thurneysen et al., 2002b), although other 
investigators have found minimal neuronal localization of NCX2 (Minelli et al., 
2007). While less expressed in neurons than NCX1, NCX3 was found to be 
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essential for the maintenance of Ca2+ homeostasis in ischemia (Jeffs et al., 2007; 
Secondo et al., 2007).  Previous research suggests that NCX1 and NCX3 both 
may be involved in glutamate-induced DCD (Luo et al., 2007). 
 NCX is an effective mechanism of Ca2+ removal, operating in the forward 
mode (or Ca2+ exit mode) in instances of large cytosolic Ca2+ increases because 
it has a low affinity for Ca2+, suggesting that this mechanism is effective only at 
relatively high cytosolic Ca2+ concentrations. The high capacity and low affinity of 
NCX make it effective for removal of Ca2+ under conditions of elevated cytosolic 
Ca2+ concentration (Tymianski et al., 1993b; Carafoli et al., 2001).  
Correspondingly, NCX is the dominant mechanism of Ca2+ extrusion in instances 
of cytosolic Ca2+ concentrations greater than 500 nM (Blaustein & Lederer, 
1999).  
 Normally, NCX operates in the forward mode (NCXfor) to extrude Ca2+ 
from the cytosol in exchange for external Na+ (Blaustein et al., 2002). An 
ischemic episode leading to elevated glutamate in the extracellular milieu and 
activation of glutamate receptors can cause an increase in cytosolic Na+ and 
depolarization of the plasma membrane, resulting in NCX operation in the 
reverse mode (NCXrev), or Ca2+ entry mode (Kiedrowski et al., 1994; Brittain et 
al., 2012b). In this case, NCXrev brings Ca2+ into the cell in exchange for cytosolic 
Na+. Consequently, instead of decreasing the concentration of cytosolic Ca2+, 
NCXrev increases it. Thus, NCXrev is critical for Ca2+ dysregulation induced by 
prolonged exposure to glutamate. We and others have previously shown that 
both NCXrev and NMDAR are required for DCD (Hoyt et al., 1998; Kiedrowski, 
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1999; Brittain et al., 2012b).  NCX has not been previously studied in the context 
of HD. 
 
i. Pharmacological Tools to Study NCX 
 Multiple inhibitors of NCXrev have been developed. In this work we use 
MK801 (described previously), an NMDAR antagonist that shows potent 
inhibition of NCXrev (Brittain et al., 2012b). Ni2+ is another inhibitor of NCXrev 
operation. Ni2+ competes with Ca2+ in every NCX isoform although with varying 
affinity among isoforms (Annunziato et al., 2004). 
 In cultured neurons, the modulation of extracellular Na+ concentrations can 
be utilized to regulate NCX activity. Replacement of Na+ from the extracellular 
bath solution with equimolar N-methyl-D-glucamine (NMDG) can be used to 
prevent NCX operation in the forward mode. NMDG cannot be exchanged for 
Ca2+ by NCX, and therefore under these conditions NCXfor is inhibited 
(Annunziato et al., 2004). 
 Additionally, replacing external Na+ for NMDG can induce NCX reversal. 
Prior to Na+/NMDG replacement, neurons have to be incubated with ouabain (1 
mM), an inhibitor of Na+/K+-ATPase, to increase cytosolic Na+ and thus facilitate 
NCX reversal. These manipulations set up conditions favorable to NCX operation 
in the reverse mode (Brittain et al., 2012a). 
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C. Hypothesis and Specific Aims 
 The evidence presented in this introduction suggests that Ca2+ handing 
may be altered in HD contributing to neurodegeneration (Tang et al., 2003; 
Bezprozvanny & Hayden, 2004). There is evidence for an increased activation of 
NMDAR in striatal neurons expressing mHtt, particularly NMDARs containing 
NR2B subunits (Chen et al., 1999b) (Zeron et al., 2002). Ca2+ influx through ion 
channels is counterbalanced by Ca2+ removal mechanisms such as mitochondria 
(Carafoli, 1988; Erecinska & Silver, 1996) and NCX operating in the forward 
mode (Yu & Choi, 1997; Carafoli et al., 2001; DiPolo & Beauge, 2006). The 
ability of mitochondria to sequester Ca2+ from the cytosol in HD is currently not 
clear. Mitochondria have been shown to be dysfunctional in HD models by some 
research groups model (Panov et al., 2002; Gellerich et al., 2008), while others 
find no defect or even increased Ca2+uptake capacity (Brustovetsky et al., 2005; 
Oliveira et al., 2007). NCX is a high-capacity mechanism important in the 
removal of Ca2+ but this mechanism has not been previously studied in HD 
models. I hypothesize that in neurons expressing mHtt, Ca2+ removal 
mechanisms compensate for increased NMDAR activation. This compensation 
could explain the late-onset of neurodegeneration and subsequent symptoms in 
HD. 
 The glutamate-induced Ca2+ dysregulation in neurons is mediated by both 
activation of NMDAR and reversal of NCX (Brittain et al., 2012b). CRMP2, 
traditionally viewed as an axonal growth protein involved in axon/dendrite 
specification, has been shown to be involved in regulation of cytosolic Ca2+ in 
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neurons exposed to glutamate. Use of a 15 amino acid fragment of CRMP2 
decreased surface expression of NMDAR in dendritic spines and antagonized 
glutamate-induced Ca2+ dysregulation (Brittain et al., 2011a). The mechanism 
behind this modulation is not fully understood. I hypothesize that CRMP2 
interacts with both NMDAR and NCX modulating their activity and that this 
mechanism might be involved in regulation of Ca2+ homeostasis in neurons 
expressing mHtt.  
 
Specific Aim 1: Determine if mitochondrial Ca2+ uptake capacity is 
decreased in a mouse model of HD. 
Specific Aim 2: Examine if NCX is altered in a mouse model of HD. 
Specific Aim 3: Determine the mechanism by which CRMP2 modulates 
NMDAR and NCXrev activities and whether this mechanism is involved in 
regulation of Ca2+ homeostasis in neurons expressing mHtt. 
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II. MATERIALS AND METHODS  
A. Materials  
 Pyruvate, malate, succinate, glutamate, glycine, N-methyl-D-aspertate 
(NMDA), EGTA, ADP, gramicidin, oligomycin, rotenone, antimycin A, 2,4-
dinitrophenol, N-methyl-D-glucamine (NMDG), tetrodotoxin, ouabain, and, 
carbonylcyanide-p-trifluoromethoxyphenylhydra-zone  (FCCP) were purchased 
from Sigma (St. Louis, MO). Tetraphenylphosphonium chloride was from Fluka 
(Buchs, Switzerland). Fura-2AM, Fura-2FF-AM, Fluo-4FF-AM, and SBFI-AM 
were from Teflabs (Austin, TX). D-(-)-2-Amino-5-phosphonopentanoic acid (AP-
5) was from Tocris (Ellisville, MO). Ionomycin was from LKT Laboratories (St. 
Paul, MN). MK801 ((5R,10S)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]-
cyclohepten-5-10-imine maleate) was purchased from Calbiochem (San Diego, 
CA). Bovine serum albumin (BSA), free from free fatty acids, was from MP 
Biomedicals (Irvine, CA). Anti-NCX1 and anti-NCX3 antibodies were kindly 
provided by Drs. Kenneth Philipson and Michela Ottolia (UCLA). Monoclonal anti-
NR2B antibody was from BD Biosciences. Polyclonal anti-CRMP2 antibody was 
purchased from Sigma. TAT (YGRKKRRQRRR), tat-scramble 
(YGRKKRRQRRRWEAKEMLYFEALVIE, a random sequence with no homology 
to any known sequence), tat-CBD3 (YGRKKRRQRRRARSRLAELRGVPRGL), 
and tat-CBD3A6K (YGRKKRRQRRRARSRLKELRGVPRGL) were synthesized 
(>95% purity) by Genscript Inc. (Piscataway, NJ). All peptides were verified in 
house by mass spectrometry (Department of Chemistry, Indiana University 
School of Medicine). 
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B. Animals 
 All procedures with animals were performed in accordance with the 
Institutional Animal Care and Use Committee approved protocol. Transgenic 
YAC128, YAC18, and WT (FVB/NJ) mice were purchased from Jackson 
Laboratories (Bar Harbor, ME) and breeding colonies were established in the 
Laboratory Animal Resource Center at Indiana University School of Medicine, 
Indianapolis, IN. YAC128 mice express full-length human mHtt containing 128 
glutamines in the polyglutamine stretch in addition to WT mouse Htt whereas 
YAC18 mice express full-length human Htt containing 18 glutamines (Slow et al., 
2003). Male YAC128 or YAC18 mice were bred with female FVB/NJ mice 
(background strain).  All offspring were genotyped with a PCR assay on tail DNA.  
The mice were housed under standard conditions with free access to water and 
food.  In our experiments, we used early symptomatic 2-month-old and mature 
12-month-old YAC128 mice and their age-matched WT littermates (background: 
FVB/NJ) for isolated mitochondria. Postnatal day 1 (PN1) pups were used for 
primary cell culture because neurons from older animals do not survive well in 
culture.  
 
C. Isolation and Purification of Brain Mitochondria  
 Brain mitochondria were isolated in mannitol-sucrose medium and purified 
on a discontinuous Percoll gradient as described previously (Brustovetsky et al., 
2002) and outlined in Figure 2. Two mouse brains per genotype were rapidly 
removed according to an IACUC-approved protocol and immediately put into ice-
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cold isolation medium containing 225 mM mannitol, 75 mM sucrose, 0.1% bovine 
serum albumin (BSA, free fatty acid-free), 1 mM EGTA, and 10 mM HEPES, pH 
7.4. The tissue was washed with the isolation medium, dissected and 
homogenized following brain tissue homogenization in 15 ml glass Dounce 
homogenizer (10 strokes with pestle A, 30 strokes with pestle B) on ice, 
homogenate was diluted with 30 ml of Isolation Buffer 1 (described below) and 
centrifuged for 10 minutes at 2,400 rpm in the Beckman Centrifuge Avanti J-
26XP, rotor JA-25.50 (650×g for 10 min) (1st centrifugation). This and all other 
procedures and centrifugations were performed at 2-4ºC. Then, supernate was 
centrifuged for 10 minutes at 12,500 rpm (18,850×g for 10 min) in the Beckman 
Centrifuge Avanti J-26XP, rotor JA-25.50 (2nd centrifugation). Supernate was 
discarded and pellet was re-suspended in 35 ml of Isolation Buffer 2 (described 
below) and centrifuged for 10 minutes at 12,500 rpm (18,850×g for 10 min) 
Beckman Centrifuge Avanti J-26XP, rotor JA-25.50 (3rd centrifugation). Next, the 
pellet was re-suspended in 5 ml of Isolation Buffer 3 (described below). The 
suspension was layered onto the top of Percoll gradient (26%/40%) in Beckman 
Ultra-Clear centrifuge tubes and centrifuged for 28 minutes at 15,500 rpm 
(41,100×g for 28 min) in the Beckman Ultracentrifuge Optima L100K, bucket 
rotor SW41Ti (4th centrifugation). After the centrifugation, there were 5 layers 
(Figure 3): 1 – clear (top); 2 – thick white-yellowish, this layer contains 
synaptosomes; 3 – slightly cloudy thick layer; 4 – thin turbid layer, this layer 
contains nonsynaptic mitochondria; 5 – clear (bottom). At this stage, 
synaptosomes were collected for isolation of synaptic mitochondria. Nonsynaptic 
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mitochondria were resuspended in Isolation Buffer 3 and centrifuged for 20 
minutes at 15,500 rpm (41,100×g for 20 min) in Beckman Ultracentrifuge Optima 
L100K, bucket rotor SW41Ti (5th centrifugation). The pellet was re-suspend in 
Isolation Buffer 3 and centrifuged again for 20 minutes at 15,500 rpm (41,100×g 
for 20 min) in Beckman Ultracentrifuge Optima L100K, bucket rotor SW41Ti (6th 
centrifugation). The pellet was collected, re-suspended in 0.25-0.3 ml of Isolation 
Buffer 3, and stored on ice. This is a stock suspension of nonsynaptic 
mitochondria.  
 Synaptic mitochondria were isolated from synaptosomes by the nitrogen 
cavitation method using a nitrogen cell disruption bomb, model 4639 (Parr 
Instrument Company, Moline, IL, USA), cooled on ice as described by Brown et 
al. (Brown et al., 2004) with some modifications. Briefly, synaptosomes were 
transferred into an ice-cold 10 ml glass beaker and placed into the nitrogen bomb 
on ice under 1,100 psi for 13 minutes. Then, the ruptured synaptosomes were 
layered on top of the discontinuous Percoll gradient (24%/40%) and centrifuged 
for 28 minutes at 15,500 rpm (41,100×g for 28 min) in Beckman Ultracentrifuge 
Optima L100K, bucket rotor SW41Ti, (4’ centrifugation). The next two 
centrifugations (5th and 6th centrifugations) were performed together with 
nonsynaptic mitochondria. The pellet of synaptic mitochondria was resuspended 
in 0.1 ml of Isolation Buffer 3 and stored on ice. Isolation Buffer 1: 225 mM 
mannitol, 75 mM sucrose, 10 mM HEPES, pH 7.4 adjusted with KOH, 0.1% BSA, 
free from fatty acids, and 1 mM EGTA. Isolation Buffer 2: 225 mM mannitol, 75 
mM sucrose, 10 mM HEPES, pH 7.4 adjusted with KOH, 0.1 mM EGTA. Isolation 
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Figure 2. Scheme of Isolation and purification of brain nonsynaptic and 
synaptic mitochondria.  
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Figure 3. Separation of nonsynaptic mitochondria and synaptosomes 
on discontinuous Percoll gradient. Layers after centrifugation. 1 – clear (top); 
2 – thick white-yellowish, (synaptosomes); 3 – slightly cloudy thick layer; 4 – thin 
turbid layer, (nonsynaptic mitochondria); 5 – clear (bottom). 
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Buffer 3: 395 mM sucrose, 0.1 mM EGTA, 10 mM HEPES, pH 7.4. Percoll Buffer: 
320 mM sucrose, 1 mM EGTA, 10 mM HEPES, pH 7.4. 
 
D. Western Blotting  
 Isolated mitochondria, cultured striatal neurons, cultured glia, or whole 
striata were pretreated with Protease Inhibitor Cocktail (Roche) and solubilized 
by incubation in NuPAGE LDS sample buffer (Invitrogen, Carlsbad, CA, USA) 
supplemented with a reducing agent at 70ºC for 15 minutes.  Bis-Tris Mops gels 
(12%; Invitrogen) and Tris-Acetate gels (3-8%; Invitrogen) were used for 
electrophoresis (20µg protein per lane). After electrophoresis, proteins were 
transferred to Hybond-ECL nitrocellulose membrane (Amersham Biosciences).  
Blots were incubated for 1 hour at room temperature in blocking solution of 5% 
dry milk, phosphate-buffered saline, pH 7.2, and 0.15% Triton X-100.  Then, blots 
were incubated with one of the following primary antibodies: mouse monoclonal 
anti-mHtt 1C2 (mAb1574, Millipore; 1:1000), mouse monoclonal anti-cyclophilin 
D (EMD, San Diego, CA; 1:1000), mouse monoclonal anti-MEK1/2 (Invitrogen; 
1:1000), rabbit polyclonal anti-VDAC1 (Calbiochem; 1:1000).  Blots were 
incubated with goat anti-mouse or goat anti-rabbit IgG (1:20000) coupled with 
horseradish peroxidase (Jackson ImmunoResearch Laboratories, West Grove, 
PA, USA) and developed with Supersignal West Pico chemiluminescent reagents 
(Pierce, Rockford, IL, USA).  Molecular mass markers See Blue Plus 2 
Standards (5µl) and HiMark Pre-stained High Molecular Weight Protein 
Standards (10µl) (Invitrogen) were used to determine molecular masses of the 
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bands.  NIH ImageJ 1.48v software (http://rsb.info.nih.gov//ij) was used to 
quantify band densities 
 
E. Mitochondrial Swelling and Membrane Potential  
 Mitochondrial swelling was evaluated at 37ºC and continuous stirring by 
following changes in light scattering of mitochondrial suspension at 525 nm with 
an incident beam under 180º in a 0.3 ml chamber. The incubation medium for 
light scattering measurements contained 215 mM mannitol, 70 mM sucrose, 0.5 
mM MgCl2, 3 mM KH2PO4, 10 mM HEPES, pH 7.4, 10µM EGTA, 3 mM 
succinate, 3 mM glutamate.  A decrease in light scattering of mitochondrial 
suspension indicated mitochondrial swelling.  Mitochondrial membrane potential 
was measured in a standard KCl-based incubation medium at 37ºC with a 
tetraphenylphosphonium (TPP+) electrode by following TPP+ distribution between 
the incubation medium and mitochondria (Kamo et al., 1979). A decrease in 
external TPP+ concentration corresponds to mitochondrial polarization, while an 
increase of TPP+ in the incubation medium corresponds to depolarization.  
 
F. Measurements of Mitochondrial Ca2+ Uptake.  
 Mitochondrial Ca2+ uptake was measured with a miniature Ca2+-selective 
electrode in a 0.3 ml chamber at 37ºC under continuous stirring. A decrease in 
the external Ca2+ concentration indicated mitochondrial Ca2+ uptake. The 
standard incubation medium contained 125 mM KCl, 0.5 mM MgCl2, 3 mM 
KH2PO4, 10 mM HEPES, pH 7.4, 10µM EGTA, and was supplemented either 
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with 3 mM pyruvate plus 1 mM malate or 3 mM succinate plus 3 mM glutamate. 
Here and in other experiments, succinate was used in combination with 
glutamate to prevent oxaloacetate inhibition of succinate dehydrogenase.  
Additionally, the incubation medium was supplemented with 0.1 mM ADP and 
1μM oligomycin. Ca2+ was added to mitochondria as 10µM CaCl2 pulses. In all 
experiments with isolated mitochondria, the concentration of mitochondrial 
protein in the chamber was 0.2 mg/ml. All data traces shown are representative 
of at least three separate experiments. 
 
G. Mitochondrial ROS Production  
 ROS production by mitochondria was monitored at 37ºC in the standard 
KCl-based incubation medium with Amplex Red assay for H2O2 (Molecular 
Probes, Eugene, OR) using a Perkin-Elmer LS 55 luminescence spectrometer 
and excitation/emission wavelengths 550/590 nm.    
 
H. Cell Culture  
 Striatal and cortical neuronal cultures were prepared from individual striata 
and cortices of postnatal day 1 YAC128 mice and their WT littermates as 
previously described (Dubinsky, 1993; Brittain et al., 2012b), but without pooling 
cells from different animals together. The striata or cortices were removed, 
minced, and incubated for 20 minutes at 37°C in L-15 containing 3 mg/mL papain 
and 3 mg/mL bovine serum albumin (BSA). After gentle trituration in growth 
medium, the cell suspension was layered on L-44 containing 100 mg/ml BSA and 
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centrifuged at 500 rpm for 5 min. The pellet was resuspended in growth medium. 
Neurons were cultured in a 5% CO2 atmosphere at 37°C in Neurobasal medium 
with B27 supplement (Life Technologies), and osmolality was adjusted to 280 
mOsm. For fluorescence measurements, neurons were plated on glass-bottomed 
Petri dishes without pre-plated glia. For all platings, 35μg/ml uridine plus 15μg/ml 
5-fluoro-2’-deoxyuridine were added 24 hours after plating to inhibit proliferation 
of non-neuronal cells.  
 Primary cultures of hippocampal neurons were prepared from postnatal 
day 1 rat pups according to institutional animal care and use committee-
approved protocols and procedures. For fluorescence measurements, neurons 
were plated on glass bottom Petri dishes without preplated glia. Twenty-four 
hours after plating, 35 g/ml uridine plus 15 g/ml 5-fluoro-2-deoxyuridine were 
added to inhibit proliferation of non-neuronal cells. Cultures were maintained in a 
5% CO2 atmosphere at 37 °C in minimum essential medium supplemented with 
10% NuSerum (BD Biosciences) and 27 mM glucose. 
 
I. Immunocytochemistry 
 Cultured neurons were fixed with 4% paraformaldehyde for 15 minutes 
and then washed with PBS. Cells were incubated with a blocking solution 
containing 2.5% IgG- and protease free BSA (Jackson ImmunoResearch 
Laboratories, West Grove, PA), 2.5% goat serum, and 0.1% Triton X-100 in PBS 
for 1 hour at room temperature. Cells were incubated overnight at 4 °C with 
primary antibodies anti-MAP2 (neuronal marker, mouse monoclonal,1 : 500; 
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Millipore), anti-GFAP (astroglial marker, rabbit polyclonal, 1 : 1000; Millipore), 
anti-DARPP-32 (marker of medium spiny neurons, rabbit monoclonal, 1 : 200; 
Pierce), and anti-GABA (rabbit polyclonal, 1 : 20 000; Pierce). Nuclei were 
stained with 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI) (nuclear 
marker; Invitrogen). Then, cells were incubated with secondary donkey anti-
mouse antibody conjugated with AlexaFluor 488 and donkey anti-rabbit 
AlexaFluor 568 (1 : 1000; Invitrogen). Brightfield and fluorescence images were 
acquired using a Nikon Eclipse TE2000-U inverted microscope equipped with a 
Nikon CFI Super Fluoro 20 x 0.75 NA objective and CCD camera Cool SNAPHQ 
(Roper Scientific, Tucson, AZ, USA) controlled by MetaMorph 6.3 software 
(Molecular Devices, Downingtown, PA, USA). 
 In experiments including treatment, cells were treated for 10 minutes then 
fixed with 4% paraformaldehyde for 15 minutes and then washed with PBS. Cells 
were incubated with a blocking solution containing 2.5% IgG- and protease free 
BSA (Jackson ImmunoResearch Laboratories, West Grove, PA), 2.5% goat 
serum, and 0.1% Triton X-100 in PBS for 1 hour at room temperature. Cells were 
incubated overnight at 4 °C with primary rabbit polyclonal anti-NCX3 (NCX3 
polyclonal antibody 95209, 1:500), mouse monoclonal anti-NR2B (1:500; BD 
Biosciences), or rabbit polyclonal anti-CRMP2 (1:500; Sigma). Then cells were 
incubated with a secondary donkey anti-rabbit antibody or goat anti-mouse 
antibody conjugated with AlexaFluor 488 for anti-NCX3 and anti-NR2B or 
AlexaFluor 568 for anti-CRMP2 (1:1000) (Invitrogen). Cells were incubated for 1 
hour at room temperature. The images were taken using a laser, spinning-disk 
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confocal microscope based on a Nikon Eclipse TE2000-U equipped with a 
Yokogawa spinning disk confocal unit CSU-10, a back-thinned EM-CCD camera 
Andor iXonEM DU-897 (Andor Technology, South Windsor, CT), and a motorized 
flat top stage Prior H-117 (Prior Scientific, Rockland, MA). This setup was 
controlled by Andor iQ version 1.4 software (Andor Technology, South Windsor, 
CT). To visualize immunostaining, neurons were illuminated at 488 nm using an 
air-cooled krypton/argon laser T643-RYB-A02 (Melles Griot, Carlsbad, CA). 
Fluorescence was collected through a 505-nm dichroic mirror and a 535±25-nm 
emission filter using an objective Nikon CFI Plan Apo 100, 1.4 numerical 
aperture. The fluorescence intensity profiles were generated through randomly 
chosen cross-sections using AutoQuant software (MediaCybernetics, Silver 
Spring, MD). 
 
J. Fluorescence Imaging of Cultured Neurons  
 In our experiments, cultured striatal or cortical neurons from mice cultured 
for 10-13 days in vitro (10-13 DIV) or hippocampal neurons from rats cultured for 
12-14 DIV were used. For all experiments, at the time of the experiments 
neurons were rinsed twice with standard bath solution: 139 mM NaCl, 3 mM KCl, 
0.8 mM MgCl2, 1.8 mM CaCl2, 10 mM NaHEPES, 5 mM glucose, 65 mM 
sucrose, as used previously in studies of DCD and excitotoxicity (Dubinsky et al., 
1995; Wang & Thayer, 1996; Brittain et al., 2012b). The pH was adjusted to 7.36-
7.38 using 1 M NaOH. Osmolarity of the bath solution was measured with an 
osmometer (Osmette II, Precision Systems Inc., Natick, MA). The osmolarity was 
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280 mOsm for striatal and cortical neurons and 340 mOsm for hippocampal 
neurons. Fluorescence imaging was performed with a Nikon Eclipse TE2000-U 
inverted microscope used a Nikon objective Plan Fluor 20X 0.45 NA and a back-
thinned EM-CCD Hamamatsu C9100-12 camera (Hamamatsu Photonic 
Systems, Bridgewater, NJ) controlled by Simple PCI software 6.1 (Compix Inc., 
Sewickley, PA) or Nikon Eclipse TE2000-U inverted microscope using Nikon 
objective Super Fluor 20, 0.75 numerical aperture and a Photometrics Cool 
SNAPHQ camera (Roper Scientific, Tucson, AZ) controlled by MetaFluor 
software version 6.3 (Molecular Devices, Downingtown, PA). The excitation light 
was delivered by a Lambda-LS system (Sutter Instruments, Novato, CA). The 
excitation light was delivered by a Lambda-LS system (Sutter Instruments, 
Novato, CA) and a Lambda 10-2 optical filter changer (Sutter Instruments, 
Novato, CA) controlled the excitation filters. To minimize photobleaching and 
phototoxicity, the images were taken every 15 seconds.  
 
a. Measurements of Cytosolic Calcium Concentration  
 To follow changes in cytosolic Ca2+, neurons were loaded with fluorescent 
dye at 37°C in the presence of 0.015% Pluronic F-127. The changes in [Ca2+]c 
were monitored by following a ratio of F340/F380 for ratiometric dyes, or a single 
wavelength for non-ratiometric dyes. After at least 1.5 minutes of fluorescence 
recording in the standard bath solution, various treatments were applied to the 
neurons. At the end of the experiment quantification of maximum signals was 
carried out (described in K, below). 
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i. Fura-2-AM  
 Fura-2-AM is a high-affinity, ratiometric, calcium-sensitive fluorescent dye 
with dissociation constant (Kd) near the typical basal calcium levels in 
mammalian cells (~100 nM) (Grynkiewicz et al., 1985). The fluorescence 
measurements from a ratiometric dye are based on the use of a ratio between 
two fluorescence emission signals recorded at two different excitation 
wavelengths. This method allows removal of artifacts due to bleaching, changes 
in focus, or other disturbances unrelated to the experiment. Additionally, the ratio 
calculation amplifies the changes in signal intensity. The Kd for Ca2+ of Fura-2 is 
~224 nM.  
 Fura-2-AM is a cell-permeant acetoxymethyl (AM) ester. Once Fura-2-AM 
crosses the plasma membrane, nonspecific esterases hydrolyze the 
acetoxymethyl ester, liberating the Ca2+-sensitive indicator and significantly 
reducing permeability of Fura-2. This traps Fura-2 inside the cells, resulting in an 
extremely low leakage rate and stabilizes the final intracellular indicator 
concentration. For calcium imaging with Fura-2, neurons are loaded with 2.6μM 
Fura-2AM at 37°C for 60 minutes. The excitation filters, 340±5 and 380±7 nm, 
were controlled by a Lambda 10-2 optical filter changer (Sutter Instruments, 
Novato, CA). Fluorescence was recorded from individual neurons through a 505 
nm dichroic mirror at 535±25 nm. The changes in [Ca2+]c were monitored by 
following Fura-2 F340/F380 ratio, after the background was subtracted from 
fluorescence signals.  
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For all calcium sensitive dyes, the maximum and minimum signals are needed to 
convert fluorescence signal into calcium concentration. To determine the 
maximum signal neurons are exposure to 5μM ionomycin plus 5μM FCCP. 
Following the collection of the maximum signal, the minimum signal was 
collected by exposing the neurons to a calcium free bath solution containing 10 
mM Mn2+ plus 10µM digitonin.  
 
ii. Fura-2FF-AM  
 Fura-2FF-AM is a low-affinity, ratiometric, calcium-sensitive fluorescent 
dye. This dye is appropriate to assess changes in cytosolic calcium during 
excitotoxic events. Fura-2FF-AM is a derivative of Fura-2 with a Kd of 5.5μM 
(dynamic range ~0.5 to 50 μM) (Miyawaki et al., 1997). Because Fura-2FF-AM is 
a derivative of Fura-2, it has similar properties and has excitation wavelengths 
that are the same as Fura-2, 340±5 and 380±7 nm. Fluorescence was recorded 
from individual neurons through a 505 nm dichroic mirror at 535±25 nm. The 
changes in [Ca2+]c were monitored by following Fura-2FF F340/F380 ratio, after the 
background was subtracted from the fluorescence signals. For calcium imaging 
with Fura-2FF, neurons are loaded with 2.6μM Fura-2FF-AM at 37°C for 60 
minutes.  
 
iii. Fluo-4FF-AM  
 Fluo-4FF-AM is a nonratiometric, low-affinity, calcium-sensitive indicator 
with a Kd of 9.7μM (Grynkiewicz et al., 1985). This allows the assessment of 
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changes in cytosolic Ca2+ from 1 to 100 μM, a similar range to Fura-2FF. Fluo-
4FF has a single excitation wavelength maximum at 494 nm with emission 
wavelength maximum at 518 nm. The advantage of using Fluo-4FF instead of 
Fura-2FF is that it can be co-loaded with a ratiometric dye sensitive to another 
ion, Na+, for example. In experiments where Fluo-4FF is used, neurons were 
loaded with 2.5μM Fluo-4FF-AM for 30 minutes at 37ºC. A single excitation 
wavelength at 480±20 nm was used, and fluorescence was recorded from 
individual neurons through a 505 nm dichroic mirror at 535±25 nm. The changes 
in fluorescence are expressed as F/F0, after the background was subtracted from 
the fluorescence signals. By calculating F/F0 rather than absolute fluorescence, 
correcting the arbitrary signal variations is possible. Similar to the other calcium 
indicators, Fluo-4FF-AM is a cell-permeant acetoxymethyl ester, which becomes 
trapped inside the cell following ester hydroxylation.  
 
b. Measurements of Cytosolic Sodium Concentration  
i. SBFI-AM  
 SBFI-AM is a ratiometric, sodium-sensitive fluorescent indicator. It is 
derived from benzofuran isophthalate with an acetoxymethyl ester to increase 
cell permeability. The selectivity for sodium over potassium for SBFI is relatively 
high with roughly an 18-fold preference for Na+. However, the presence of K+ has 
an effect on the affinity of SBFI for Na+. The Kd for SBFI in regard to Na+ in the 
absence of K+ is 3.8 mM, but the Kd for Na+ in the presence of physiological 
concentrations of potassium is 11.3 mM. All of the experiments in this thesis 
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contain K+, thus the Kd that has been used is 11.3 mM (Diarra et al., 2001). In 
experiments using SBFI, neurons were loaded with 5.3μM of the Na+-sensitive 
fluorescent dye SBFI-AM at 37ºC for 60 minutes. The excitation filters 340±5 and 
380±7 nm were used. Fluorescence was recorded through a 505 nm dichroic 
mirror at 535±25 nm. The changes in [Na+]c were calculated as F340/F380 after 
subtracting the background from both channels. SBFI is a ratiometric dye, thus 
the benefits of the ratio calculation concerning data correction and signal 
amplification apply to this indicator.  
The maximum and minimum signals are needed to convert fluorescence 
signal into sodium concentration. To determine the minimum and maximum 
signal neurons are exposure to 5μM gramicidin with known concentrations (0-130 
mM) of extracellular Na+ in the bath solution. 
 
K. Calcium and Sodium Fluorescence Signal Converted to Concentration  
 Cytosolic Ca2+ concentrations ([Ca2+]c) and cytosolic Na+ concentrations 
([Na+]c) were calculated using the Grynkiewicz method and a modification of the 
method for Na+ (Grynkiewicz et al., 1985; Diarra et al., 2001) from the ratio 
following the background subtraction. To perform this calculation, following the 
experiment calibration points must have been made. These points consist of the 
maximum and minimum signal. If these calibration points have been collected, 
the fluorescence signal can be converted to an approximate ion concentration 
using the Kd from the specific dye that was used. This conversion is done using 
this equation: [ion] = Kd x ((F – Fmin) / (Fmax – F))  (Grynkiewicz et al., 1985).  
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This conversion calculation must be taken as an approximation of the 
cytosolic ion concentration (Stanika et al., 2009). Two assumptions exist 
concerning this calculation method. The first is that Kd used for the indicator acts 
the same inside the cellular environment as it does in an experiment, calculating 
it in a non-cellular environment. The cellular environment is complex, and slight 
variations in the actual Kd could greatly affect the actual concentration in 
comparison to the calculated concentration. The second assumption is that 
minimum and maximum calibration points are accurate. The minimal calibration 
point is where the ion of interest is completely prevented from interacting with the 
indicators, however, this results in an incomplete quenching of the signal, and the 
process of saturating the signal for max fluorescence is also imperfect (Stanika et 
al., 2009). When using indicators with high Kd values, the amount of ions that is 
needed to completely saturate the signal sometimes exceeds the content in the 
bath solution. This makes it difficult to produce a maximum fluorescence signal.  
 
L. Co-immunoprecipitation 
 Co-immunoprecipitation (co-IP) experiments were performed on freshly 
prepared cell lysates from rat hippocampal neuronal cultures at 12–14 days in 
vitro. Lysates were clarified to remove any additional precipitate by incubating 
with Protein A-agarose beads for experiments with rabbit primary antibodies or 
Protein G-agarose beads for experiments with mouse primary antibodies (Santa 
Cruz Biotechnology, Inc.) for 2 hours at 4 °C. Then the lysates were incubated 
overnight with primary anti-NCX1, anti-NCX3, or anti-CRMP2 antibodies under 
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gentle agitation at 4 °C followed by incubation with Protein A-agarose beads or 
Protein G-agarose beads for 2 hours at 4 °C. The immunocaptured complexes 
were then washed three times with lysis buffer before being heated at 70 °C in 
equal volumes of SDS loading dye (Invitrogen). Samples were then processed by 
immunoblotting as described previously (5, 16). Blots were probed with anti-
NCX1 (NCX1 mAb R3F1), anti-NCX3 (NCX3 polyclonal antibody 95209), anti-
NR2B (BD Biosciences), or anti-CRMP2 (Sigma-Aldrich) (all 1:1000). All blots 
are representative of at least three experiments.  
 
M. Patch-Clamp Electrophysiology  
 Whole-cell voltage clamp recordings were performed as described 
previously (Brittain et al., 2012b). Briefly, patch clamp experiments were 
conducted at room temperature using a HEKA EPC-10 amplifier. Data were 
collected using the Pulse program (HEKA Elektronik, Lambrecht/Pfalz, 
Germany). The electrode solution used for recording voltage ramp currents 
mediated by NCXrev contained 20 mM KCl, 100 mM potassium aspartate, 20 mM 
tetraethylammonium-Cl, 10 mM HEPES, 0.01 mM K-EGTA, 4.5 mM MgCl2, and 4 
mM Na-ATP, pH 7.3, adjusted with KOH (Smith et al., 2006). The external 
solution used for recording currents contained 129 mM NaCl, 10 mM CsCl (to 
block K+ channels), 3 mM KCl, 0.8 mM MgCl2, 1.8 mM CaCl2, 5mM glucose, 10 
mM NaHEPES, pH 7.2, 65 mM sucrose, 10 µM nifedipine (to block voltage-gated 
Ca2+ channels), 20 µM ouabain (to inhibit Na+/K+-ATPase), and 1 µM tetrodotoxin 
(to block Na+ channels). In our experiments, the first voltage ramp generated ion 
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current that was used as an internal control. Ni2+ (5 mM), tat-CBD3 (10 µM), or 
CBD3 without tat (10 µM) was applied to neurons 5 minutes before the second 
voltage ramp. 
 
N. Transfection 
 To down-regulate CRMP2, hippocampal neurons in culture were 
transfected in suspension during plating using an electroporator BTX 630 ECM 
(Harvard Apparatus, Holliston, MA) with a plasmid encoding GFP (green 
fluorescent protein) (4 µg/100µl of cell suspension, 5x106 cells; Clontech) and 
siRNA (250 nM; Sigma) against CRMP2. This procedure usually provided 10-
15% transfection efficacy, depending on plasmid quality, compared to <1% 
efficacy with commercial cationic lipid liposomes applied to primary neuronal 
cultures.  
 
O. Statistics  
 Data are shown as mean ± standard error of mean (SEM) of at least three 
independent experiments. Statistical analysis of the experimental results 
consisted of unpaired t-test or one-way ANOVA followed by Bonferroni’s post hoc 
test (GraphPad Prism® 4.0, GraphPad Software Inc., SanDiego, CA, USA). 
Every experiment was performed using at least three different preparations of 
isolated mitochondria or three separate neuronal-glial platings. 
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III. RESULTS 
A. Mitochondrial Ca2+ uptake capacity in a mouse model of HD  
  A major hypothesis in HD pathology is that mHtt leads to abnormalities in 
Ca2+ signaling (Tang et al., 2003; Bezprozvanny & Hayden, 2004). Defects in 
mitochondrial Ca2+ handling have been proposed as a cause of these 
abnormalities (Panov et al., 2002; Gellerich et al., 2008). Previous studies have 
shown defects as well as no effect in mitochondrial Ca2+ handling (Brustovetsky 
et al., 2005; Oliveira et al., 2007).  The question of whether mHtt increases 
sensitivity of brain mitochondria and, particularly, neuronal mitochondria to Ca2+-
induced damage remains open. 
 
a. Mutant Htt associates with mitochondria 
 In our studies, we used both synaptic and non-synaptic mitochondria 
isolated from the YAC128 mouse model of HD and their WT littermates. Synaptic 
mitochondria are neuronal, whereas the non-synaptic fraction contains 
mitochondria from astrocytes as well. Following isolation and discontinuous 
Percoll-gradient purification, both synaptic and non-synaptic mitochondria from 
YAC128 mice were tested for purity. The purity of isolated mitochondria was 
assessed by western blotting with antibodies against calnexin (an endoplasmic 
reticulum marker), MEK1/2 (a cytosolic marker), and COX IV (a mitochondrial 
marker). The purity control data are shown in Fig. 4(a). These data show the lack 
of endoplasmic reticulum and cytosolic contaminations in synaptic and non-
synaptic mitochondria isolated and purified from WT (FVB/NJ) and YAC128 
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mice. Since mHtt is predominantly localized in the cytosol, this data confirms that 
if mHtt is detected in mitochondrial fractions, it is not because of cytosolic 
contamination. 
We then asked if mHtt associates with mitochondria.  To assess this, we 
used Western blotting to probe for mHtt following isolation. Both synaptic and 
nonsynaptic mitochondria from YAC128 mice retained attached mHtt that could 
not be washed out after 30 minutes of incubation at 37ºC in the standard KCl-
based incubation medium with or without 0.1% BSA (Fig. 4). BSA was previously 
hypothesized to displace mHtt from binding to mitochondria (Panov et al., 2003).  
We next asked if mHtt associates with the outside of mitochondria or if mHtt is 
inserted into the mitochondrial membrane. We tested this using alkali treatment 
for 30 minutes at pH 13. This method is used to remove peripheral proteins from 
membranes (Griparic & van der Bliek, 2005). After this treatment, the mHtt level 
was decreased below the detection limit of Western blotting (Fig. 4). These data 
suggest that mHtt is associated with the mitochondria but is not inserted into the 
mitochondrial membrane, consistent with previous findings in a study using 
clonal striatal STHdhQ111 cells (Choo et al., 2004). 
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Figure 4.  
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Figure 4. Detection of mutant human huntingtin (mHtt) in brain nonsynaptic 
and synaptic mitochondria isolated from YAC128 mice. Purity of synaptic 
and non-synaptic mitochondria isolated from YAC128 and WT (FVB/NJ) mice (a). 
Detection of human mutant huntingtin (mHtt) in brain non-synaptic (a) and 
synaptic (b) mitochondria isolated from YAC128 mice (b–e). In (a), homogenates, 
cytosolic and mitochondrial fractions were analyzed using western blotting with 
antibodies against calnexin (ER marker), MEK1/2 (cytosolic marker), and COXIV 
(mitochondrial marker). Fractions were solubilized and proteins were resolved by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) using 
4–12% Bis-Tris gels. In (b and d), mitochondria (Mtc) were analyzed immediately 
after isolation (Mtc from ice), after 30 minutes of incubation in the standard 
incubation medium supplemented with 3 mM succinate and 3 mM glutamate 
without (washing) and with 0.1% bovine serum albumin (BSA), free from fatty 
acids, (washing with BSA), and after 30 minutes of incubation at pH 13 (alkali 
treatment). Mitochondrial porin (voltage-dependent anion channel, VDAC) was 
used as a loading control. In (c and e), the western blotting data were quantified 
using NIH ImageJ software and presented as a mHtt/VDAC ratio. Data are mean 
± SEM, *p < 0.01 compared with mitochondria from ice and after washing, n = 7. 
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b. Mutant Htt does not increase propensity to PTP in synaptic mitochondria 
 An increased propensity to PTP induction in mitochondria exposed to mHtt 
has been previously reported (Choo et al., 2004; Fernandes et al., 2007; Lim et 
al., 2008; Quintanilla et al., 2013b). However, in previous studies in our 
laboratory we did not find evidence for increased susceptibility to PTP induction 
in striatal and cortical mitochondria from HD mice compared with mitochondria 
from WT mice (Brustovetsky et al., 2005). In this earlier study, we investigated 
PTP induction in nonsynaptic mitochondria. In the present study, we asked if 
PTP susceptibility was altered in synaptic (neuronal) mitochondria from YAC128 
(Fig. 5 B,D,F) mice compared with synaptic mitochondria from WT mice (Fig. 5 
A,C,E). This has not been previously investigated in synaptic mitochondria. 
Mitochondrial swelling and depolarization are the major manifestations of PTP 
induction (Bernardi, 1999). Consequently, we investigated an induction of the 
PTP by simultaneously monitoring a decrease in light scattering of mitochondrial 
suspension, indicative of swelling of the organelles, and a release of TPP+ from 
mitochondria, indicative of mitochondrial depolarization. Ca2+, in a concentration-
dependent manner, induced swelling and depolarization of synaptic mitochondria 
(Fig. 5). To quantify swelling of mitochondria, data were calculated as a 
percentage of maximal swelling. Both mitochondrial swelling and depolarization 
in response to Ca2+ were comparable in mitochondria isolated from YAC128 and 
WT mice (Fig. 5G). These data suggest that synaptic mitochondria from YAC128 
mice are not more susceptible to PTP than synaptic mitochondria from WT mice.
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Figure 5.  
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Figure 5. Ca2+-induced mitochondrial swelling and depolarization in 
synaptic mitochondria from WT (FVB/NJ) and YAC128 mice. Mitochondrial 
swelling was evaluated in mitochondria from WT (FVB/NJ) (A, C, E) and YAC128 
(B, D, F) mice, by following a decline in light scattering of mitochondrial 
suspension (red traces). A decrease in light scattering indicates mitochondrial 
swelling. Changes in mitochondrial membrane potential were evaluated following 
distribution of tetraphenylphosphonium (TPP+) between incubation medium and 
mitochondrial matrix (black traces). The decrease in TPP+ concentration in the 
incubation medium ([TPP+]ext) indicates TPP+ accumulation in mitochondria and 
high membrane potential. The release of TPP+ from mitochondria indicates a 
decrease in membrane potential. Mitochondrial swelling and membrane potential 
were evaluated simultaneously at 37ºC. Where indicated 25, 50, or 100μM Ca2+ 
was applied to mitochondria (Mtc). At the end of the experiments, 60μM 2,4-
dinitrophenol (2,4-DNP) was applied to completely depolarize mitochondria and, 
then, 30μg/ml alamethicin (AL) was added to induce maximal mitochondrial 
swelling, taken as 100%. The amount of Ca2+-induced swelling was determined 
as percentage of maximal swelling (shown in A as X%). In G, percentage of 
Ca2+-induced mitochondrial swelling. Data are mean±SEM, N=6. 
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c. Mitochondria from YAC128 mice have increased Ca2+ uptake capacity 
compared with mitochondria from YAC18 and WT mice 
 Next, we asked if mHtt altered Ca2+ uptake capacity of mitochondria 
isolated from YAC128 mice. In these experiments we assessed Ca2+ uptake 
capacity in mitochondria from YAC128, YAC18 (a control YAC strain, expressing 
non-pathological full-length human Htt), and WT FVB/NJ mice. We applied 
pulses of Ca2+ until mitochondria fail to take up additional Ca2+.  In our hands, 
Ca2+ uptake capacity of nonsynaptic mitochondria from 2- and 12-month-old 
YAC128 mice was slightly but statistically significantly increased compared with 
mitochondria from YAC18 and WT mice (Fig. 6). This result is consistent with 
data previously reported by Oliveira et al. (Oliveira et al., 2007). The slight 
increase in Ca2+ uptake capacity was observed with both Complex I substrates 
pyruvate/malate (Fig.6B) and Complex II substrate succinate (Fig. 6C) used in 
combination with glutamate to prevent accumulation of oxaloacetate and 
inhibition of succinate dehydrogenase (Brustovetsky & Dubinsky, 2000).  
Synaptic mitochondria from 2-month-old YAC128 mice also had a slight 
but statistically significant increase in Ca2+ uptake capacity compared with 
mitochondria from age-matched YAC18 (control) and WT mice regardless of 
oxidative substrates (Fig. 7A, D). BSA (Fig. 7B) considerably increased Ca2+ 
uptake capacity in synaptic mitochondria from all types of animals. Interestingly, 
Ca2+ uptake capacity of synaptic mitochondria from 12-month-old YAC128 mice 
was noticeably increased compared with mitochondria from 2-month-old YAC128 
mice and age-matched 12-month-old YAC18 and WT mice (Fig. 7C).  
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Figure 6. Ca2+ uptake capacity of brain nonsynaptic mitochondria isolated 
from YAC128, YAC18, and WT (FVB/NJ) mice. Mitochondria were incubated at 
37ºC in the standard incubation medium supplemented either with 3 mM 
succinate plus 3 mM glutamate or with 3 mM pyruvate plus 1 mM malate as 
indicated in the Figure. In all Ca2+ uptake experiments, 100μM ADP and 1μM 
oligomycin were present in the incubation medium. In A and B, mitochondria 
were isolated from 2-month-old mice. In C, mitochondria were isolated from 12- 
month-old mice. In A-C, where indicated 10μM Ca2+ pulses were applied to 
mitochondria until mitochondria fail to take Ca2+ up. In D, statistical analysis of 
Ca2+ uptake capacity of mitochondria from YAC128, YAC18, and WT (FVB/NJ) 
mice. Data are mean±SEM, *p<0.05, N=5.  
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Figure 7. Ca2+ uptake capacity of brain synaptic mitochondria isolated from 
YAC128, YAC18, and WT (FVB/NJ) mice. Ca2+ uptake capacity of brain 
synaptic mitochondria isolated from YAC128, YAC18, and WT (FVB/NJ) mice. 
Mitochondria were incubated at 37°C in the standard incubation medium 
supplemented either with 3 mM succinate plus 3 mM glutamate or with 3 mM 
pyruvate plus 1 mM malate as indicated in the Figure. In all Ca2+ uptake 
experiments, 100 µM ADP and 1 µM oligomycin were present in the incubation 
medium. In B, incubation medium was additionally supplemented with 0.1% 
bovine serum albumin (BSA) (free from fatty acids). In (a, b, and d), mitochondria 
were isolated from 2-month-old mice. In C, mitochondria were isolated from 12-
month-old mice. In A-D, where indicated 10 µM Ca2+ pulses were applied to 
mitochondria until mitochondria fail to uptake additional Ca2+. In E, statistical 
analysis of Ca2+ uptake capacity of mitochondria from YAC128, YAC18, and 
wildtype FVB/NJ mice. Data are mean ±SEM, *p < 0.05 comparing with FVB/NJ 
and YAC18 mitochondria; **p < 0.01 compared with mitochondria from 12-month-
old FVB/NJ and YAC18 mice, n = 9. 
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These experiments also showed that Ca2+ uptake capacity of mitochondria from 
YAC18 mice was indistinguishable from Ca2+ capacity of mitochondria derived 
from WT mice. Therefore, in the following experiments we used only 
mitochondria from YAC128 and WT mice. 
 
d. Cyclophilin D expression and ROS levels are not altered by mHtt 
Previously, it was reported that the level of cyclophilin D (CyD), a key 
regulatory component of the PTP that sensitizes it to Ca2+ (Baines et al., 2005; 
Schinzel et al., 2005), was reduced in mitochondria from older animals (Eliseev 
et al., 2007). Therefore, we asked whether the increased Ca2+ uptake capacity in 
mitochondria from YAC128 mice, particularly, in synaptic mitochondria from 12-
month-old transgenic animals, correlates with a decrease in CyD. Our 
experiments revealed a lack of difference in the amount of CyD in synaptic and 
nonsynaptic mitochondria from 2- and 12-month-old YAC128 and WT mice (Fig. 
8A, B). Consequently, this could not explain increased Ca2+ uptake capacity in 
mitochondria from YAC128 mice compared with mitochondria from WT animals. 
ROS are major activators of the PTP (Bernardi, 1999) and PTP induction 
is the key factor that restricts Ca2+ uptake capacity (Chalmers & Nicholls, 2003). 
It seemed conceivable that altered ROS production could underlie the difference 
in Ca2+ uptake capacity. Therefore, in the following experiments we examined 
mitochondrial H2O2 generation by synaptic mitochondria from YAC128 and WT 
mice using Amplex Red assay (Brustovetsky et al., 2003).   
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Figure 8. Expression of mitochondrial cyclophilin D in brain mitochondria 
isolated from 2- and 12-month-old YAC128 and WT (FVB/NJ) mice. In A, 
representative western blots of brain nonsynaptic and synaptic mitochondria from 
2- and 12-month-old FVB/NJ and YAC128 mice with anti-cyclophilin D 
antibodies. Isolated mitochondria were solubilized and proteins were resolved by 
SDS-PAGE using 12% Bis-Tris gels. Mitochondrial porin (voltage-dependent 
anion channel, VDAC) was used as a loading control. In B, statistical analysis of 
western blot densitometry with data expressed in arbitrary units (a.u.) as a ratio 
of cyclophilin D band intensity to band intensity of VDAC. Data are mean ± SEM, 
N=5.  
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With succinate plus glutamate, ROS generation was much higher than with 
pyruvate plus malate. BSA further augmented ROS generation (Fig. 9A,B), 
presumably due to an increase in membrane potential in both YAC128 and WT 
mitochondria that may lead to an increase in ROS generation (Korshunov et al., 
1997). Ca2+, on the other hand, depolarizes mitochondria (Bernardi, 1999) and, 
consequently, inhibited ROS generation with succinate plus glutamate (Fig. 9C), 
but did not significantly change ROS generation in the presence of pyruvate plus 
malate (Fig. 9D). Importantly, there was no difference in ROS generation 
between mitochondria from YAC128 and WT mice. Thus, ROS production could 
not account for the difference in Ca2+ uptake capacity between mitochondria from 
transgenic and WT animals. 
 
e. Greater levels of mHtt are associated with synaptic mitochondria from 
12- compared with 2-month-old YAC128 mice 
To further examine the increase in Ca2+ uptake capacity in 12-month 
compared with 2-month-old YAC128 mice, we asked if the level of mHtt 
associated with mitochondria changes with age. We found a 2-fold increase in 
the amount of mHtt bound to synaptic mitochondria from 12-month-old YAC128 
mice compared with mitochondria from 2-month-old YAC128 mice (Fig. 10A, B). 
This increase was not due to an increase in cytosolic mHtt because cytosolic 
levels remained the same (Fig. 10C, D).  
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Figure 9. H2O2 production by synaptic mitochondria from 2-month-old 
YAC128 and WT (FVB/NJ) mice. Mitochondrial H2O2 production was measured 
under continuous stirring in 0.4 ml cuvette at 37ºC in the standard KCl-based 
incubation medium. In A-C, the standard incubation medium was supplemented 
with 3 mM succinate plus 3 mM glutamate. In D, the incubation medium was 
supplemented with 3 mM pyruvate plus 1 mM malate. In B, 0.1% BSA (free from 
fatty acids) was present in the medium. 12.5 or 200μM Ca2+ was applied to 
mitochondria in C and D, as indicated. In E, a statistical analysis of H2O2 
production under different experimental conditions. Data are mean±SEM, N=6. 
*p<0.01 compared to H2O2 generation by WT mitochondria oxidizing succinate 
plus glutamate, but without BSA and Ca2+; #p<0.01 compared to H2O2 generation 
by YAC128 mitochondria oxidizing succinate plus glutamate, but without BSA 
and Ca2+ 
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Figure 10. The level of mutant huntingtin (mHtt) associated with brain 
mitochondria isolated from 2- and 12-month-old YAC128 mice. The level of 
mutant huntingtin (mHtt) associated with brain mitochondria isolated from 2- and 
12-month-old YAC128 mice. In A, western blots of brain synaptic mitochondria 
from 2- and 12-month-old YAC128 mice with anti-polyQ 1C2 antibody, specific 
for mHtt. Isolated mitochondria were solubilized and proteins were resolved by 
sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) using 
3–8% Trisacetate gels. Calnexin was used as a marker of endoplasmic 
reticulum. MEK1/2 was used as a cytosolic marker. Mitochondrial porin (voltage-
dependent anion channel, VDAC) was used as a mitochondrial marker and 
loading control. In B, statistical analysis of western blot densitometry with data 
expressed as a ratio of mHtt band intensity to band intensity of VDAC. Data are 
mean ± SEM, *p < 0.05 compared with mitochondria from 2-month-old YAC128 
mice, n = 8. In C, western blots of brain cytosolic fractions from 2- and 12-month-
old YAC128 mice with anti-polyQ 1C2 antibody, specific for mHtt. Cytosolic 
fractions were resolved by SDS-PAGE using 3–8% Tris-acetate gels. MEK1/2 
was used as a cytosolic marker and loading control. In D, statistical analysis of 
western blot densitometry with data expressed as a ratio of mHtt band intensity 
to band intensity of MEK1/2. Data are mean ±SEM, n = 8. 
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Thus, augmented Ca2+ uptake capacity of synaptic mitochondria from 12-month-
old YAC128 mice correlated with the increased amount of mHtt associated with 
these mitochondria. These data suggest that mHtt association with mitochondria 
may augment mitochondrial Ca2+ uptake capacity. 
 
B. Ca2+dysregulation in culture neurons from a mouse model of HD 
Studies with isolated mitochondria provide important information about the 
function of the organelles, but under these conditions mitochondria are removed 
from the complexity of the whole cell. To further examine Ca2+ handling in the 
presence of mHtt, we used primary striatal neurons plated with glia. Ca2+ has 
been shown to be altered in HD contributing to neurodegeneration (Tang et al., 
2003; Bezprozvanny & Hayden, 2004). This is likely due to increased activation 
of NMDAR in striatal neurons expressing mHtt (Zeron et al., 2002).  
 
a. Characterization of striatal neurons in culture 
Prior to experiments with primary striatal neurons, characterization was 
required to confirm that the neurons were medium spiny neuron, the primary 
neuronal type in the straium. A representative bright-field image of cell culture is 
shown in Fig. 11A. All pups used for harvesting neurons were genotyped and 
cultured cells were tested for the presence of mHtt using Western blotting 
(Fig.11B).  Our cell culture contained both neurons and astrocytes stained by 
neuronal marker, microtubule associated protein (MAP-2, green) and glial 
marker, glial fibrillary acidic protein (GFAP, red) (Mao & Wang, 2001), 
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respectively (Fig.11D). To characterize that the striatal neurons were medium 
spiny neurons, the primary neuronal type in the striatum, we stained with anti-
GABA (red) (Ivkovic & Ehrlich, 1999; Mao & Wang, 2001) (Fig.11F) and anti-
dopamine and cyclic AMP-regulated phosphoprotein relative molecular mass 
32,000 (DARPP-32, red) (Ivkovic & Ehrlich, 1999) (Fig. 11H) antibodies. The 
majority of neurons (85%) were GABA positive, and 50% of neurons were 
positive for DARPP-32, typical for striatal neurons (Ivkovic & Ehrlich, 1999).  
Figures 11C, E, and G show bright-field images for the corresponding 
immunofluorescence images. 
To determine consistency in glia/neuron ratio, we performed western blotting with 
antibodies against MAP-2 and GFAP. GAPDH was used as a loading control. 
Then, we performed densitometry and calculated MAP2/GFAP ratio as a 
characteristic of our cell cultures (Figure 12). These experiments showed very 
small variability (mean ± SEM: 1.10 ± 0.08 for FVB/NJ mice, n = 6, and 1.12 ± 
0.07 for YAC128 mice, n = 6) between different platings as well as the lack of 
difference between cell cultures prepared from YAC128 and WT littermates. 
 We next asked if the basal cytosolic Ca2+ concentration was altered in 
striatal neurons from YAC128 mice compared with their WT littermates. Other 
groups have previously shown no difference in basal cytosolic Ca2+ concentration 
in medium spiny neurons plated from the R6/2 (Cepeda et al., 2001) and 
YAC128 (Zhang et al., 2008) mouse models of HD.  
 
 
 80 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11.  
 81 
Figure 11. Characterization of striatal neuronal culture from YAC128 mice. 
A, a representative live-cell, bright field image of striatal neuronal-glial co-culture 
used in this study; B, genotyping of mice and western blotting of striatal neuronal 
cultures from the same animals, “+” – YAC128 mice, “-“ – WT littermates; C and 
D, bright field image (C) and immunofluorescence image (D) of neuronal culture 
stained with anti-MAP-2 antibody (neuronal marker), anti-GFAP antibody 
(astroglial marker), and DAPI (nuclear marker); E and F, bright field image (E) 
and immunofluorescence image (F) of neuronal culture stained with anti-GABA 
antibody; G and H, bright field image (G) and immunofluorescence image (H) of 
neuronal culture stained with anti-DARPP-32 antibody (marker of medium spiny 
neurons), anti-MAP-2 antibody (general neuronal marker). 
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Figure 12. Consistency in neuron to glia ratio in neuronal-glial co-cultures. 
In A, western blotting with three representative neuronalglial co-cultures from 
three different platings derived from WT (FVB/NJ) and YAC128 mice. MAP2, 
neuronal marker; GFAP, glial marker; GAPDH, loading control. In B, MAP2 to 
GFAP ratio in arbitrary unites (a.u.) based on densitometry analysis. N=7.
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To characterize the cells in our culture system, we evaluated resting 
(basal) Ca2+ concentrations using fluorescent microscopy. Representative traces 
are shown in Fig. 13A and B. The cytosolic Ca2+ concentration was calculated for 
individual cells and then averaged. There was no significant difference in 
cytosolic Ca2+ concentration between WT (0.087 ± 0.007µM) and YAC128 (0.090 
± 0.004 µM) mice.  
 To further characterize striatal neurons in culture, we examined resting 
(basal) cytosolic Na+ concentration. This has not previously been investigated in 
cultured neurons. Representative traces of Na+ calibration are shown in Figure 
14 A and B. Cytosolic Na+ concentration was calculated for each neuron 
separately and concentrations were averaged. Na+ concentrations in striatal 
neurons derived from YAC128 mice were slightly but statistically significantly 
elevated (p<0.05, N=62-75 individual neurons), although only slightly greater 
(10.49 ± 0.32 mM) than WT (8.39 ± 0.47 mM) (Fig. 14C). Increased Na+ 
concentration has been reported in the striatum of HD patients in vivo in studies 
using magnetic resonance imaging (MRI) (Reetz et al., 2012; Gramsbergen et 
al., 1986). These data could suggest increased activity or expression of sodium 
calcium exchangers to maintain basal cytosolic Ca2+ concentration. 
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Figure 13. Resting (basal) cytosolic Ca2+ concentrations are similar in 
striatal neurons from YAC128 and WT mice.  In A and B, the individual (thin 
grey traces obtained from individual neurons) and the averaged fluorescence 
signals (thick red traces, mean±SEM) from the representative experiments are 
shown. Cytosolic Ca2+ was followed by monitoring Fura-2 F340/F380 fluorescence 
ratio at 37ºC. In these experiments, neurons were recorded for ten minutes 
without any treatment. Data are mean±SEM.  In C, averages of individual 
neurons, n=95-97 individual neurons evaluated for each strain. 
  
 85 
0 300 600 900 1200 1500
0.50
0.75
1.00
1.25
1.50
0 Na
10 Na
40 Na
130 Na
Time, s
SB
FI
, F
34
0/
F 3
80
0 300 600 900 1200 1500
0.50
0.75
1.00
1.25
1.50
0 Na
10 Na
40 Na
130 Na
Time, s
SB
FI
, F
34
0/
F 3
80
WT YAC128
0
1
2
3
4
5
6
7
8
9
10
11 *
[N
a+
] c,
m
M
A
C
B
WT
YAC128
Figure 14. Resting (basal) cytosolic Na+ concentration is slightly but 
statistically significantly greater in striatal neurons from YAC128 mice 
compared with WT mice. In A and B, the individual (thin grey traces obtained 
from individual neurons) and the averaged fluorescence signals (thick green 
traces, mean±SEM) from the representative experiments are shown. Cytosolic 
Na+ was followed by monitoring SBFI F340/F380 fluorescence ratio at 37ºC. In 
these experiments, neurons were recorded for ten minutes without any treatment 
then gramicidin was applied along with solutions of known Na+ concentration for 
calibration. Data are mean±SEM.  In C, averages of individual neurons, n=62-75 
individual neurons evaluated for each strain. 
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b. Striatal neurons undergo DCD more quickly than cortical neurons 
 Striatal neurons are the most vulnerable neuronal population in HD. We 
asked if striatal neurons are more vulnerable to excitotoxic insult in WT cultured 
neurons, without the contribution of mHtt. To evaluate this, we cultured striatal 
and cortical neurons from WT mice and evaluated glutamate-induced increase in 
cytosolic Ca2+ concentration. The recording was performed at 1 image per 15 
seconds acquisition rate for 20 minutes to ensure DCD plateau. Application of 
15µM glutamate plus 10µM glycine resulted in DCD within 5 minutes of 
glutamate application (Fig. 15A). Cortical neurons, on the other hand, recovered 
to basal levels, eventually undergoing DCD after 20 minutes (Fig.15B). These 
data were quantified by calculating the area under the curve (AUC). AUC 
indicates the increase in cytosolic Ca2+ over time. AUC for striatal neurons was 
significantly greater than cortical neurons (p<0.05, N=4), 2318 ± 335.8 arbitrary 
units (a.u.) compared with 594 ± 229.4 a.u. respectively (Fig. 15C). These data 
suggest that striatal neurons from WT animals are more vulnerable to 
excitotoxicity than cortical neurons from WT animals. 
 
c. Delayed calcium dysregulation occurs more quickly in striatal neurons 
from YAC128 mice compared with striatal neurons from WT mice 
 Next, we asked if mHtt expression further increased the vulnerability of 
striatal neurons to excitotoxic insult. To evaluate the effect of mHtt, we applied 
25µM glutamate plus 10µM glycine to striatal neurons from YAC128 and WT 
mice. 
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Figure 15. Ca2+ dysregulation occurs more quickly in striatal neurons 
compared with cortical neurons. Striatal and cortical neurons (10-14 days in 
vitro) from WT mice were loaded with Ca2+-sensitive dye Fura-2FF-AM to monitor 
changes in cytosolic Ca2+ concentration ([Ca2+]c). In A and B, thin, grey traces 
show fluorescent signals from individual neurons whereas thick, red traces 
represent mean±SEM from individual experiments (n=20-25 neurons per 
experiment). Where indicated, 15μM glutamate plus 10μM glycine (Glu) were 
applied to neurons. In C, the summary graph shows average area under the 
curve (AUC; a.u., arbitrary units), that represents a measure of [Ca2+]c increase 
over time. (*p<0.05, N=3-4).  
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We assessed glutamate-induced increase in cytosolic Ca2+ concentration using 
fluorescent imaging (Figure 16A, B). These data were quantified in two ways. In 
Figure 16C, the slopes of the average traces are reported. The slope indicates 
the rate of the response to glutamate. A greater slope correlates with faster onset 
of DCD. The slope of glutamate-induced increase in cytosolic Ca2+ concentration 
from YAC128 striatal neurons (0.019±0.004) is significantly greater (p<0.05, N=4) 
than the slope observed in WT neurons (0.007±0.002). These data are also 
represented as AUC in Figure 16D. Evaluation of the AUC also shows 
statistically significant (p<0.05, N=4) increase in neurons from YAC128 striatal 
neurons (1236±117.3 a.u.) compared with WT neurons (885±87.4 a.u.). These 
data suggest that the presence of mHtt further increases the vulnerability of 
striatal neurons to excitotoxic insult. 
 
d. NMDA-induced Ca2+ increases are similar in striatal neurons from 
YAC128 and WT mice 
 In response to glutamate application, Ca2+ predominantly enters the 
neuron through NMDARs. It has been proposed that NMDAR activity is 
increased in HD but there are contradictory results in the literature. Fernandes 
and colleagues (Fernandes et al., 2007) have shown in electrophysiological 
studies that NMDAR are more active in striatal neurons from YAC72 but not in 
YAC46 or YAC128 models of HD.    
 89 
WT YAC128
0.000
0.005
0.010
0.015
0.020
0.025 *
Sl
op
e
0 300 600 900 1200
0.0
2.5
5.0
7.5
10.0 YAC128
Glu 25M
Time, s
[C
a2
+ ]
c
M
WT YAC128
0
250
500
750
1000
1250
1500 *
AU
C
, a
.u
.
0 300 600 900 1200
0.0
2.5
5.0
7.5
10.0 WT
Glu 25M
Time, s
[C
a2
+ ]
c
M
A
DC
B
 
 
Figure 16. Ca2+ dysregulation occurs more quickly in YAC128 striatal 
neurons compared with WT neurons. Striatal neurons (10-13 days in vitro) 
were loaded with Ca2+-sensitive dye Fura-2FF-AM to monitor changes in 
cytosolic Ca2+ concentration ([Ca2+]c). In A and B, thin, grey traces show 
fluorescent signals from individual neurons whereas thick, red traces represent 
mean±SEM from individual experiments (n=20-25 neurons per experiment). 
Where indicated, 25μM glutamate plus 10μM glycine (Glu) were applied to WT 
(A) and YAC128 (B) neurons. In C, the summary graph shows the slope, 
indicating the rate of the response to glutamate. (*p<0.05 N=4). In D, the graph 
shows average area under the curve (AUC; a.u., arbitrary units), that represents 
a measure of [Ca2+]c increase over time. (*p<0.05, N=4)  
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Other laboratories, however, have shown increased NMDAR currents in striatal 
neurons derived from YAC128 mice (Zhang et al., 2008), although all conditions 
are reported as similar to those used by Fernandes et al. This research group 
also used fluorescent imaging to measure cytosolic Ca2+ concentration in 
response to 100µM or 500µM NMDA for 5 minutes and reported no difference 
between WT and YAC128 (Fernandes et al., 2007). Many factors contribute to 
cytosolic Ca2+ concentration, not only Ca2+ influx, but also mechanisms of Ca2+ 
removal to maintain Ca2+ homeostasis and fight excitotoxicity. Furthermore, we 
have previously used a lower concentration of NMDA (30µM plus 10µM glycine) 
in a 30 second pulse protocol to evaluate NMDAR activity (Brustovetsky et al., 
2011; Brittain et al., 2012a). To decrease the possibility of a ceiling effect, we 
used lower concentrations of NMDA than the previous study (10µM, 15µM, and 
30µM) plus 10µM glycine. Representative traces of cytosolic Ca2+ concentration 
from WT striatal neurons are shown in Figure 17A, B, and C and neurons from 
YAC128 in Fig. 17D, E, and F. Data are quantified as peak cytosolic Ca2+ 
concentration in Fig. 17G and AUC in Fig. 17H. The peak Ca2+ concentration 
indicates the initial Ca2+ increase, whereas AUC indicates the increase in Ca2+ 
over time. Regardless of the quantification, there is no statistically significant 
difference between NMDA-induced cytosolic Ca2+ increases from WT or YAC128 
striatal neurons using this protocol. These data could suggest that there is no 
difference in NMDAR activity in mHtt expressing striatal neurons or that 
mechanisms of Ca2+ removal are compensating for increased Ca2+ influx. 
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Figure 17. NMDA-induced cytosolic Ca2+ increases are similar in striatal 
neurons from YAC128 and WT mice. Striatal neurons (10-13 days in vitro) 
were loaded with Ca2+-sensitive dye Fura-2AM to monitor changes in [Ca2+]c. In 
these experiments, where indicated, short pulses of 10μM (A,D), 15μM (B,E) or 
30μM (C,F) NMDA (plus 10μM glycine) were applied to WT (A,B,C) or YAC128 
(D, E, F) neurons. In G, the summary graph shows changes in average peak 
cytosolic Ca2+ concentration in response to various NMDA concentrations. In H, 
data is shown as area under the curve. N=3-4 separate, individual experiments.  
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e. Mitochondrial Ca2+ uptake is similar in striatal neurons from YAC128 
mice compared with neurons from WT mice 
We showed that synaptic and nonsynaptic isolated mitochondria from 2- 
and 12-month-old YAC128 mice are capable of taking up as much and more 
Ca2+ compared with WT isolated mitochondria. Therefore, we asked if 
mitochondrial Ca2+ uptake is also increased in striatal neurons expressing mHtt. 
We evaluated the mitochondrial accumulation of Ca2+ in striatal neurons exposed 
to excitotoxic glutamate. Previously, this approach was used in studies with 
cortical neurons expressing mHtt (Chang & Reynolds, 2006). We used short 
applications of 25 and 100µM glutamate and after recovery to resting 
concentration, evaluated subsequent release of mitochondrial Ca2+ into the 
cytosol induced by depolarization of the organelles with 1µM FCCP. The 
magnitude of elevation in cytosolic Ca2+ due to Ca2+ release from mitochondria 
was used to evaluate mitochondrial Ca2+ uptake capacity in situ (Chang et al., 
2006).  
Simultaneously with FCCP application, we replaced external Na+ for N-
methyl-D-glucamine (NMDG), a bulk organic cation that cannot be transported by 
the Na+/Ca2+ exchanger and hence prevents Ca2+ extrusion from the cell by this 
mechanism. In these experiments, glutamate applications produced transient 
increases in cytosolic Ca2+ followed by recovery of cytosolic Ca2+ to near resting 
level after removal of glutamate (Fig. 18). Neurons from YAC128 mice had a 
more robust response to glutamate consistent with Fig. 16.  
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Figure 18. Striatal neurons from YAC128 mice have comparable 
mitochondrial Ca2+ accumulation following transient glutamate-induced 
elevations in cytosolic Ca2+.   In A, B, E, and F, the averaged fluorescence 
signals (mean±SEM) from the representative experiments are shown. Cytosolic 
Ca2+ was followed by monitoring Fura-2FF F340/F380 fluorescence ratio at 37ºC. In 
these experiments, neurons were exposed to 25μM or 100µM glutamate (in both 
cases, with 10µM glycine) for 2 minutes as indicated. Then, glutamate and 
glycine were removed to let [Ca2+]c recover. After [Ca2+]c reached near resting 
level (7 minutes after glutamate removal) neurons were treated with 1µM FCCP 
to depolarize mitochondria and release accumulated Ca2+.  To avoid ambiguity 
concerning possible Ca2+ influx from the outside of the cell, external Ca2+ was 
removed simultaneously with glutamate and glycine.  In addition, to prevent Ca2+ 
extrusion from the cell by Na+/Ca2+ exchanger, the external Na+ was replaced by 
equimolar N-methyl-D-glucamine (NMDG) as indicated.  In C, D, G, and H, the 
areas under the curve (AUC) for the averaged fluorescence signals are shown.  
The AUC for glutamate-induced increase in [Ca2+]c (Glu AUC) was calculated for 
the 120 second period beginning with glutamate application.  The AUC for 
FCCP-induced increase in [Ca2+]c (FCCP Glu) was calculated for the 300 second 
period following FCCP application.  Data are mean±SEM.  In C, *p<0.05 
compared to WT cells, n=6-9 separate experiments with 20-25 individual neurons 
in each experiment. 
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Depolarization of mitochondria with 1µM FCCP in Ca2+-free bath solution 
(to prevent influx of external Ca2+) triggered a massive increase in cytosolic Ca2+ 
that was similar in neurons from both YAC128 and WT mice. This result suggests 
that mHtt does not decrease the ability of neuronal mitochondria to accumulate 
Ca2+ and, therefore, most likely does not affect mitochondrial contribution to 
maintenance of Ca2+ homeostasis in striatal neurons exposed to excitotoxic 
glutamate. 
 
f. NCX1 expression in striata of YAC128 mice increases with age 
NCX is a low affinity, high capacity exchanger and therefore another major 
mechanism important in the removal of elevated cytosolic Ca2+. We asked if the 
expression of plasmalemmal NCX isoforms present in lysate from striatum, 
NCX1 and NCX3, were altered. Our earlier findings of a slight but statistically 
significant increase in resting sodium concentrations in neurons from YAC128 
compared with WT neurons (Fig. 14) suggest increased NCX activity or 
increased NCX expression. Therefore, we examined the expression of NCX1 and 
NCX3 in striatal lysate from both 3-week and 3-month-old WT and YAC128 mice. 
These time points correlate with pre-symptomatic in YAC128 and show no 
detectable striatal atrophy (Slow et al., 2003). NCX1 expression is statistically 
significantly increased, by two-fold, at 3 months compared with striata from age 
matched WT mice (p<0.05, N=5) (Fig. 19B, D). At 3-weeks, however, NCX1 
expression is not significantly different in striatal lysate from YAC128 mice 
compared with striatal lysate from WT mice (Fig. 19 A,C).   
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Figure 19. Expression of NCX1 and NCX3 in striata from 3-week and 3-
month-old YAC128 and WT mice. In A, Western blots of lysate from striata from 
3-week-old YAC128 and WT mice with anti-NCX1 antibody. Lysate from striata 
from 3-month-old YAC128 and WT mice are show in B. In C and D, statistical 
analysis of Western blot densitometry with data expressed as percent of WT. In 
E, Western blots of lysate from striata from 3-week-old YAC128 and WT mice 
with anti-NCX3 antibody and striata from 3-month-old YAC128 and WT mice are 
show in F. In C and D, statistical analysis of Western blot densitometry with data 
expressed as a percentage of WT. β-actin was used as a loading control. Data 
are mean±SEM, (*p<0.05, N=3-4). 
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There was no change in NCX3 expression at either age (Fig. 19 E-H). 
These data suggest that the increase in NCX1 expression could be a 
compensation for increased cytosolic Ca2+ concentrations mediated by increased 
extracellular Ca2+ influx or dysfunction of other Ca2+ removal mechanisms. 
  
C. Role of CRMP2 in glutamate-induced Ca2+ dysregulation 
Our laboratory, in collaboration with Dr. Khanna’s laboratory, recently 
found that CRMP2 is involved in regulation of cytosolic Ca2+ in neurons exposed 
to glutamate (Brittain et al., 2011a). The mechanism of CRMP2’s involvement in 
Ca2+ regulation is not fully understood.  As a first step in our research, we chose 
to use rat hippocampal neurons in culture to examine the role of CRMP2 without 
the added variable of mHtt. 
 
a. Glutamate-induced Ca2+ dysregulation is reduced after application of tat-
CBD3, a small peptide derived from CRMP2 
First, we asked if CRMP2 is involved in glutamate-induced Ca2+ 
dysregulation. We used tat-CBD3, a 15-amino acid peptide derived from CRMP2 
fused to the cell penetrating motif of HIV-1 (tat), as a tool to disrupt CRMP2 
binding. Tat-CBD3 has previously been shown to disrupt interaction between 
CRMP2 and CaV2.2 (Brittain et al., 2011b). Application of tat-CBD3 significantly 
decreased glutamate-induced DCD (Fig. 20A) compared with vehicle control 
(Fig. 20B).   
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Figure 20.  Tat-CBD3, but not CBD3 sans tat or tat alone, strongly inhibits 
glutamate-induced Ca2+ dysregulation. Rat hippocampal neurons (12-14 days 
in vitro) were loaded with Ca2+-sensitive dye Fura-2FF-AM to monitor changes in 
cytosolic Ca2+ concentration ([Ca2+]c). Thin, grey traces show fluorescent signals 
from individual neurons whereas thick, red traces represent mean±SEM from 
individual experiments (n=20-25 neurons per experiment). Here and in all 
subsequent Figures, where indicated, neurons were treated either with vehicle 
(A, DMSO, 0.1%) or 10μM tat-CBD3 (B) for 10 minutes prior to glutamate 
exposure. In C, neurons were treated with 10μM CBD3 sans tat. The peptide 
remained in the bath solution throughout the experiment. In D, neurons were 
treated with 10μM tat for 10 minutes prior to glutamate exposure. Where 
indicated, 25μM glutamate plus 10μM glycine (Glu) were applied. In E, the 
summary graph shows the average area under the curve (AUC; a.u., arbitrary 
units), that represents a measure of [Ca2+]c increase over time. A representative 
AUC is shown in panel A as a grey area under the mean±SEM trace. Under each 
experimental condition, the AUC was calculated for the same time (1080 
seconds) following glutamate application. *p<0.01 comparing vehicle- and tat-
CBD3-treated neurons. N=5 separate, individual experiments; total number of 
analyzed neurons is 383.  
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Furthermore, CBD3 alone (without the tat motif) which cannot cross the 
membrane, resulted in no change in DCD (Fig. 20B). Treatment with tat alone 
also had no effect on DCD (Fig. 20D).  
The change in cytosolic Ca2+ concentration in neurons exposed to tat-
CBD3, expressed as AUC, showed a 70% decrease compared with control 
treatments (Fig.  20E). These data suggest that CRMP2 may be involved in Ca2+ 
handling mechanisms important in DCD.  
 
b. NMDA-induced cytosolic Ca2+ concentration increase is reduced after 
application of tat-CBD3 
Since NMDAR is a primary source of Ca2+ influx in response to glutamate 
and CRMP2 has previously been shown to modulate NMDAR (Brittain et al., 
2011a), we asked if tat-CBD3 alters cytosolic Ca2+ concentration in response to 
NMDA application. We used an NMDA pulse protocol where NMDA was applied 
for 30 seconds then cytosolic Ca2+ was allowed to return resting. A treatment was 
applied followed by a second pulse. The treatment was then removed and a final 
pulse was applied. Similar to glutamate-induced DCD, tat-CBD3 (10µM) 
statistically significantly reduced NMDA-evoked increases in cytosolic Ca2+ 
concentration (0.17±0.05μM) compared with vehicle treated (1.03±0.05μM)  
neurons (Fig. 21 A,C). CBD3 without tat was ineffective (1.10±0.07μM) (Fig. 
21D). As a positive control, we used AP-5 (20μM), a potent NMDAR antagonist 
(Morris et al., 1986). AP-5 completely blocked NMDA-induced increase in 
cytosolic Ca2+ (Fig. 21B).  
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Figure 21. Tat-CBD3, but not CBD3 sans tat, strongly inhibits NMDA-
induced increases in cytosolic Ca2+. Rat hippocampal neurons (12-14 days in 
vitro) were loaded with Ca2+-sensitive dye Fura-2AM to monitor changes in 
[Ca2+]c. In these experiments, where indicated, short pulses of 30μM NMDA (plus 
10μM glycine) were applied to neurons. Following recovery of [Ca2+]c after the 
first NMDA pulse, neurons were treated with either vehicle (A, DMSO, 0.1%), 
10μM tat-CBD3 (C), or 10μM CBD3 (D) as indicated. Then, one or two more 
NMDA pulses were applied. In B, before the second NMDA pulse, neurons were 
treated with 20μM AP-5 as a positive control. In E, the summary graph shows 
changes in average peak cytosolic Ca2+ concentration under different conditions. 
#p<0.01 compared to [Ca2+]c before treatment (NT, non-treated cells). N=5 
separate, individual experiments, total number of analyzed neurons is 217. 
*p<0.01 compared to changes in average peak [Ca2+]c in NMDA-treated cells. 
N=5 separate, individual experiments; total number of analyzed neurons is 205.
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These data suggest that tat-CBD3 interacts with an intracellular target to reduce 
NMDA-induced increases in cytosolic Ca2+ concentration. 
 
c. CRMP2 interacts with NR2B-NMDAR and tat-CBD3 disrupts this 
interaction  
Inhibition of NMDAR activity by tat-CBD3 suggested a direct interaction 
between CRMP2 and NMDAR. Therefore we asked if CRMP2 interacts with 
NMDAR and if tat-CBD3 disrupts this interaction. We used co-IP experiments to 
examine an interaction between CRMP2 and NMDAR. Probing for the NR2B 
subunit of NMDAR, shown previously to be involved in excitotoxicity (Zhou & 
Baudry, 2006; Liu et al., 2007), we found an interaction between CRMP2 and 
NR2B-containing NMDARs (Fig. 22A). This is consistent with previous findings 
(Al-Hallaq et al., 2007). Moreover, tat-CBD3 disrupted the interaction between 
CRMP2 and NMDAR (Fig. 22A). These data suggest that CRMP2 regulates 
NMDAR activity via binding to the NR2B subunit and tat-CBD3-mediated 
dissociation of CRMP2 from NMDAR leads to decreased NMDAR activity.  
 
d. CRMP2 is not required for NMDAR localization to the membrane 
Another possibility to explain the impact of CRMP2 on NMDAR activity is 
that CRMP2 anchors NMDAR to the plasma membrane. If this is how the 
interaction works, disruption of the interaction between CRMP2 and NMDAR 
should lead to NMDAR internalization.  
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Figure 22. Tat-CBD3 disrupts CRMP2 interaction with NR2B-NMDAR, but 
does not cause NMDAR re-localization. In A, immunoprecipitation was 
performed with IgG or anti-CRMP2 antibody (Sigma-Aldrich) followed by western 
blotting with anti-NR2B antibody (BD Biosciences). Where indicated, prior to 
immunoprecipitation cells were incubated with a vehicle (0.1% DMSO) or 10μM 
tat-CBD3 for 10 minutes. In B and D, confocal, inverted fluorescence images of 
representative neurons stained with anti-NR2B antibody (BD Bioscience). In C 
and E, fluorescence intensity profiles for straight lines in panels B and D, 
respectively. N=3 separate, individual experiments. The Inset in B shows western 
blot produced with cell lysate and anti-NR2B antibody (BD Bioscience) to 
illustrate antibody specificity. Scale bars are 15 μm.  
 107 
Internalization of NMDAR could explain tat-CBD3-evoked suppression of 
NMDAR activity. We asked if CRMP2 interaction with NMDAR is required for 
NMDAR membrane localization. To test this possibility, we used 
immunocytochemistry in conjunction with confocal fluorescent microscopy. 
Figure 22B-E shows representative inverted fluorescent images and 
fluorescence intensity profiles for the respective images. All analyzed cells, 
regardless of treatment, had similar patterns of NR2B distribution (Fig. 22, B, D). 
NMDARs appear to be localized at the plasma membrane as well as the 
cytoplasm. The cytoplasmic localization is likely internalized NMDAR (Fig. 22B-
E). These patterns of localization are consistent with previous reports of NMDAR 
distribution (Hallett et al., 2006). The monoclonal anti-NR2B antibody used in 
these experiments detected only a single band in immunoblotting experiments 
(Fig. 22B, Inset) indicating specificity. This assures that immunostaining shown in 
Fig. 22B,D is due to NR2B NMDARs. These data suggest that disruption of 
CRMP2 interaction with NR2B affects NMDAR activity without altering its 
localization in the plasma membrane.  
 
e. NCXrev is decreased by tat-CBD3 
 Our laboratory has shown that inhibition of both NMDAR and NCXrev is 
required for ablation of glutamate-induced Ca2+ dysregulation (Brittain et al., 
2012b). Based on these findings and the results show in Figure 20, we 
hypothesized that tat-CBD3, in addition to inhibiting NMDAR, also inhibits NCXrev. 
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Figure 23. Na+/NMDG replacement in the bath solution induces reversal of 
Na+/Ca2+ exchanger. Neurons were co-loaded with a Na+-sensitive dye SBFI-AM 
(A and C) and Ca2+-sensitive dye Fluo-4FFAM (B and D). Measurements of 
cytosolic Ca2+ and Na+ were performed simultaneously. The thin, grey traces 
show fluorescent signals from individual neurons. The thick, red traces represent 
cytosolic Ca2+ mean±SEM whereas thick, green traces represent cytosolic Na+ 
mean±SEM from individual experiments (n=20-25 neurons per experiment). The 
bath solution was supplemented with 5μM nifedipine to block L-type voltage-
gated Ca2+ channels, 1μM tetrodotoxin (TTX) to block Na+ channels, and 20μM 
AP-5, to antagonize NMDA receptor. To elevate cytosolic Na+, neurons were pre-
incubated for 10 minutes with 1 mM ouabain (Ouab). Ouabain remained in the 
bath solution throughout the experiment. Where indicated, Na+ was replaced by 
equimolar NMDG to trigger NCX reversal. In C and D, 10μM MK801, an inhibitor 
of reverse NCX (12), was applied to link Na+/NMDG-induced increase in cytosolic 
Ca2+ to NCXrev activity. N=5 separate, individual experiments; total number of 
analyzed neurons is 121.  
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To examine NCXrev activity, we induced NCX reversal by replacing external Na+ 
for equimolar N-methyl-D-glucamine (NMDG). Prior to Na+/NMDG replacement, 
neurons were incubated with ouabain (1 mM), an inhibitor of Na+/K+-ATPase, for 
10 minutes to increase cytosolic Na+ and thus facilitate NCX reversal.  
The Na+/NMDG replacement produced an increase in cytosolic Ca2+ and a 
decrease in cytosolic Na+ (Fig. 23A,B). Since Na+/NMDG replacement could 
evoke release of endogenous glutamate (Brittain et al., 2012a), these 
experiments were performed in the presence of AP-5 (20μM) to prevent 
activation of NMDAR and exclude Ca2+ influx via this mechanism. Our laboratory 
has also previously demonstrated that MK801, an NMDAR antagonist, inhibits 
NCXrev (Brittain et al., 2012b). In these experiments we used MK801 to 
demonstrate inhibition of NCXrev. Application of MK801 completely inhibited 
Na+/NMDG-induced increase in cytosolic Ca2+ concentration and slowed a 
decrease in cytosolic Na+ concentration (Fig. 23 C,D), implicating NCXrev in these 
ion alterations. Thus, in our experiments Na+/NMDG replacement caused an 
increase in cytosolic Ca2+ due to a reversal of NCX.  
 Next we use the protocol to induce NCXrev shown in Fig. 23 along with 
application of various treatments. Tat-CBD3 strongly inhibited the Na+/NMDG-
induced increase in cytosolic Ca2+ compared with vehicle treatment (Fig. 24A,B). 
Tat-CBD3 A6K, a mutated version of CBD3 that demonstrated increased 
conformational stability (Piekarz et al., 2012), also significantly inhibited 
Na+/NMDG-induced increase in cytosolic Ca2+ concentrations (Fig. 24C).  
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Figure 24. Na+/Ca2+ exchanger reversal induced by Na+/NMDG replacement 
is inhibited by tat-CBD3. Neurons were loaded with Fura-2FF-AM. Where 
indicated, neurons were treated either with vehicle (A), 10μM tat-CBD3 (B), 
10μM tat-CBD3 A6K (C), or 10μM tat-scramble peptide (D) for 10 minutes prior to 
NCX reversal induced by Na+/NMDG replacement. In E, neurons were treated 
with 10μM CBD3 and the peptide remained in the bath solution throughout the 
experiment. The bath solution was supplemented with 5μM nifedipine, 1μM TTX, 
and 20μM AP-5. In addition, neurons were preincubated for 10 minutes with 1 
mM ouabain (Ouab). Ouabain remained in the bath solution throughout the 
experiment. In F, the summary graph shows the average area under the curve 
(AUC; a.u., arbitrary units) that represents a measure of [Ca2+]c increase over 
time. Under each experimental condition, the AUC was calculated for the same 
time (1080 seconds) following Na+/NMDG replacement. Data are mean±SEM, 
*p<0.01 comparing tat-CBD3-, tat-CBD3 A6K- and vehicle-treated neurons. N=4 
separate, individual experiments with each condition; total number of analyzed 
neurons is 404.  
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Tat-scramble peptide and CBD3 alone were without effect (Fig. 24D,E). Figure 
24F shows a summary of the data, expressed as average AUC, obtained with  
Na+/NMDG-induced increases in cytosolic Ca2+ and the effects of various 
peptides. These data suggest that tat-CBD3 inhibits NCXrev. 
To further investigate NCXrev activity we used electrophysiology. Since 
Na+/Ca2+ exchange is electrogenic, it is possible to record ion currents mediated 
by NCX (Kimura et al., 1986; Mechmann & Pott, 1986). This approach was first 
used in experiments with cardiomyocytes (Convery & Hancox, 1999; Smith et al., 
2006) but as also been adapted to neurons in culture (Brustovetsky et al., 2011; 
Brittain et al., 2012a; Brittain et al., 2012b). The exchange of Na+ for Ca2+ results 
in a net outward current, which can be used as a measure of NCXrev activity 
(Brittain et al., 2012b). In Fig. 21A we used Ni2+, an NCX inhibitor (Convery & 
Hancox, 1999; Smith et al., 2006), as a positive control. Application of 5mM Ni2+ 
significantly decreased (by 62 ± 7%, N=5) the peak ion current generated by the 
voltage ramp, which indicates that the current is predominantly mediated by 
NCXrev. Tat-CBD3 (10μM), but not tat-scramble (10μM), applied to neurons for 5 
minutes, also significantly attenuated the peak ion current (by 53±6%, N=5), this 
suggests that CRMP2 regulates NCXrev activity (Fig. 25B,C). Peak currents are 
summarized in Fig. 25D. These data further suggest that tat-CBD3 decreases 
NCXrev. 
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Figure 25. Ni2+ and tat-CBD3, but not tat-scramble peptide, suppress ion 
currents mediated by NCXrev. In A, the ascending voltage ramp protocol 
employed in these experiments and current traces obtained in the absence 
(black and blue) and in the presence of 5 mM Ni2+ (green) applied to neurons 2 
minutes prior to the voltage ramp. In B and C, current traces obtained with 
untreated neurons (black and blue) and neurons treated with either 10μM tat-
CBD3 (B, red trace) or 10μM tat-scramble (C, orange trace) applied 5 minutes 
prior to the voltage ramp. In D, the summary graph shows changes in the peak 
ion current under different conditions. *p<0.05 compared to vehicle-treated cells 
(vehicle). N=5. Kindly provided by Xiao-Fang Yang, Khanna Laboratory. 
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f. CRMP2 directly interacts with NCX3 and tat-CBD3 strengthens this 
interaction 
To examine how CRMP2 regulates NCX activity and because CRMP2 has 
been shown to interact with CaV2.2 (Brittain et al., 2011b) and NMDAR (Fig. 22) 
we asked if CRMP2 also interacts with NCX. We used co-IP experiments to 
investigate an interaction.  
We found no evidence for interaction of NCX1 with CRMP2 (Fig. 26A). 
However, CRMP2 did co-immunoprecipitate with NCX3 (Fig. 26B, C), suggesting 
a physical interaction between these proteins. Surprisingly, application of tat-
CBD3 increased the interaction between CRMP2 and NCX3 interaction instead 
of disrupting an interaction. Tat-scramble was without effect (Fig. 26C). These 
data suggest that CRMP2 interacts with NCX3 and could regulate NCX activity. 
 
g. Increased interaction between NCX and CRMP2 leads to NCX3 
internalization 
In Figure 22, we showed that tat-CBD3 disrupts the interaction between 
CRMP2 and NMDAR. NMDAR interaction did not alter NMDAR surface 
expression. Surprisingly, application of tat-CBD3 enhanced the interaction 
between CRMP2 and NCX3. Therefore, we asked if the increased interaction of 
CRMP2 and NCX3 caused an increase in NCX3 surface expression. We used 
immunocytochemistry experiments to examine the expression of NCX3. Neurons 
were treated and then analyzed using confocal microscopy. Figure 27 shows 
representative inverted fluorescent images and fluorescence intensity profiles for 
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the respective images. In vehicle-treated neurons, NCX3 was found to be 
localized in both plasma membrane and to a lesser extent in the cytoplasm (Fig. 
27A,B). The cytoplasmic localization of NCX3 most likely reflects a pool of 
internalized NCX. The specificity of the anti-NCX3 antibody used in these 
experiments is demonstrated in the inset of Fig. 27A. This selectivity assures that 
immunostaining shown in Fig. 27A,C,E is exclusively due to NCX3.  
Interestingly, we found that treatment with tat-CBD3 lead to internalization 
of NCX3, resulting in a decreased expression in the plasma membrane (Fig. 
27C,D). Tat scramble did not change NCX3 localization (Fig. 27E,F). These data 
suggest that increased interaction between CRMP2 and NCX3 leads to 
internalization. 
 
h. CRMP2 is necessary for tat-CBD3 induced internalization of NCX3 and 
inhibition of NCXrev 
The internalization of NCX3 induced by tat-CBD3 likely explains the 
decrease in NCXrev activity following pre-incubation with tat-CBD3. Next we 
asked if CRMP2 was required for NCX3 internalization. To examine the link 
between CRMP2 and tat-CBD3-triggered NCX3 internalization, we 
downregulated CRMP2, using siRNA. Neurons were transfected during plating 
with both a GFP construct and siRNA against CRMP2. Neurons expressing GFP 
had an almost complete lack of CRMP2 (Fig. 28A-D). In all analyzed neurons 
(N=21), expression of GFP corresponded with significant CRMP2 
downregulation.   
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Figure 26. CRMP2 co-immunoprecipitates with NCX3, but not with NCX1. 
Tat-CBD3 strengthens CRMP2-NCX3 interaction. In A, immunoprecipitation 
was performed with IgG or anti-CRMP2 antibody followed by western blotting 
with anti-NCX1 antibody. In B, immunoprecipitation was performed with IgG or 
anti-NCX3 antibody followed by western blotting with anti-CRMP2 antibody. In C, 
prior to immunoprecipitation, where indicated, neurons were incubated either with 
10μM tat-CBD3 or 10μM tat-scramble peptide for 10 minutes. Each experiment 
was repeated three times.  
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Figure 27. 
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Figure 27. Tat-CBD3 triggers NCX3 internalization. In A, C, and E, confocal, 
inverted fluorescence images of representative neurons stained with anti-NCX3 
antibody. In B, D, and F, fluorescence intensity profiles for straight lines in panels 
A, C, and E, respectively. N=3 separate, individual experiments. Total number of 
analyzed neurons is 59 (vehicle-treated), 65 (tat-CBD3-treated) and 51 (tat-
scramble-treated). The Inset in A shows western blot produced with cell lysate 
and anti-NCX3 antibody (provided by Drs. Kenneth Philipson and Michela Ottolia, 
UCLA ) to illustrate antibody specificity. Scale bars are 15 μm.  
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We compared NCX3 expression in non-transfected with transfected cells. NCX3 
expression pattern did not differ regardless of transfection (Fig. 28E-H and I,L). 
Importantly, pre-treatment with tat-CBD3 did not induce internalization of NCX3 
in neurons with downregulated CRMP2 (Fig. 28 I-L). Furthermore, GFP 
transfection alone (Fig. 29) did not alter CRMP2 expression. 
Next, we asked if CRMP2 is required tat-CBD3 inhibition of NCXrev activity. 
We investigated this by downregulating CRMP2 and inducing NCXrev. Application 
of tat-CBD3 robustly attenuated NCXrev in neurons with CRMP2 (black traces, 
Fig. 30E) but not in neurons with downregulated CRMP2 (Fig. 30B, green trace, 
Fig. 30E). The results of these experiments taken together suggest that CRMP2 
is necessary for tat-CBD3-induced internalization of NCX3 and subsequent 
inhibition of NCXrev. 
 
i. NCXfor is decreased by tat-CBD3 application 
 Our data show that the increased CRMP2 association with NCX3 
correlates with tat-CBD3-induced NCX3 internalization and subsequent inhibition 
of NCXrev. Internalization of NCX3 should, in addition to inhibition of NCXrev 
activity, also decrease NCXfor. To test this hypothesis, we treated neurons with 
ionomycin (5μM), a Ca2+ ionophore. Ionomycin caused delayed Ca2+ 
dysregulation in neurons (Fig. 31A), demonstrating that neurons effectively fight 
against elevations in cytosolic Ca2+. NCXfor cannot function in the absence of 
external Na+ (Annunziato et al., 2004).  
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Figure 28. CRMP2 downregulation prevents tat-CBD3-induced NCX3 
internalization. Neurons were transfected during plating with a GFP construct 
and siRNA against CRMP2. In A-C, a representative experiment is shown: A – 
bright field, B – GFP fluorescence, C – CRMP2 immunostaining. In this 
experiment, neuron without GFP has robust CRMP2 expression whereas neuron 
with GFP fluorescence demonstrates significantly decreased CRMP2 expression 
(marked by arrow). In D, a summary of CRMP2 expression measurements based 
on fluorescence intensity measurements. The fluorescence measurements were 
performed in somata of individual neurons, using 3x3μm region of interest. The 
fluorescence intensity is expressed in arbitrary units (a.u.). The data are 
mean±SEM, N=21. In E-G, a representative experiment without tat-CBD3 pre-
treatment is shown: E – bright field, F – GFP fluorescence, G – NCX3 
immunofluorescence (inverted). In H, fluorescence intensity profile for a straight 
line in panel G. In these experiments, 18 cells were analyzed; each cell had a 
similar pattern of NCX3 distribution. In I-K, a representative experiment with 
10μM tat-CBD3 pre-treatment for 10 minutes: I – bright field, J – GFP 
fluorescence, K – NCX3 immunofluorescence (inverted). In L, fluorescence 
intensity profile for a straight line in panel K. In these experiments, 24 cells were 
analyzed; each cell had a similar pattern of NCX3 distribution. Scale bars are 15 
μm.  
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Figure 29. GFP transfection does not alter CRMP2 expression. Neurons 
were transfected during plating with a GFP construct. In A, a representative 
bright field, B, GFP fluorescence, and C, CRMP2 immunostaining. In this 
experiment, the neuron expressing GFP has robust CRMP2 expression similar to 
those without GFP expression. In D, a summary of CRMP2 expression 
measurements based on fluorescence intensity measurements. The 
fluorescence measurements were performed in somata of individual neurons, 
using 3x3μm region of interest. The fluorescence intensity is expressed in 
arbitrary units (a.u.). The data are mean±SEM, N=3. Scale bars are 15 μm 
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Figure 30.  
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Figure 30. CRMP2 downregulation strongly attenuates tat-CBD3-induced 
inhibition of NCXrev. Neurons, transfected during plating with a GFP construct 
and siRNA against CRMP2, were loaded with Fura-2FF-AM. In A-E, a 
representative experiment is shown: A – bright field, B – GFP fluorescence, C – 
pseudocolored image of Fura-2FF F340/F380 ratio taken prior to Na+/NMDG 
replacement at 300 second, D – pseudocolored image of Fura-2FF F340/F380 
ratio taken after Na+/NMDG replacement at 1500 second, E – changes in 
cytosolic Ca2+ concentration over time in the same experiment. Where indicated, 
neurons were treated with 10μM tat-CBD3 for 10 minutes. The bath solution was 
supplemented with 5μM nifedipine, 1μM TTX, and 20μM AP-5. In addition, 
neurons were pre-incubated for 10 minutes with 1 mM ouabain prior to 
Na+/NMDG replacement. Ouabain remained in the bath solution throughout the 
experiment. In A-D, arrows indicate a neuron that expresses GFP and has 
downregulated CRMP2. In E, green trace shows fluorescent signal from this 
neuron whereas black traces show fluorescent signals from other neurons in the 
field. In F, the summary graph shows the average area under the curve (AUC; 
a.u., arbitrary units) that represents a measure of [Ca2+]c increase over time. 
Under each experimental condition, the AUC was calculated for the same time 
(900 seconds) following Na+/NMDG replacement. Data are mean±SEM, *p<0.01 
comparing siRNA-transfected (siRNA) and non-transfected (NT) neurons. N=3 
separate, individual experiments; total number of analyzed neurons is 57. Scale 
bar in panel A is 30 μm and is applicable to panels A-D. 
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Therefore, to demonstrate the role of NCXfor in ionomycin-induced Ca2+ increase, 
we inhibited NCXfor activity by removing external Na+ and replacing it with 
equimolar NMDG. This protocol differs from that used in Figure 23 by omitting 
ouabain from the bath solution. Cytosolic Na+ remained low, so Na+/NMDG 
replacement did not cause an increase in cytosolic Ca2+. 
These experiments were also performed in the presence of the NMDAR 
antagonist AP-5 (20μM), to exclude any contribution by NMDARs in ionomycin-
induced Ca2+ increase. The removal of external Na+ significantly accelerated the 
onset of ionomycin-induced Ca2+ dysregulation, illustrating a key role for NCXfor 
in maintaining low cytosolic Ca2+ (Fig. 31B). Treatment with tat-CBD3 
significantly accelerated Ca2+ dysregulation in neurons treated with ionomycin 
(Fig. 31C). These data were quantified by measuring the time from the beginning 
of ionomycin application to the onset of Ca2+ dysregulation (tdys) (Fig. 31D). A 
similar approach has previously been used to provide analysis of glutamate-
induced Ca2+ dysregulation (Brustovetsky et al., 2009; Li et al., 2009). These 
data, summarized in Fig. 27D, show that -Na+/NMDG+ replacement and tat-
CBD3 treatment significantly accelerated the onset of Ca2+ dysregulation in 
neurons. These observations suggest that tat-CBD3 decreases NCX activity, 
regardless of the mode of operation, likely due to increased interaction between 
CRMP2 and NCX3 and subsequent NCX3 internalization. 
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Figure 31. Tat-CBD3 inhibits the forward mode of NCX. Neurons were loaded 
with Fura-2FF. In A, 5μM ionomycin in combination with 20μM AP-5 was applied 
to neurons. Where indicated, neurons were subjected to Na+/NMDG replacement 
(B) or treated with 10μM tat-CBD3 (C) for 10 minutes prior to addition of 
ionomycin. In D, the summary graph shows the time from the beginning of 
ionomycin application to the onset of Ca2+ dysregulation (tdys) that reflects NCXfor 
activity. Data are mean±SEM, *p<0.01 comparing the effect of Na+/NMDG 
replacement, tat-CBD3- and vehicle-treated neurons; N=5 separate, individual 
experiments; total number of analyzed neurons is 101.  
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j. CRMP2 expression is not altered in striata from YAC128 mice and CRMP2 
does not interact with Htt or mHtt 
 Based on our findings that NMDAR and NCX are regulated by CRMP2, 
we next asked if CRMP2 expression is altered in YAC128 animals. We 
hypothesized that alteration in CRMP2 expression could alter NCXfor activity, 
leading to faster DCD (as demonstrated in Fig. 15). We used Western blotting to 
probe for CRMP2. We assessed CRMP2 protein levels in striatal lysate from both 
3-week and 3-month-old mice. We found that CRMP2 expression is not altered in 
striata from either age WT mouse compared with age-matched YAC128 mice 
(Fig. 32). We showed that alterations in CRMP2 interaction (decreased, Fig. 18 
or increased, Fig. 26) with NMDAR and NCX3 could regulate their activity. 
Therefore, we asked if mHtt interacts with CRMP2. We hypothesized that mHtt 
could compete with other CRMP2 interacting partners interfering with their 
interaction with CRMP2. We also investigated the interaction between WT Htt 
and CRMP2. The interaction between either form of Htt and CRMP2 using co-IP 
appeared to be below the limit of co-IP resolution (Fig. 32E). These data suggest 
that CRMP2 expression most likely is not altered by mHtt and that Htt, WT or 
mutant, may not interact with CRMP2. However, CRMP2 shares many common 
binding partners with mHtt and Htt. It is possible that CRMP2 does not directly 
interact with Htt or mHtt, but they interact with the same protein or proteins or as 
part of a complex. It is also possible that an interaction exists, but it is very weak, 
and is not captured using this methodology. Given these data, however, CRMP2 
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may not be involved in the increase in glutamate-induced DCD observed in 
Figure 15. 
 
k. NCX3 interacts with mHtt and Htt 
We showed in Figure 31 that increased CRMP2 interaction with NCX3 
correlates with NCX3 internalization and decreased activity in both the reverse 
and forward modes. Using this model of NCX regulation, we asked if WT Htt or 
mHtt interacted with NCX1 or NCX3. We found that NCX1 did not interact with 
either form of Htt (Fig. 33 A). Interestingly, we found that NCX3 interacts with 
both WT Htt and mHtt (Fig. 33 B, C enlarged). An interaction has not been 
previously reported between Htt or mHtt and NCX3. These novel interactions 
could be responsible for additional regulation of NCX, but require further 
investigation. 
 128 
WT
YAC
128
0
25
50
75
100
125
150 3 wk
C
R
M
P2
/ -
ac
tin
 (%
 o
f W
T)
WT
YAC
128
0
25
50
75
100
125
150 3 mo
C
R
M
P2
/ -
ac
tin
 (%
 o
f W
T)
A
DC
B
E
 
 
Figure 32. Expression of CRMP2 in striata from 3-week and 3-month-old 
YAC128 and WT mice. In A, Western blots of lysate from striata from 3-week-old 
(A,C) YAC128 and WT mice with anti-CRMP2 antibody. Lysate from striata from 
3-month-old (B,D) YAC128 and WT mice are show in B. β-actin was used as a 
loading control. In C and D, statistical analysis of Western blot densitometry with 
data expressed as a percentage of WT. Data are mean±SEM, N=3. In E, 
immunoprecipitation was performed with IgG or anti-CRMP antibody followed by 
Western blotting with 2166 antibody, which recognizes both Htt and mHtt. 
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Figure 33. Htt and mHtt co-immunoprecipitate with NCX3, but not with 
NCX1. In A, immunoprecipitation was performed with IgG or anti-NCX1 antibody 
followed by Western blotting with 2166 antibody, which recognizes both Htt and 
mHtt. In B, immunoprecipitation was performed with IgG or anti-NCX3 antibody 
followed by Western blotting with 2166 antibody. In C, a portion of B enlarged for 
better visualization of the bands corresponding with mHtt and Htt. 
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IV. DISCUSSION AND CONCLUSIONS  
a.  Mitochondrial Ca2+ uptake capacity is not decreased by mHtt 
 In earlier studies, mitochondrial dysfunction and a decreased ability of 
mitochondria to accumulate Ca2+ had been proposed to contribute to HD 
pathogenesis (Panov et al. 2002; Choo et al. 2004). In experiments with non-
synaptic mitochondria, we and other investigators failed to find an increase in 
sensitivity to deleterious Ca2+ and instead observed an increase in resistance to 
Ca2+ that was manifested in reduced propensity to PTP induction and augmented 
Ca2+ uptake capacity (Brustovetsky et al., 2005).  
 In the current work, we demonstrated that both synaptic and non-synaptic 
mitochondria isolated from YAC128 mice retain their ability to accumulate Ca2+ 
compared with mitochondria from WT animals. Moreover, synaptic mitochondria 
from 12-month-old YAC128 mice had larger Ca2+ uptake capacity compared with 
mitochondria from WT littermates and this correlated with an increased amount 
of mHtt associated with these mitochondria.  
 However, mHtt failed to reduce Ca2+ uptake capacity in brain mitochondria 
from YAC128 mice. On the contrary, the level of mHtt binding to mitochondria 
positively correlates with mitochondrial resistance to deleterious Ca2+. In our 
experiments, we found that BSA increased Ca2+ uptake capacity of brain 
mitochondria isolated from both YAC128 mice and their WT littermates.  
 It is known that ROS production by mitochondria, oxidizing succinate, 
depends on the reverse electron flow in the mitochondrial electron transport 
chain that brings electrons back to Complex I. The reverse electron flow, in turn, 
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depends on mitochondrial membrane potential: hyperpolarization leads to an 
increase in reverse electron flow and, subsequently, to elevated ROS production 
(Korshunov et al., 1998; Korshunov et al., 1997). It is established that ROS 
increase propensity to PTP induction in mitochondria (Zoratti & Szabo, 1995). 
However, it is also known that free fatty acids (FFA) increase propensity of PTP 
induction as well (Zoratti & Szabo, 1995). BSA binds FFA (Spector, 1975) and 
exerts a strong protective effect against PTP (Wieckowski et al., 2000).  
 Based on these observations, our data concerning BSA effects suggest 
that the protective action of BSA prevails over deleterious effect of augmented 
ROS generation. Panov et al. (2003) reported that ‘the defect in Ca2+ handling in 
brain mitochondria was consistently observed only if brain mitochondria were 
isolated without BSA’. The authors presumed that BSA could displace mHtt from 
its binding sites on mitochondria. Our data do not support this hypothesis. We 
found that mHtt is associated with mitochondria, consistent with previous reports 
(Choo et al. 2004), but BSA does not displace mHtt from mitochondria. 
  In a previous study in our laboratory, we did not observe an increased 
predisposition to Ca2+-induced PTP induction in striatal and cortical non-synaptic 
mitochondria from HD mice compared with mitochondria from WT littermates 
(Brustovetsky et al., 2005). On the contrary, we found increased resistance to 
Ca2+ in striatal mitochondria exposed to mHtt. Other researchers also reported 
that non-synaptic mitochondria from R6/2 and YAC128 mice had increased Ca2+ 
uptake capacity compared with mitochondria from WT animals. Both our study 
(Brustovetsky et al., 2005) and a study by Oliveira et al. (2007) suggested the 
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lack of mHtt-induced impairment of mitochondrial Ca2+ handling, argued against 
facilitation of PTP induction by mHtt, and did not support involvement of PTP in 
HD pathogenesis.  
In our study, we did not find evidence of impaired Ca2+ uptake capacity in 
either synaptic or non-synaptic mitochondria from YAC128 mice. On the contrary, 
both types of mitochondria had increased Ca2+ capacity, especially, synaptic 
mitochondria from 12-month-old YAC128 mice. The mechanism underlying 
augmented Ca2+ uptake capacity of mitochondria that are associated with 
increased levels of mHtt remains unknown. At the moment, we can only 
speculate about a possible scenario. Mitochondrial Ca2+ uptake capacity mainly 
depends on the ability of mitochondria to resist an induction of the PTP 
(Chalmers and Nicholls 2003). Induction of the PTP causes mitochondrial 
depolarization that precludes further Ca2+ uptake and results in a release of 
previously accumulated Ca2+ (Rasola & Bernardi 2011).  
FFA are effective activators of PTP (Zoratti and Szabo 1995) and FFA 
binding by BSA most likely underlies BSA-mediated protection against PTP 
induction (Wieckowski et al. 2000). In our experiments, BSA significantly 
increased Ca2+ uptake capacity of synaptic and non-synaptic mitochondria from 
2-month-old FVB/NJ, YAC18, and YAC128 mice. Furthermore, in experiments 
with 12-month-old mice, we found that BSA significantly increased Ca2+ uptake 
capacity of mitochondria from FVB/NJ mice, but was ineffective in mitochondria 
from YAC128 mice. Keeping in mind the increased amount of mHtt associated 
with mitochondria from 12-month-old YAC128 mice and elevated Ca2+ uptake 
 133 
capacity in these mitochondria, the lack of further augmentation with BSA 
suggests that mHtt and BSA effects may have a similar mechanism, for example, 
binding of FFA. Although additional experiments are necessary to test this 
hypothesis and untangle the potential mechanism of FFA binding to mHtt, 
existing literature lends support to this notion.  
The increased Ca2+ uptake capacity of mitochondria from YAC128 mice 
may reflect compensatory adaptation to augmented Ca2+ influx via over-activated 
NMDA receptors and/or increased Ca2+ release from endoplasmic reticulum via 
abnormally activated IP3 receptors (Bezprozvanny and Hayden 2004). Similar to 
findings by Chang et al. (2006) and Wang et al. (2013), in experiments with 
cultured striatal neurons from YAC128 mice and WT littermates, we did not find 
evidence of the decreased ability of neuronal mitochondria to accumulate Ca2+. 
Consequently, comparable susceptibility to PTP induction and the lack of mHtt-
induced deficiency in mitochondrial Ca2+ uptake capacity in mitochondria from 
YAC128 and WT mice argue against possible involvement of these mechanisms 
in HD pathogenesis. 
 
b. Striatal neurons from YAC128 are more sensitive to glutamate than 
neurons from WT mice 
 In HD, the striatum is the most vulnerable brain region (Vonsattel & 
DiFiglia, 1998; Bates et al., 2002; Walker & Raymond, 2004; Li et al., 2014). 
Striatal atrophy also occurs in most mouse models of HD ((Bates et al., 2002; 
Slow et al., 2003; Ramaswamy et al., 2007). In our experiments, we found that 
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striatal neurons in culture are more sensitive to glutamate than cultured cortical 
neurons. This is in agreement with the striatal vulnerability seen in HD patients 
and mouse models. The mechanism responsible for the increased vulnerability in 
striatum is not known. Other investigators have shown increased NR2B 
expression in striatum compared with other brain regions (Li et al., 2003). NR2B 
subunits of NMDAR are linked to cell death compared with NR2A, making 
increased expression a conceivable reason for increased sensitivity. 
 Consistent with previous findings, striatal neurons from YAC128 mice 
underwent DCD more quickly (reaching phase 3) than neurons from WT animals. 
Interestingly, no difference was seen in NMDA-induced Ca2+ influx. This is likely 
because the Ca2+ influx from a 30 second application of NMDA can be removed 
from the cytosol by Ca2+ removal mechanisms. Increased Ca2+ influx may occur, 
but there is no additional increase in the total cytosolic Ca2+ concentration due to 
the efficacy of the removal mechanisms. This may suggest some compensation 
by these mechanisms to maintain tight control on cytosolic Ca2+ concentration 
 Application of glutamate to cultured striatal neurons from YAC128 mice to 
‘load’ neuronal mitochondria, showed that mitochondria accumulated similar 
amounts of Ca2+ compared with mitochondria in striatal neurons from WT 
animals. This data supports but does not match the isolated mitochondria data. 
There could be multiple reasons for this. Most likely, in isolated mitochondria 
experiments no other Ca2+ removal mechanisms present therefore only 
mitochondrial Ca2+ is observed. However, in the presence of high and low 
capacity mechanisms for Ca2+ regulation, the mitochondria have assistance in 
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Ca2+ removal and control. Furthermore, we found that mHtt association with 
isolated mitochondria increased with age. Primary neurons in culture are DIV 10-
13 from PN1 mice, therefore they do not likely have the increased levels of mHtt 
seen associated with mitochondria from older animals. 
 
c. NCX1 expression is increased in striatal lysate from older YAC128 mice 
 The contribution of NCX to Ca2+ homeostasis in HD deserves additional 
investigation. We found augmented basal cytosolic Na+ concentrations in striatal 
neurons from YAC128 mice compared with WT. This was a slight but statistically 
significant increase which could suggest a few different scenarios. One possibility 
is that the increased striatal sensitivity to glutamate requires frequent action of 
NCXfor resulting in increased intracellular Na+ concentrations. Another possibility 
is that another mechanism, an ion channel or exchanger, is not operating 
properly and is allowing influx of Na+. This could result in an increased propensity 
for NCX reversal. Since NCXrev is a major contributor to DCD, high Na+ levels 
could lead to aberrant NCXrev and Ca2+ dysregulation. It is also possible that the 
increased Na+ concentration is not great enough to have a physiological 
consequence. Further investigation of NCX actvity in both the forward and 
reverse modes in neurons expressing mHtt should be done to better understand 
the possible effect of mHtt on NCX activity.  
 We found increased NCX1 expression in striatal lysate from 3-month-old 
YAC128 mice compared with WT. This could suggest upregulation due to 
compensation for increased Ca2+ influx. Transcriptional regulation has been 
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shown to be altered by mHtt which could potentially explain the upregulation 
(Hogel et al., 2012). Another possiblity is that NCX1 upregulation is 
compensatory for aberrant Ca2+ signalling. In ischemic preconditioning studies, 
upregulation of both NCX1 and NCX3 bas been observed, and the upregulation 
correlated with neuroprotection (Pignataro et al., 2013). Interestingly, NCX3 
expression is unchanged. Further experiments are required to understand the 
increased expression of NCX1 with age in striata expressing mHtt, as well as the 
differential expression between the subtypes in a mouse model of HD.  
 NCX3 and CRMP2 interaction may also contribute to NCX1 upregulation. 
CRMP2, mHtt, and Htt interact with NCX3 but not NCX1. These interacting 
proteins (or others) may regulate NCX3 localization and expression. It is 
conceivable that mHtt leads to increased CRMP2 binding to NCX3, leading to 
internalization. Furthermore, the localization of NCX1 should be investigated. If 
NCX1 in HD is intrenalized instead of localized to the plasma membrane, this 
could suggest that the increased expression is not altering function. 
Electrophysiology should be done to study the activity of NCX in striatal neurons 
from HD mouse models. These experiments were attempted with Ca2+ imaging 
but the number of manipulations required made the data difficult to interpret.  
 
d. CRMP2 regulates NMDAR and NCX 
Sustained elevations in cytosolic Ca2+ play a causative role in glutamate-
induced neuronal death. Elevated cytosolic Ca2+ activates Ca2+-dependent 
degradation enzymes, such as proteases and phospholipases, and thus hastens 
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cell death (Bano et al., 2005; Farooqui et al., 2006; Brustovetsky et al., 2010). 
Therefore, it is vitally important for neurons to remove excessive Ca2+ elevations 
and maintain low cytosolic Ca2+. In neurons, Ca2+ extrusion by NCXfor and Ca2+ 
uptake by mitochondria are major mechanisms that antagonize Ca2+ increases in 
the cytosol. Mitochondria may accumulate substantial amounts of Ca2+ before 
they undergo permeability transition and become damaged (Chalmers & Nicholls, 
2003). Following Ca2+-dependent activation of the permeability transition pore, 
mitochondria lose the ability to accumulate Ca2+ and, subsequently, release 
previously accumulated Ca2+ (Bernardi, 1999). Thus, although mitochondria can 
accumulate large amounts of Ca2+, their Ca2+ uptake capacity is finite. On the 
other hand, the amount of Ca2+ in the extracellular milieu is practically infinite, 
and consequently, attenuation of Ca2+ influx into neurons could be a much more 
effective strategy in neuronal defense against glutamate-induced Ca2+ 
dysregulation.  
Ca2+ influx via NMDAR and NCXrev are two major mechanisms of Ca2+ 
entry into neurons exposed to glutamate (Tymianski et al., 1993b; Czyz & 
Kiedrowski, 2002). Recently, we demonstrated that both mechanisms have to be 
suppressed to prevent glutamate-induced Ca2+ dysregulation (Brittain et al., 
2012b). Tat-CBD3 strongly attenuates glutamate-induced Ca2+ dysregulation. 
Based on these observations, we hypothesized that tat-CBD3 should inhibit both 
NMDAR and NCXrev. The results presented in this study strongly support this 
hypothesis and link NMDAR and NCX activity to CRMP2 signaling.  
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CRMP2 is a member of the CRMP protein family originally known as an 
axon guidance and outgrowth regulator (Schmidt & Strittmatter, 2007; Hensley et 
al., 2011; Khanna et al., 2012). CRMP2 is cleaved by calpain following focal 
ischemia, thereby implicating it in neurotoxicity associated with ischemia (Bretin 
et al., 2006). It appears that cleaved CRMP2 is neuroprotective, whereas 
cleavage of CRMP3 and CRMP4 is detrimental for neurons (Kowara et al., 2005; 
Bretin et al., 2006; Liu et al., 2009) . CRMP2 physically interacts with numerous 
proteins in the cell, including NMDAR and CaV2.2. It has been shown that tat-
CBD3 disrupts interaction of CRMP2 with CaV2.2, leading to its internalization 
and a decrease in ion currents mediated by this channel (Brittain et al., 2011b). 
In a previous paper from our laboratory, using a pH-sensitive fluorescent NR2B 
sensor, we showed that tat-CBD3 decreases surface expression of NMDAR in 
dendritic spines (Brittain et al., 2011a), but it remained unclear whether tat-CBD3 
disrupts a CRMP2-NMDAR interaction. It was also unknown whether CRMP2 
interacts with NCX and whether tat-CBD3 affects NCXrev activity. In these 
studies, we demonstrate for the first time that CRMP2 physically interacts with 
NCX3 and that tat-CBD3 strengthens this interaction, triggers NCX3 
internalization, and consequently suppresses NCX activity in both forward and 
reverse modes. In contrast to strengthening the CRMP2-NCX3 complex, tat-
CBD3 disrupted CRMP2-NMDAR interaction, suggesting different mechanisms 
by which CRMP2 interacts with NMDAR and NCX3.  
Although NCX3 internalization may account for the suppression of NCX 
activity, the mechanism of NCX3 internalization and the role of tat-CBD3-
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augmented CRMP2-NCX3 interaction in this process are not clear. It is 
conceivable that tat-CBD3 competes with CRMP2 for binding with other proteins 
(e.g. CaV2.2 (and NMDAR)) and releases CRMP2 from complexes with these 
proteins. If so, then the liberated CRMP2 may bind to other proteins (e.g. NCX3) 
possibly via a different binding site, with which tat-CBD3 does not interfere. 
Overall, this may lead to CRMP2 redistribution and increased binding to NCX3. 
That NCX3 internalization is no longer induced by tat-CBD3 in CRMP2- ablated 
neurons suggests a causative link between increased CRMP2 association with 
NCX3 and NCX3 internalization. However, additional experiments are necessary 
to completely prove this hypothesis.  
One of the goals of our study was to test the hypothesis that tat-CBD3 
inhibits deleterious NCXrev, which, instead of extruding Ca2+ from the cell, causes 
Ca2+ influx (Kiedrowski et al., 1994). Our results strongly support this hypothesis. 
However, our study also revealed an unexpected consequence of tat-CBD3 
treatment. Because tat-CBD3 triggers NCX internalization, it suppresses both 
forward and reverse modes of NCX. However, NCXfor is critical for mitigating 
increases in cytosolic Ca2+ and, thus, maintaining cytosolic Ca2+ at the low, 
physiological level. Consequently, suppression of NCXfor should be detrimental 
for the cell. The question remains, how then can one reconcile this, given tat-
CBD3-mediated protection against glutamate-induced Ca2+ dysregulation? A 
likely explanation is that tat-CBD3-induced inhibition of NMDAR plays the 
dominant role in this protection. The significantly lower Ca2+ influx via NMDAR 
creates conditions in which, despite suppression of NCXfor, cytosolic Ca2+ 
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remains at a low level. Mitochondrial Ca2+ uptake and Ca2+ extrusion by plasma 
membrane Ca2+-ATPase might also contribute to keeping cytosolic Ca2+ low 
under these conditions. However, as we reported earlier, inhibition of NMDAR 
alone is not sufficient to prevent glutamate-induced Ca2+ dysregulation. 
Suppression of NCXrev, in addition to NMDAR, is critical for maintaining low 
cytosolic Ca2+ following exposure to glutamate (Brittain et al., 2012b). Our 
present study unequivocally demonstrates that tat-CBD3 inhibits both NMDAR 
and NCXrev, hence filling a significant gap in our understanding of the mechanism 
of TAT-CBD3-mediated neuroprotection. Thus, a sum of the tat-CBD3 inhibitory 
effects on NMDAR and NCXrev collectively results in a net protection against 
glutamate-induced Ca2+ dysregulation.  
For the first time we demonstrated a link between CRMP2 signaling, 
NMDAR and NCX3 activities, and maintenance of Ca2+ homeostasis in neurons 
exposed to excitotoxic levels of glutamate. Our experiments revealed that 
CRMP2 physically interacts with both NMDAR and NCX3. Moreover, we showed 
that TAT-CBD3 strengthens CRMP2-NCX3 interaction and induces NCX3 
internalization, leading to suppression of NCX activity. Concomitantly, tat-CBD3 
disrupts the CRMP2-NMDAR interaction without detectable relocalization of 
NMDAR. Nevertheless, this also leads to suppression of NMDAR activity. Thus, 
our study implicates CRMP2 signaling in regulation of cytosolic Ca2+ in neurons 
exposed to glutamate, suggests different mechanisms of CRMP2 interaction with 
NMDAR and NCX, and further clarifies the mechanism of tat-CBD3-mediated 
defense against glutamate-induced Ca2+ dysregulation. Our experiments with tat-
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CBD3 provide further support to our hypothesis that inhibition of both NMDAR 
and NCXrev is essential for robust attenuation of glutamate-induced Ca2+ 
dysregulation. Overall, the new knowledge obtained in our study could be 
instrumental in designing new neuroprotective agents and in a better 
understanding of the mechanisms of their action.  
 
e. Possiblity for CRMP2 modulation in HD 
CRMP2 expression was not found to change in HD models. We were 
unable to show an interaction between CRMP2 and Htt or mHtt but this does not 
mean that no interaction exists. Perhaps the interaction is weak or transient and 
is unable to be detected in co-IP experiments. It is also possible that CRMP2 and 
mHtt or Htt may both interact with another protein. For example, both CRMP2 
and mHtt interact with tubulin. PSD-95 or another scaffold protein may participate 
in a complex. CRMP2 and PSD-95 both interact with NMDAR and mHtt has been 
shown to modulate NMDAR via PSD-95 (Sun et al., 2001; Harjes & Wanker, 
2003; Fan et al., 2009). Further investigation should be done to further 
understand the implications of CRMP2 modulation of NMDAR in the presence of 
mHtt. CRMP2 is a phosphoprotein and phosphorylation of CRMP2 modulates its 
activity. It is conceivable that the phosphorylation state of CRMP2 may be altered 
in neurons expressing mHtt. There are many avenues to further explore CRMP2 
in HD mouse models beyond expression levels and association with mHtt. 
CRMP2’s modulation of NMDAR makes it an attractive target in further 
understanding the mechanism of Ca2+ dysregulation in neurons expressing mHtt.  
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f. Conclusion 
Taken together, the increased Ca2+ uptake capacity of mitochondria from 
the YAC128 mouse model and the increased NCX1 expression correlated with 
increased age, suggest a compensation for increased Ca2+ influx or perhaps Ca2+ 
removal failure. This may explain the late onset of HD, neurons may compensate 
for sensitivity to glutamate  and subsequent increased cytosolic Ca2+ 
concentrations until the insult overcomes the compensation. The role of Ca2+ 
removal mechanisms and regulation should be investigated further in HD. 
Furthermore, CRMP2 modulation of NMDAR and NCX3 may be important 
in HD as well. Our experiments revealed that CRMP2 physically interacts with 
both NMDAR and NCX3, important in Ca2+ dysregulation. Disrupting the 
interaction between NMDAR and CRMP leads to decreased activity, whereas 
increased NCX3-CRMP2 interaction leads to internalization and decreased 
activity. A model of these interactions is shown in Figure 34. The novel regulation 
of Ca2+ homeostasis in neurons expressing mHtt could help better understand 
HD and lead to improved therapeutics. 
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Figure 34. Model of Ca2+ regulation in striatal neurons with and without the 
presence of mHtt. In WT neurons (A), in response to NMDAR activation results 
in Ca2+ influx through NMDAR associated with CRMP2. Mtc and NCX work to 
maintain Ca2+ homeostasis. Increased binding of CRMP2 to NCX3 causes 
internalization and inactivation. In the presence of mHtt (B), increased NMDAR 
activity results in greater increase in Ca2+ concentrations. To maintain Ca2+ 
homeostasis, Mtc Ca2+ uptake is increased and NCX1 expression is upregulated. 
 
 
A 
B 
 144 
Reference List 
 
Al-Hallaq RA, Conrads TP, Veenstra TD, & Wenthold RJ (2007). NMDA di-
heteromeric receptor populations and associated proteins in rat hippocampus. J 
Neurosci 27, 8334-8343. 
Ali NJ & Levine MS (2006). Changes in expression of N-methyl-D-aspartate 
receptor subunits occur early in the R6/2 mouse model of Huntington's disease. 
Dev Neurosci 28, 230-238. 
Anderson KE (2011). Huntington's disease. Handb Clin Neurol 100, 15-24. 
Andre VM, Cepeda C, Venegas A, Gomez Y, & Levine MS (2006). Altered 
cortical glutamate receptor function in the R6/2 model of Huntington's disease. J 
Neurophysiol 95, 2108-2119. 
Annunziato L, Pignataro G, & Di Renzo GF (2004). Pharmacology of brain 
Na+/Ca2+ exchanger: from molecular biology to therapeutic perspectives. 
Pharmacol Rev 56, 633-654. 
Arimura N, Menager C, Kawano Y, Yoshimura T, Kawabata S, Hattori A, Fukata 
Y, Amano M, Goshima Y, Inagaki M, Morone N, Usukura J, & Kaibuchi K (2005). 
Phosphorylation by Rho kinase regulates CRMP-2 activity in growth cones. Mol 
Cell Biol 25, 9973-9984. 
Arzberger T, Krampfl K, Leimgruber S, & Weindl A (1997). Changes of NMDA 
receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA 
expression in Huntington's disease--an in situ hybridization study. J Neuropathol 
Exp Neurol 56, 440-454. 
Ashizawa T, Wong LJ, Richards CS, Caskey CT, & Jankovic J (1994). CAG 
repeat size and clinical presentation in Huntington's disease. Neurology 44, 
1137-1143. 
Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, 
Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, & Ross CA (2004). Onset 
and rate of striatal atrophy in preclinical Huntington disease. Neurology 63, 66-
72. 
 145 
Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, 
Brunskill EW, Sayen MR, Gottlieb RA, Dorn GW, Robbins J, & Molkentin JD 
(2005). Loss of cyclophilin D reveals a critical role for mitochondrial permeability 
transition in cell death. Nature 434, 658-662. 
Balasuriya D, Takahashi H, Srivats S, & Edwardson JM (2014). Activation-
induced structural change in the GluN1/GluN3A excitatory glycine receptor. 
Biochem Biophys Res Commun 450, 1452-1457. 
Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, 
Carafoli E, & Nicotera P (2005). Cleavage of the plasma membrane Na+/Ca2+ 
exchanger in excitotoxicity. Cell 120, 275-285. 
Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, & Bernardi P (2005). 
Properties of the permeability transition pore in mitochondria devoid of 
Cyclophilin D. J Biol Chem 280, 18558-18561. 
Bates GP, Harper PS, & Jones L. Huntington's Disease.  2002.  Oxford 
University Press.  
Ref Type: Edited Book 
Baughman JM, Perocchi F, Girgis HS, Plovanich M, Belcher-Timme CA, Sancak 
Y, Bao XR, Strittmatter L, Goldberger O, Bogorad RL, Koteliansky V, & Mootha 
VK (2011). Integrative genomics identifies MCU as an essential component of 
the mitochondrial calcium uniporter. Nature 476, 341-345. 
Beal MF, Hyman BT, & Koroshetz W (1993). Do defects in mitochondrial energy 
metabolism underlie the pathology of neurodegenerative diseases? Trends 
Neurosci 16, 125-131. 
Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, & Martin JB (1986). 
Replication of the neurochemical characteristics of Huntington's disease by 
quinolinic acid. Nature 321, 168-171. 
Bernardi P (1999). Mitochondrial transport of cations: channels, exchangers, and 
permeability transition. Physiol Rev 79, 1127-1155. 
Bernardi P & Petronilli V (1996). The permeability transition pore as a 
mitochondrial calcium release channel: a critical appraisal. J Bioenerg Biomembr 
28, 131-138. 
 146 
Bezprozvanny I (2011). Role of inositol 1,4,5-trisphosphate receptors in 
pathogenesis of Huntington's disease and spinocerebellar ataxias. Neurochem 
Res 36, 1186-1197. 
Bezprozvanny I & Hayden MR (2004). Deranged neuronal calcium signaling and 
Huntington disease. Biochem Biophys Res Commun 322, 1310-1317. 
Bizat N, Hermel JM, Boyer F, Jacquard C, Creminon C, Ouary S, Escartin C, 
Hantraye P, Kajewski S, & Brouillet E (2003). Calpain is a major cell death 
effector in selective striatal degeneration induced in vivo by 3-nitropropionate: 
implications for Huntington's disease. J Neurosci 23, 5020-5030. 
Bjorkqvist M, Fex M, Renstrom E, Wierup N, Petersen A, Gil J, Bacos K, Popovic 
N, Li JY, Sundler F, Brundin P, & Mulder H (2005). The R6/2 transgenic mouse 
model of Huntington's disease develops diabetes due to deficient beta-cell mass 
and exocytosis. Hum Mol Genet 14, 565-574. 
Blaustein MP, Juhaszova M, Golovina VA, Church PJ, & Stanley EF (2002). 
Na/Ca exchanger and PMCA localization in neurons and astrocytes: functional 
implications. Ann N Y Acad Sci 976, 356-366. 
Blaustein MP & Lederer WJ (1999). Sodium/calcium exchange: its physiological 
implications. Physiol Rev 79, 763-854. 
Bonventre JV (1997). Roles of phospholipases A2 in brain cell and tissue injury 
associated with ischemia and excitotoxicity. J Lipid Mediat Cell Signal 17, 71-79. 
Borlongan CV, Koutouzis TK, Freeman TB, Cahill DW, & Sanberg PR (1995). 
Behavioral pathology induced by repeated systemic injections of 3-nitropropionic 
acid mimics the motoric symptoms of Huntington's disease. Brain Res 697, 254-
257. 
Brandstaetter H, Kruppa AJ, & Buss F (2014). Huntingtin is required for ER-to-
Golgi transport and for secretory vesicle fusion at the plasma membrane. Dis 
Model Mech 7, 1335-1340. 
Bretin S, Rogemond V, Marin P, Maus M, Torrens Y, Honnorat J, Glowinski J, 
Premont J, & Gauchy C (2006). Calpain product of WT-CRMP2 reduces the 
amount of surface NR2B NMDA receptor subunit. J Neurochem 98, 1252-1265. 
 147 
Brewer LD, Thibault O, Staton J, Thibault V, Rogers JT, Garcia-Ramos G, Kraner 
S, Landfield PW, & Porter NM (2007). Increased vulnerability of hippocampal 
neurons with age in culture: temporal association with increases in NMDA 
receptor current, NR2A subunit expression and recruitment of L-type calcium 
channels. Brain Res 1151, 20-31. 
Brini M, Manni S, & Carafoli E (2002). A study of the activity of the plasma 
membrane Na/Ca exchanger in the cellular environment. Ann N Y Acad Sci 976, 
376-381. 
Brittain JM, Chen L, Wilson SM, Brustovetsky T, Gao X, Ashpole NM, Molosh AI, 
You H, Hudmon A, Shekhar A, White FA, Zamponi GW, Brustovetsky N, Chen J, 
& Khanna R (2011a). Neuroprotection against traumatic brain injury by a peptide 
derived from the collapsin response mediator protein 2 (CRMP2). J Biol Chem 
286, 37778-37792. 
Brittain JM, Duarte DB, Wilson SM, Zhu W, Ballard C, Johnson PL, Liu N, Xiong 
W, Ripsch MS, Wang Y, Fehrenbacher JC, Fitz SD, Khanna M, Park CK, 
Schmutzler BS, Cheon BM, Due MR, Brustovetsky T, Ashpole NM, Hudmon A, 
Meroueh SO, Hingtgen CM, Brustovetsky N, Ji RR, Hurley JH, Jin X, Shekhar A, 
Xu XM, Oxford GS, Vasko MR, White FA, & Khanna R (2011b). Suppression of 
inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic 
Ca(2) channel complex. Nat Med 17, 822-829. 
Brittain JM, Piekarz AD, Wang Y, Kondo T, Cummins TR, & Khanna R (2009). 
An atypical role for collapsin response mediator protein 2 (CRMP-2) in 
neurotransmitter release via interaction with presynaptic voltage-gated calcium 
channels. J Biol Chem 284, 31375-31390. 
Brittain MK, Brustovetsky T, Brittain JM, Khanna R, Cummins TR, & Brustovetsky 
N (2012a). Ifenprodil, a NR2B-selective antagonist of NMDA receptor, inhibits 
reverse Na+/Ca2+ exchanger in neurons. Neuropharmacology 63, 974-982. 
Brittain MK, Brustovetsky T, Sheets PL, Brittain JM, Khanna R, Cummins TR, & 
Brustovetsky N (2012b). Delayed calcium dysregulation in neurons requires both 
the NMDA receptor and the reverse Na+/Ca2+ exchanger. Neurobiol Dis 46, 
109-117. 
Broekemeier KM, Dempsey ME, & Pfeiffer DR (1989). Cyclosporin A is a potent 
inhibitor of the inner membrane permeability transition in liver mitochondria. J 
Biol Chem 264, 7826-7830. 
 148 
Brouillet E, Conde F, Beal MF, & Hantraye P (1999). Replicating Huntington's 
disease phenotype in experimental animals. Prog Neurobiol 59, 427-468. 
Brown MR, Sullivan PG, Dorenbos KA, Modafferi EA, Geddes JW, & Steward O 
(2004). Nitrogen disruption of synaptoneurosomes: an alternative method to 
isolate brain mitochondria. J Neurosci Methods 137, 299-303. 
Brown TB, Bogush AI, & Ehrlich ME (2008). Neocortical expression of mutant 
huntingtin is not required for alterations in striatal gene expression or motor 
dysfunction in a transgenic mouse. Hum Mol Genet 17, 3095-3104. 
Brustovetsky N, Brustovetsky T, Jemmerson R, & Dubinsky JM (2002). Calcium-
induced cytochrome c release from CNS mitochondria is associated with the 
permeability transition and rupture of the outer membrane. J Neurochem 80, 207-
218. 
Brustovetsky N, Brustovetsky T, Purl KJ, Capano M, Crompton M, & Dubinsky 
JM (2003). Increased susceptibility of striatal mitochondria to calcium-induced 
permeability transition. J Neurosci 23, 4858-4867. 
Brustovetsky N & Dubinsky JM (2000). Dual responses of CNS mitochondria to 
elevated calcium. J Neurosci 20, 103-113. 
Brustovetsky N, LaFrance R, Purl KJ, Brustovetsky T, Keene CD, Low WC, & 
Dubinsky JM (2005). Age-dependent changes in the calcium sensitivity of striatal 
mitochondria in mouse models of Huntington's Disease. J Neurochem 93, 1361-
1370. 
Brustovetsky T, Bolshakov A, & Brustovetsky N (2010). Calpain activation and 
Na(+)/Ca(2+) exchanger degradation occur downstream of calcium deregulation 
in hippocampal neurons exposed to excitotoxic glutamate. J Neurosci Res 88, 
1317-1328. 
Brustovetsky T, Brittain MK, Sheets PL, Cummins TR, Pinelis V, & Brustovetsky 
N (2011). KB-R7943, an inhibitor of the reverse Na+ /Ca2+ exchanger, blocks N-
methyl-D-aspartate receptor and inhibits mitochondrial complex I. Br J Pharmacol 
162, 255-270. 
 149 
Brustovetsky T, Li V, & Brustovetsky N (2009). Stimulation of glutamate 
receptors in cultured hippocampal neurons causes Ca2+-dependent 
mitochondrial contraction. Cell Calcium 46, 18-29. 
Budd SL & Nicholls DG (1996). A reevaluation of the role of mitochondria in 
neuronal Ca2+ homeostasis. J Neurochem 66, 403-411. 
Byk T, Ozon S, & Sobel A (1998). The Ulip family phosphoproteins--common and 
specific properties. Eur J Biochem 254, 14-24. 
Canitano A, Papa M, Boscia F, Castaldo P, Sellitti S, Taglialatela M, & 
Annunziato L (2002). Brain distribution of the Na+/Ca2+ exchanger-encoding 
genes NCX1, NCX2, and NCX3 and their related proteins in the central nervous 
system. Ann N Y Acad Sci 976, 394-404. 
Carafoli E (1988). The intracellular homeostasis of calcium: an overview. Ann N 
Y Acad Sci 551, 147-157. 
Carafoli E & Lehninger AL (1971). A survey of the interaction of calcium ions with 
mitochondria from different tissues and species. Biochem J 122, 681-690. 
Carafoli E, Santella L, Branca D, & Brini M (2001). Generation, control, and 
processing of cellular calcium signals. Crit Rev Biochem Mol Biol 36, 107-260. 
Cepeda C, Ariano MA, Calvert CR, Flores-Hernandez J, Chandler SH, Leavitt 
BR, Hayden MR, & Levine MS (2001). NMDA receptor function in mouse models 
of Huntington disease. J Neurosci Res 66, 525-539. 
Cha JH (2007). Transcriptional signatures in Huntington's disease. Prog 
Neurobiol 83, 228-248. 
Chalmers S & Nicholls DG (2003). The relationship between free and total 
calcium concentrations in the matrix of liver and brain mitochondria. J Biol Chem 
278, 19062-19070. 
Chan SL & Mattson MP (1999). Caspase and calpain substrates: roles in 
synaptic plasticity and cell death. J Neurosci Res 58, 167-190. 
 150 
Chang DT & Reynolds IJ (2006). Differences in mitochondrial movement and 
morphology in young and mature primary cortical neurons in culture. 
Neuroscience 141, 727-736. 
Chang DT, Rintoul GL, Pandipati S, & Reynolds IJ (2006). Mutant huntingtin 
aggregates impair mitochondrial movement and trafficking in cortical neurons. 
Neurobiol Dis 22, 388-400. 
Charrier E, Reibel S, Rogemond V, Aguera M, Thomasset N, & Honnorat J 
(2003). Collapsin response mediator proteins (CRMPs): involvement in nervous 
system development and adult neurodegenerative disorders. Mol Neurobiol 28, 
51-64. 
Chen N, Luo T, & Raymond LA (1999a). Subtype-dependence of NMDA receptor 
channel open probability. J Neurosci 19, 6844-6854. 
Chen N, Luo T, Wellington C, Metzler M, McCutcheon K, Hayden MR, & 
Raymond LA (1999b). Subtype-specific enhancement of NMDA receptor currents 
by mutant huntingtin. J Neurochem 72, 1890-1898. 
Chen S, Berthelier V, Hamilton JB, O'Nuallain B, & Wetzel R (2002). Amyloid-like 
features of polyglutamine aggregates and their assembly kinetics. Biochemistry 
41, 7391-7399. 
Choi DW & Hartley DM (1993). Calcium and glutamate-induced cortical neuronal 
death. Res Publ Assoc Res Nerv Ment Dis 71, 23-34. 
Choo YS, Johnson GV, MacDonald M, Detloff PJ, & Lesort M (2004). Mutant 
huntingtin directly increases susceptibility of mitochondria to the calcium-induced 
permeability transition and cytochrome c release. Hum Mol Genet 13, 1407-
1420. 
Clements JD & Westbrook GL (1994). Kinetics of AP5 dissociation from NMDA 
receptors: evidence for two identical cooperative binding sites. J Neurophysiol 
71, 2566-2569. 
Convery MK & Hancox JC (1999). Comparison of Na+-Ca2+ exchange current 
elicited from isolated rabbit ventricular myocytes by voltage ramp and step 
protocols. Pflugers Arch 437, 944-954. 
 151 
Costa V, Giacomello M, Hudec R, Lopreiato R, Ermak G, Lim D, Malorni W, 
Davies KJ, Carafoli E, & Scorrano L (2010). Mitochondrial fission and cristae 
disruption increase the response of cell models of Huntington's disease to 
apoptotic stimuli. EMBO Mol Med 2, 490-503. 
Coyle JT & Schwarcz R (1976). Lesion of striatal neurones with kainic acid 
provides a model for Huntington's chorea. Nature 263, 244-246. 
Crompton M (1999). The mitochondrial permeability transition pore and its role in 
cell death. Biochem J 341 ( Pt 2), 233-249. 
Czyz A & Kiedrowski L (2002). In depolarized and glucose-deprived neurons, 
Na+ influx reverses plasmalemmal K+-dependent and K+-independent 
Na+/Ca2+ exchangers and contributes to NMDA excitotoxicity. J Neurochem 83, 
1321-1328. 
De SD, Raffaello A, Teardo E, Szabo I, & Rizzuto R (2011). A forty-kilodalton 
protein of the inner membrane is the mitochondrial calcium uniporter. Nature 476, 
336-340. 
Dehorter N, Vinay L, Hammond C, & Ben-Ari Y (2012). Timing of developmental 
sequences in different brain structures: physiological and pathological 
implications. Eur J Neurosci 35, 1846-1856. 
Diarra A, Sheldon C, & Church J (2001). In situ calibration and [H+] sensitivity of 
the fluorescent Na+ indicator SBFI. Am J Physiol Cell Physiol 280, C1623-
C1633. 
DiFiglia M, Sapp E, Chase K, Schwarz C, Meloni A, Young C, Martin E, Vonsattel 
JP, Carraway R, Reeves SA, & . (1995). Huntingtin is a cytoplasmic protein 
associated with vesicles in human and rat brain neurons. Neuron 14, 1075-1081. 
Dingledine R, Borges K, Bowie D, & Traynelis SF (1999). The glutamate receptor 
ion channels. Pharmacol Rev 51, 7-61. 
DiPolo R & Beauge L (2006). Sodium/calcium exchanger: influence of metabolic 
regulation on ion carrier interactions. Physiol Rev 86, 155-203. 
 152 
Douaud G, Gaura V, Ribeiro MJ, Lethimonnier F, Maroy R, Verny C, Krystkowiak 
P, Damier P, Bachoud-Levi AC, Hantraye P, & Remy P (2006). Distribution of 
grey matter atrophy in Huntington's disease patients: a combined ROI-based and 
voxel-based morphometric study. Neuroimage 32, 1562-1575. 
Dragatsis I, Levine MS, & Zeitlin S (2000). Inactivation of Hdh in the brain and 
testis results in progressive neurodegeneration and sterility in mice. Nat Genet 
26, 300-306. 
Dubinsky JM (1993). Intracellular calcium levels during the period of delayed 
excitotoxicity. Journal of Neuroscience 13, 623-631. 
Dubinsky JM, Kristal BS, & Elizondo-Fournier M (1995). On the probabilistic 
nature of excitotoxic neuronal death in hippocampal neurons. 
Neuropharmacology 34, 701-711. 
Ehrlich ME (2012). Huntington's disease and the striatal medium spiny neuron: 
cell-autonomous and non-cell-autonomous mechanisms of disease. 
Neurotherapeutics 9, 270-284. 
Eliseev RA, Filippov G, Velos J, VanWinkle B, Goldman A, Rosier RN, & Gunter 
TE (2007). Role of cyclophilin D in the resistance of brain mitochondria to the 
permeability transition. Neurobiol Aging 28, 1532-1542. 
Erecinska M & Silver IA (1996). Calcium handling by hippocampal neurons under 
physiologic and pathologic conditions. Adv Neurol 71, 119-136. 
Faden AI, Demediuk P, Panter SS, & Vink R (1989). The role of excitatory amino 
acids and NMDA receptors in traumatic brain injury. Science 244, 798-800. 
Fan J, Cowan CM, Zhang LY, Hayden MR, & Raymond LA (2009). Interaction of 
postsynaptic density protein-95 with NMDA receptors influences excitotoxicity in 
the yeast artificial chromosome mouse model of Huntington's disease. J Neurosci 
29, 10928-10938. 
Fan MM & Raymond LA (2007). N-methyl-D-aspartate (NMDA) receptor function 
and excitotoxicity in Huntington's disease. Prog Neurobiol 81, 272-293. 
 153 
Fan TJ, Xia L, & Han YR (2001). Mitochondrion and Apoptosis. Sheng Wu Hua 
Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 33, 7-12. 
Farooqui AA, Ong WY, & Horrocks LA (2006). Inhibitors of brain phospholipase 
A2 activity: their neuropharmacological effects and therapeutic importance for the 
treatment of neurologic disorders. Pharmacol Rev 58, 591-620. 
Fernandes HB, Baimbridge KG, Church J, Hayden MR, & Raymond LA (2007). 
Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-
induced apoptosis in YAC128 model of Huntington's disease. J Neurosci 27, 
13614-13623. 
Foster AC & Wong EH (1987). The novel anticonvulsant MK-801 binds to the 
activated state of the N-methyl-D-aspartate receptor in rat brain. Br J Pharmacol 
91, 403-409. 
Fukata Y, Itoh TJ, Kimura T, Menager C, Nishimura T, Shiromizu T, Watanabe H, 
Inagaki N, Iwamatsu A, Hotani H, & Kaibuchi K (2002). CRMP-2 binds to tubulin 
heterodimers to promote microtubule assembly. Nat Cell Biol 4, 583-591. 
Fusco FR, Chen Q, Lamoreaux WJ, Figueredo-Cardenas G, Jiao Y, Coffman JA, 
Surmeier DJ, Honig MG, Carlock LR, & Reiner A (1999). Cellular localization of 
huntingtin in striatal and cortical neurons in rats: lack of correlation with neuronal 
vulnerability in Huntington's disease. J Neurosci 19, 1189-1202. 
Gafni J, Hermel E, Young JE, Wellington CL, Hayden MR, & Ellerby LM (2004). 
Inhibition of calpain cleavage of huntingtin reduces toxicity: accumulation of 
calpain/caspase fragments in the nucleus. J Biol Chem 279, 20211-20220. 
Gauthier LR, Charrin BC, Borrell-Pages M, Dompierre JP, Rangone H, 
Cordelieres FP, De MJ, MacDonald ME, Lessmann V, Humbert S, & Saudou F 
(2004). Huntingtin controls neurotrophic support and survival of neurons by 
enhancing BDNF vesicular transport along microtubules. Cell 118, 127-138. 
Gellerich FN, Gizatullina ZZ, Nguyen HP, Trumbeckaite S, Vielhaber S, Seppet 
E, Zierz S, Landwehrmeyer B, Ries O, von HS, & Striggow F (2008). Impaired 
regulation of brain mitochondria by extramitochondrial Ca2+ in transgenic 
Huntington disease rats. J Biol Chem 283, 30715-30724. 
 154 
Glasgow NG, Siegler RB, & Johnson JW (2015). Molecular bases of NMDA 
receptor subtype-dependent properties. J Physiol 593, 83-95. 
Gleichmann M & Mattson MP (2010). Neuronal Calcium Homeostasis and 
Dysregulation. Antioxid Redox Signal. 
Goldberg YP, Nicholson DW, Rasper DM, Kalchman MA, Koide HB, Graham RK, 
Bromm M, Kazemi-Esfarjani P, Thornberry NA, Vaillancourt JP, & Hayden MR 
(1996). Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is 
modulated by the polyglutamine tract. Nat Genet 13, 442-449. 
Goldstein JC, Munoz-Pinedo C, Ricci JE, Adams SR, Kelekar A, Schuler M, 
Tsien RY, & Green DR (2005). Cytochrome c is released in a single step during 
apoptosis. Cell Death Differ 12, 453-462. 
Goll DE, Thompson VF, Li H, Wei W, & Cong J (2003). The calpain system. 
Physiol Rev 83, 731-801. 
Govert F & Schneider SA (2013). Huntington's disease and Huntington's 
disease-like syndromes: an overview. Curr Opin Neurol 26, 420-427. 
Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh 
J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, 
Raymond LA, Nicholson DW, & Hayden MR (2006). Cleavage at the caspase-6 
site is required for neuronal dysfunction and degeneration due to mutant 
huntingtin. Cell 125, 1179-1191. 
Gramsbergen JB, Veenma-Van der Duin L, Venema K, & Korf J (1986). Cerebral 
cation shifts and amino acids in Huntington's disease. Arch Neurol 43, 1276-
1281. 
Gray M, Shirasaki DI, Cepeda C, Andre VM, Wilburn B, Lu XH, Tao J, Yamazaki 
I, Li SH, Sun YE, Li XJ, Levine MS, & Yang XW (2008). Full-length human 
mutant huntingtin with a stable polyglutamine repeat can elicit progressive and 
selective neuropathogenesis in BACHD mice. J Neurosci 28, 6182-6195. 
Green DR & Kroemer G (2004). The pathophysiology of mitochondrial cell death. 
Science 305, 626-629. 
 155 
Gregory KJ, Noetzel MJ, & Niswender CM (2013). Pharmacology of metabotropic 
glutamate receptor allosteric modulators: structural basis and therapeutic 
potential for CNS disorders. Prog Mol Biol Transl Sci 115, 61-121. 
Griparic L & van der Bliek AM (2005). Assay and properties of the mitochondrial 
dynamin related protein Opa1. Methods Enzymol 404, 620-631. 
Groc L, Heine M, Cousins SL, Stephenson FA, Lounis B, Cognet L, & Choquet D 
(2006). NMDA receptor surface mobility depends on NR2A-2B subunits. Proc 
Natl Acad Sci U S A 103, 18769-18774. 
Grynkiewicz G, Poenie M, & Tsien RY (1985). A new generation of Ca2+ 
indicators with greatly improved fluorescence properties. J Biol Chem 260, 3440-
3450. 
Guerini D, Coletto L, & Carafoli E (2005). Exporting calcium from cells. Cell 
Calcium 38, 281-289. 
Hagberg H (2004). Mitochondrial impairment in the developing brain after 
hypoxia-ischemia. J Bioenerg Biomembr 36, 369-373. 
Haines JL & Conneally PM (1986). Causes of death in Huntington disease as 
reported on death certificates. Genet Epidemiol 3, 417-423. 
Halestrap AP & Davidson AM (1990). Inhibition of Ca2(+)-induced large-
amplitude swelling of liver and heart mitochondria by cyclosporin is probably 
caused by the inhibitor binding to mitochondrial-matrix peptidyl-prolyl cis-trans 
isomerase and preventing it interacting with the adenine nucleotide translocase. 
Biochem J 268, 153-160. 
Hallett PJ, Spoelgen R, Hyman BT, Standaert DG, & Dunah AW (2006). 
Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine 
phosphorylation-dependent subunit trafficking. J Neurosci 26, 4690-4700. 
Han I, You Y, Kordower JH, Brady ST, & Morfini GA (2010). Differential 
vulnerability of neurons in Huntington's disease: The role of cell type-specific 
features. J Neurochem. 
 156 
Harjes P & Wanker EE (2003). The hunt for huntingtin function: interaction 
partners tell many different stories. Trends Biochem Sci 28, 425-433. 
Harper PS & Jones L (2002). Huntington's disease: genetic and molecular 
studies. In Huntington's Disease, eds. Bates GP, Harper PS, & Jones L, pp. 113-
158. Oxford University Press, New York. 
Harper PS (2002). Huntgington's Disease: a historical background. In 
Huntington's Disease, eds. Bates GP, Harper PS, & Jones L, pp. 3-27. Oxford 
University Press, New York. 
Heemskerk AW & Roos RA (2012). Aspiration pneumonia and death in 
Huntington's disease. PLoS Curr 4, RRN1293. 
Hensley K, Venkova K, Christov A, Gunning W, & Park J (2011). Collapsin 
response mediator protein-2: an emerging pathologic feature and therapeutic 
target for neurodisease indications. Mol Neurobiol 43, 180-191. 
Hodgson JG, Agopyan N, Gutekunst CA, Leavitt BR, LePiane F, Singaraja R, 
Smith DJ, Bissada N, McCutcheon K, Nasir J, Jamot L, Li XJ, Stevens ME, 
Rosemond E, Roder JC, Phillips AG, Rubin EM, Hersch SM, & Hayden MR 
(1999). A YAC mouse model for Huntington's disease with full-length mutant 
huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 
23, 181-192. 
Hodgson JG, Smith DJ, McCutcheon K, Koide HB, Nishiyama K, Dinulos MB, 
Stevens ME, Bissada N, Nasir J, Kanazawa I, Disteche CM, Rubin EM, & 
Hayden MR (1996). Human huntingtin derived from YAC transgenes 
compensates for loss of murine huntingtin by rescue of the embryonic lethal 
phenotype. Hum Mol Genet 5, 1875-1885. 
Hogel M, Laprairie RB, & Denovan-Wright EM (2012). Promoters are 
differentially sensitive to N-terminal mutant huntingtin-mediated transcriptional 
repression. PLoS ONE 7, e41152. 
Hoyt KR, Arden SR, Aizenman E, & Reynolds IJ (1998). Reverse Na+/Ca2+ 
exchange contributes to glutamate-induced intracellular Ca2+ concentration 
increases in cultured rat forebrain neurons. Mol Pharmacol 53, 742-749. 
 157 
Huettner JE & Bean BP (1988). Block of N-methyl-D-aspartate-activated current 
by the anticonvulsant MK-801: selective binding to open channels. Proc Natl 
Acad Sci U S A 85, 1307-1311. 
Huntington G (1872). On Chorea. Medical and Surgical Reporter 26, 320-321. 
Ivkovic S & Ehrlich ME (1999). Expression of the striatal DARPP-32/ARPP-21 
phenotype in GABAergic neurons requires neurotrophins in vivo and in vitro. J 
Neurosci 19, 5409-5419. 
Janssens N & Lesage AS (2001). Glutamate receptor subunit expression in 
primary neuronal and secondary glial cultures. J Neurochem 77, 1457-1474. 
Javadov S & Kuznetsov A (2013). Mitochondrial permeability transition and cell 
death: the role of cyclophilin d. Front Physiol 4, 76. 
Jeffs GJ, Meloni BP, Bakker AJ, & Knuckey NW (2007). The role of the 
Na(+)/Ca(2+) exchanger (NCX) in neurons following ischaemia. J Clin Neurosci 
14, 507-514. 
Kamo N, Muratsugu M, Hongoh R, & Kobatake Y (1979). Membrane potential of 
mitochondria measured with an electrode sensitive to tetraphenyl phosphonium 
and relationship between proton electrochemical potential and phosphorylation 
potential in steady state. J Membr Biol 49, 105-121. 
Kegel KB, Meloni AR, Yi Y, Kim YJ, Doyle E, Cuiffo BG, Sapp E, Wang Y, Qin 
ZH, Chen JD, Nevins JR, Aronin N, & DiFiglia M (2002). Huntingtin is present in 
the nucleus, interacts with the transcriptional corepressor C-terminal binding 
protein, and represses transcription. J Biol Chem 277, 7466-7476. 
Kehoe LA, Bernardinelli Y, & Muller D (2013). GluN3A: an NMDA receptor 
subunit with exquisite properties and functions. Neural Plast 2013, 145387. 
Kells AP, Fong DM, Dragunow M, During MJ, Young D, & Connor B (2004). 
AAV-mediated gene delivery of BDNF or GDNF is neuroprotective in a model of 
Huntington disease. Mol Ther 9, 682-688. 
Khanna R, Wilson SM, Brittain JM, Weimer J, Sultana R, Butterfield A, & Hensley 
K (2012). Opening Pandora's jar: a primer on the putative roles of CRMP2 in a 
 158 
panoply of neurodegenerative, sensory and motor neuron, and central disorders. 
Future Neurol 7, 749-771. 
Kiedrowski L (1999). N-methyl-D-aspartate excitotoxicity: relationships among 
plasma membrane potential, Na(+)/Ca(2+) exchange, mitochondrial Ca(2+) 
overload, and cytoplasmic concentrations of Ca(2+), H(+), and K(+). Mol 
Pharmacol 56, 619-632. 
Kiedrowski L, Brooker G, Costa E, & Wroblewski JT (1994). Glutamate impairs 
neuronal calcium extrusion while reducing sodium gradient. Neuron 12, 295-300. 
Kiedrowski L & Costa E (1995). Glutamate-induced destabilization of intracellular 
calcium concentration homeostasis in cultured cerebellar granule cells: role of 
mitochondria in calcium buffering. Mol Pharmacol 47, 140-147. 
Kiedrowski L, Czyz A, Baranauskas G, Li XF, & Lytton J (2004). Differential 
contribution of plasmalemmal Na/Ca exchange isoforms to sodium-dependent 
calcium influx and NMDA excitotoxicity in depolarized neurons. J Neurochem 90, 
117-128. 
Kim SH, Thomas CA, Andre VM, Cummings DM, Cepeda C, Levine MS, & 
Ehrlich ME (2011). Forebrain striatal-specific expression of mutant huntingtin 
protein in vivo induces cell-autonomous age-dependent alterations in sensitivity 
to excitotoxicity and mitochondrial function. ASN Neuro 3, e00060. 
Kimura J, Noma A, & Irisawa H (1986). Na-Ca exchange current in mammalian 
heart cells. Nature 319, 596-597. 
Kohr G (2006). NMDA receptor function: subunit composition versus spatial 
distribution. Cell Tissue Res 326, 439-446. 
Korshunov SS, Korkina OV, Ruuge EK, Skulachev VP, & Starkov AA (1998). 
Fatty acids as natural uncouplers preventing generation of O2.- and H2O2 by 
mitochondria in the resting state. FEBS Lett 435, 215-218. 
Korshunov SS, Skulachev VP, & Starkov AA (1997). High protonic potential 
actuates a mechanism of production of reactive oxygen species in mitochondria. 
FEBS Lett 416, 15-18. 
 159 
Kowara R, Chen Q, Milliken M, & Chakravarthy B (2005). Calpain-mediated 
truncation of dihydropyrimidinase-like 3 protein (DPYSL3) in response to NMDA 
and H2O2 toxicity. J Neurochem 95, 466-474. 
Kritis AA, Stamoula EG, Paniskaki KA, & Vavilis TD (2015). Researching 
glutamate-induced cytotoxicity in different cell lines: a comparative/collective 
analysis/study. Front Cell Neurosci 9. 
Kumar A, Kumar SS, Kumar V, Kumar D, Agarwal S, & Rana MK (2015). 
Huntington's disease: An update of therapeutic strategies. Gene 556, 91-97. 
Kushnareva YE, Wiley SE, Ward MW, Andreyev AY, & Murphy AN (2005). 
Excitotoxic injury to mitochondria isolated from cultured neurons. J Biol Chem 
280, 28894-28902. 
La Spada AR, Weydt P, & Pineda VV (2011). Huntington's Disease 
Pathogenesis. In Neurobiology of Huntington's Disease: Applications to Drug 
Discovery, eds. Lo DC & Hughes RE, CRC Press, Boca Raton, FL. 
Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB, Jr., & Young AB 
(1995). NMDA receptor subunit mRNA expression by projection neurons and 
interneurons in rat striatum. J Neurosci 15, 5297-5307. 
Lankiewicz S, Marc LC, Truc BN, Krohn AJ, Poppe M, Cole GM, Saido TC, & 
Prehn JH (2000). Activation of calpain I converts excitotoxic neuron death into a 
caspase-independent cell death. J Biol Chem 275, 17064-17071. 
Leavitt BR, Guttman JA, Hodgson JG, Kimel GH, Singaraja R, Vogl AW, & 
Hayden MR (2001). Wild-type huntingtin reduces the cellular toxicity of mutant 
huntingtin in vivo. Am J Hum Genet 68, 313-324. 
Lester RA, Clements JD, Westbrook GL, & Jahr CE (1990). Channel kinetics 
determine the time course of NMDA receptor-mediated synaptic currents. Nature 
346, 565-567. 
Li B, Otsu Y, Murphy TH, & Raymond LA (2014). Developmental decrease in 
NMDA receptor desensitization associated with shift to synapse and interaction 
with postsynaptic density-95. Journal of Neuroscience 23, 11244-11254. 
 160 
Li L, Fan M, Icton CD, Chen N, Leavitt BR, Hayden MR, Murphy TH, & Raymond 
LA (2003). Role of NR2B-type NMDA receptors in selective neurodegeneration in 
Huntington disease. Neurobiol Aging 24, 1113-1121. 
Li SH & Li XJ (2004). Huntingtin-protein interactions and the pathogenesis of 
Huntington's disease. Trends Genet 20, 146-154. 
Li Y, Bondada V, Joshi A, & Geddes JW (2009). Calpain 1 and Calpastatin 
expression is developmentally regulated in rat brain. Exp Neurol 220, 316-319. 
Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, & Carafoli E (2008). 
Calcium homeostasis and mitochondrial dysfunction in striatal neurons of 
Huntington disease. J Biol Chem 283, 5780-5789. 
Lim NK, Hung LW, Pang TY, Mclean CA, Liddell JR, Hilton JB, Li QX, White AR, 
Hannan AJ, & Crouch PJ (2014). Localized changes to glycogen synthase 
kinase-3 and collapsin response mediator protein-2 in the Huntington's disease 
affected brain. Hum Mol Genet 23, 4051-4063. 
Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, 
Ren S, Li XJ, Albin RL, & Detloff PJ (2001). Neurological abnormalities in a 
knock-in mouse model of Huntington's disease. Hum Mol Genet 10, 137-144. 
Lin Y, Jover-Mengual T, Wong J, Bennett MV, & Zukin RS (2006). PSD-95 and 
PKC converge in regulating NMDA receptor trafficking and gating. Proc Natl 
Acad Sci U S A 103, 19902-19907. 
Liu JC, DeFazio RA, Espinosa-Jeffrey A, Cepeda C, de VJ, & Levine MS (2004). 
Calcium modulates dopamine potentiation of N-methyl-D-aspartate responses: 
electrophysiological and imaging evidence. J Neurosci Res 76, 315-322. 
Liu W, Zhou XW, Liu S, Hu K, Wang C, He Q, & Li M (2009). Calpain-truncated 
CRMP-3 and -4 contribute to potassium deprivation-induced apoptosis of 
cerebellar granule neurons. Proteomics 9, 3712-3728. 
Liu Y, Wong TP, Aarts M, Rooyakkers A, Liu L, Lai TW, Wu DC, Lu J, Tymianski 
M, Craig AM, & Wang YT (2007). NMDA receptor subunits have differential roles 
in mediating excitotoxic neuronal death both in vitro and in vivo. J Neurosci 27, 
2846-2857. 
 161 
Luo J, Wang Y, Chen H, Kintner DB, Cramer SW, Gerdts JK, Chen X, Shull GE, 
Philipson KD, & Sun D (2007). A concerted role of Na(+)-K(+)-Cl(-) cotransporter 
and Na(+)/Ca(2+) exchanger in ischemic damage. J Cereb Blood Flow Metab 1-
10. 
Luthi-Carter R, Apostol BL, Dunah AW, DeJohn MM, Farrell LA, Bates GP, 
Young AB, Standaert DG, Thompson LM, & Cha JH (2003). Complex alteration 
of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of 
mRNA and protein expression, plasma membrane association, interacting 
proteins, and phosphorylation. Neurobiol Dis 14, 624-636. 
Luthi-Carter R, Strand A, Peters NL, Solano SM, Hollingsworth ZR, Menon AS, 
Frey AS, Spektor BS, Penney EB, Schilling G, Ross CA, Borchelt DR, Tapscott 
SJ, Young AB, Cha JH, & Olson JM (2000). Decreased expression of striatal 
signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 9, 
1259-1271. 
MacDermott AB, Mayer ML, Westbrook GL, Smith SJ, & Barker JL (1986). 
NMDA-receptor activation increases cytoplasmic calcium concentration in 
cultured spinal cord neurones. Nature 321, 519-522. 
MacDonald ME, Ambrose CM, Duyao MP, Myers RH, Lin C, Srinidhi L, Barnes 
G, Taylor SA, James M, Groot N, MacFarlane H, Jenkins B, Anderson MA, 
Wexler NS, Gusella JF, Bates GP, Baxendale S, Hummerich H, Kirby S, North 
M, Youngman S, Mott R, Zehetner G, Sedlacek Z, Poustka A, Frischauf AM, 
Lehrach H, Buckler AJ, Church D, Doucette-Stamm L, O'Donovan MC, Riba-
Ramirez L, Shah M, Stanton VP, Strobel SA, Draths KM, Wales JL, Dervan P, 
Housman DE, Altherr M, Shiang R, Thompson L, Fielder T, Wasmuth JJ, Tagle 
D, Valdes J, Elmer L, Allard M, Castilla L, Swaroop M, Blanchard K, Collins FS, 
Snell R, Holloway T, Gillespie K, Datson N, Shaw D, & Harper PS (1993). A 
novel gene containing a trinucleotide repeat that is expanded and unstable on 
Huntington's disease chromosomes. Cell 72, 971-983. 
Malouitre S, Dube H, Selwood D, & Crompton M (2010). Mitochondrial targeting 
of cyclosporin A enables selective inhibition of cyclophilin-D and enhanced 
cytoprotection after glucose and oxygen deprivation. Biochem J 425, 137-148. 
Manev H, Favaron M, Guidotti A, & Costa E (1989). Delayed increase of Ca2+ 
influx elicited by glutamate: role in neuronal death. Mol Pharmacol 36, 106-112. 
 162 
Mangiarini L, Sathasivam K, Seller M, Cozens B, Harper A, Hetherington C, 
Lawton M, Trottier Y, Lehrach H, Davies SW, & Bates GP (1996). Exon 1 of the 
HD gene with an expanded CAG repeat is sufficient to cause a progressive 
neurological phenotype in transgenic mice. Cell 87, 493-506. 
Mao L & Wang JQ (2001). Upregulation of preprodynorphin and 
preproenkephalin mRNA expression by selective activation of group I 
metabotropic glutamate receptors in characterized primary cultures of rat striatal 
neurons. Brain Res Mol Brain Res 86, 125-137. 
Martinez-Vicente M, Talloczy Z, Wong E, Tang G, Koga H, Kaushik S, de VR, 
Arias E, Harris S, Sulzer D, & Cuervo AM (2010). Cargo recognition failure is 
responsible for inefficient autophagy in Huntington's disease. Nat Neurosci 13, 
567-576. 
Masu M, Nakajima Y, Moriyoshi K, Ishii T, Akazawa C, & Nakanashi S (1993). 
Molecular characterization of NMDA and metabotropic glutamate receptors. Ann 
N Y Acad Sci 707, 153-164. 
Mattson MP (2003). Excitotoxic and excitoprotective mechanisms: abundant 
targets for the prevention and treatment of neurodegenerative disorders. 
Neuromolecular Med 3, 65-94. 
McBain CJ & Mayer ML (1994). N-methyl-D-aspartic acid receptor structure and 
function. Physiol Rev 74, 723-760. 
McBride JL, Ramaswamy S, Gasmi M, Bartus RT, Herzog CD, Brandon EP, 
Zhou L, Pitzer MR, Berry-Kravis EM, & Kordower JH (2006). Viral delivery of glial 
cell line-derived neurotrophic factor improves behavior and protects striatal 
neurons in a mouse model of Huntington's disease. Proc Natl Acad Sci U S A 
103, 9345-9350. 
McCormack JG, Halestrap AP, & Denton RM (1990). Role of calcium ions in 
regulation of mammalian intramitochondrial metabolism. Physiol Rev 70, 391-
425. 
McEntee WJ & Crook TH (1993). Glutamate: its role in learning, memory, and the 
aging brain. Psychopharmacology (Berl) 111, 391-401. 
 163 
McGeer EG & McGeer PL (1976). Duplication of biochemical changes of 
Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 
263, 517-519. 
Mechmann S & Pott L (1986). Identification of Na-Ca exchange current in single 
cardiac myocytes. Nature 319, 597-599. 
Milakovic T, Quintanilla RA, & Johnson GV (2006). Mutant huntingtin expression 
induces mitochondrial calcium handling defects in clonal striatal cells: functional 
consequences. J Biol Chem 281, 34785-34795. 
Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, 
Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, & Raymond LA 
(2010). Early increase in extrasynaptic NMDA receptor signaling and expression 
contributes to phenotype onset in Huntington's disease mice. Neuron 65, 178-
190. 
Minelli A, Castaldo P, Gobbi P, Salucci S, Magi S, & Amoroso S (2007). Cellular 
and subcellular localization of Na+-Ca2+ exchanger protein isoforms, NCX1, 
NCX2, and NCX3 in cerebral cortex and hippocampus of adult rat. Cell Calcium 
41, 221-234. 
Miyawaki A, Llopis J, Heim R, McCaffery JM, Adams JA, Ikura M, & Tsien RY 
(1997). Fluorescent indicators for Ca2+ based on green fluorescent proteins and 
calmodulin. Nature 388, 882-887. 
Monyer H, Burnashev N, Laurie DJ, Sakmann B, & Seeburg PH (1994). 
Developmental and regional expression in the rat brain and functional properties 
of four NMDA receptors. Neuron 12, 529-540. 
Morris RG, Anderson E, Lynch GS, & Baudry M (1986). Selective impairment of 
learning and blockade of long-term potentiation by an N-methyl-D-aspartate 
receptor antagonist, AP5. Nature 319, 774-776. 
Myers RH (2004). Huntington's disease genetics. NeuroRx 1, 255-262. 
Nance MA & Myers RH (2001). Juvenile onset Huntington's disease--clinical and 
research perspectives. Ment Retard Dev Disabil Res Rev 7, 153-157. 
 164 
Nicholls DG (1986). Intracellular calcium homeostasis. Br Med Bull 42, 353-358. 
Nicholls DG (2004). Mitochondrial dysfunction and glutamate excitotoxicity 
studied in primary neuronal cultures. Curr Mol Med 4, 149-177. 
Nicholls DG & Budd SL (1998). Mitochondria and neuronal glutamate 
excitotoxicity. Biochim Biophys Acta 1366, 97-112. 
Nixon RA (2003). The calpains in aging and aging-related diseases. Ageing Res 
Rev 2, 407-418. 
Novgorodov SA, Gudz TI, Milgrom YM, & Brierley GP (1992). The permeability 
transition in heart mitochondria is regulated synergistically by ADP and 
cyclosporin A. J Biol Chem 267, 16274-16282. 
Nowak L, Bregestovski P, Ascher P, Herbet A, & Prochiantz A (1984). 
Magnesium gates glutamate-activated channels in mouse central neurones. 
Nature 307, 462-465. 
Okubo Y, Sekiya H, Namiki S, Sakamoto H, Iinuma S, Yamasaki M, Watanabe 
M, Hirose K, & Iino M (2010). Imaging extrasynaptic glutamate dynamics in the 
brain. Proc Natl Acad Sci U S A 107, 6526-6531. 
Oliveira JM, Jekabsons MB, Chen S, Lin A, Rego AC, Goncalves J, Ellerby LM, 
& Nicholls DG (2007). Mitochondrial dysfunction in Huntington's disease: the 
bioenergetics of isolated and in situ mitochondria from transgenic mice. J 
Neurochem 101, 241-249. 
Orrenius S, Gogvadze V, & Zhivotovsky B (2015). Calcium and mitochondria in 
the regulation of cell death. Biochem Biophys Res Commun 460, 72-81. 
Panov AV, Burke JR, Strittmatter WJ, & Greenamyre JT (2003). In vitro effects of 
polyglutamine tracts on Ca2+-dependent depolarization of rat and human 
mitochondria: relevance to Huntington's disease. Arch Biochem Biophys 410, 1-
6. 
Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, & 
Greenamyre JT (2002). Early mitochondrial calcium defects in Huntington's 
disease are a direct effect of polyglutamines. Nat Neurosci 5, 731-736. 
 165 
Paoletti P & Neyton J (2007). NMDA receptor subunits: function and 
pharmacology. Curr Opin Pharmacol 7, 39-47. 
Papa M, Canitano A, Boscia F, Castaldo P, Sellitti S, Porzig H, Taglialatela M, & 
Annunziato L (2003). Differential expression of the Na+-Ca2+ exchanger 
transcripts and proteins in rat brain regions. J Comp Neurol 461, 31-48. 
Paulson HL & Albin RL (2011). Huntington's Disease Clinical Features and 
Routes to Therapy. In Neurobiology of Huntington's Disease Applications to Drug 
Discovery, eds. Lo DC & Hughes RE, pp. 1-27. CRC Press, Boca Raton. 
Perry GM, Tallaksen-Greene S, Kumar A, Heng MY, Kneynsberg A, van GT, 
Detloff PJ, Albin RL, & Lesort M (2010). Mitochondrial calcium uptake capacity as 
a therapeutic target in the R6/2 mouse model of Huntington's disease. Hum Mol 
Genet 19, 3354-3371. 
Piekarz AD, Due MR, Khanna M, Wang B, Ripsch MS, Wang R, Meroueh SO, 
Vasko MR, White FA, & Khanna R (2012). CRMP-2 peptide mediated decrease 
of high and low voltage-activated calcium channels, attenuation of nociceptor 
excitability, and anti-nociception in a model of AIDS therapy-induced painful 
peripheral neuropathy. Mol Pain 8, 54. 
Pignataro G, Cuomo O, Vinciguerra A, Sirabella R, Esposito E, Boscia F, Di RG, 
& Annunziato L (2013). NCX as a key player in the neuroprotection exerted by 
ischemic preconditioning and postconditioning. Adv Exp Med Biol 961, 223-240. 
Planells-Cases R, Lerma J, & Ferrer-Montiel A (2006). Pharmacological 
intervention at ionotropic glutamate receptor complexes. Curr Pharm Des 12, 
3583-3596. 
Pouladi MA, Morton AJ, & Hayden MR (2013). Choosing an animal model for the 
study of Huntington's disease. Nat Rev Neurosci 14, 708-721. 
Quinn CC, Chen E, Kinjo TG, Kelly G, Bell AW, Elliott RC, McPherson PS, & 
Hockfield S (2003). TUC-4b, a novel TUC family variant, regulates neurite 
outgrowth and associates with vesicles in the growth cone. J Neurosci 23, 2815-
2823. 
 166 
Quintanilla RA, Jin YN, von BR, & Johnson GV (2013a). Mitochondrial 
permeability transition pore induces mitochondria injury in Huntington disease. 
Mol Neurodegener 8, 45. 
Quintanilla RA, Jin YN, von BR, & Johnson GV (2013b). Mitochondrial 
permeability transition pore induces mitochondria injury in Huntington disease. 
Mol Neurodegener 8, 45. 
Ramaswamy S, McBride JL, & Kordower JH (2007). Animal models of 
Huntington's disease. ILAR J 48, 356-373. 
Rasola A & Bernardi P (2011). Mitochondrial permeability transition in Ca(2+)-
dependent apoptosis and necrosis. Cell Calcium 50, 222-233. 
Reddy PH, Charles V, Williams M, Miller G, Whetsell WO, Jr., & Tagle DA 
(1999). Transgenic mice expressing mutated full-length HD cDNA: a paradigm 
for locomotor changes and selective neuronal loss in Huntington's disease. 
Philos Trans R Soc Lond B Biol Sci 354, 1035-1045. 
Reetz K, Romanzetti S, Dogan I, Sass C, Werner CJ, Schiefer J, Schulz JB, & 
Shah NJ (2012). Increased brain tissue sodium concentration in Huntington's 
Disease - a sodium imaging study at 4 T. Neuroimage 63, 517-524. 
Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, & Young AB (1988). 
Differential loss of striatal projection neurons in Huntington disease. Proc Natl 
Acad Sci U S A 85, 5733-5737. 
Ricard D, Rogemond V, Charrier E, Aguera M, Bagnard D, Belin MF, Thomasset 
N, & Honnorat J (2001). Isolation and expression pattern of human Unc-33-like 
phosphoprotein 6/collapsin response mediator protein 5 (Ulip6/CRMP5): 
coexistence with Ulip2/CRMP2 in Sema3a- sensitive oligodendrocytes. J 
Neurosci 21, 7203-7214. 
Rigamonti D, Bauer JH, De-Fraja C, Conti L, Sipione S, Sciorati C, Clementi E, 
Hackam A, Hayden MR, Li Y, Cooper JK, Ross CA, Govoni S, Vincenz C, & 
Cattaneo E (2000). Wild-type huntingtin protects from apoptosis upstream of 
caspase-3. J Neurosci 20, 3705-3713. 
Roze E, Bonnet C, Betuing S, & Caboche J (2010). Huntington's disease. Adv 
Exp Med Biol 685, 45-63. 
 167 
Sakaue M, Nakamura H, Kaneko I, Kawasaki Y, Arakawa N, Hashimoto H, 
Koyama Y, Baba A, & Matsuda T (2000). Na(+)-Ca(2+) exchanger isoforms in rat 
neuronal preparations: different changes in their expression during postnatal 
development. Brain Res 881, 212-216. 
Salinska E, Danysz W, & Lazarewicz JW (2005). The role of excitotoxicity in 
neurodegeneration. Folia Neuropathol 43, 322-339. 
Sattler R & Tymianski M (2000). Molecular mechanisms of calcium-dependent 
excitotoxicity. J Mol Med 78, 3-13. 
Schilling G, Becher MW, Sharp AH, Jinnah HA, Duan K, Kotzuk JA, Slunt HH, 
Ratovitski T, Cooper JK, Jenkins NA, Copeland NG, Price DL, Ross CA, & 
Borchelt DR (1999). Intranuclear inclusions and neuritic aggregates in transgenic 
mice expressing a mutant N-terminal fragment of huntingtin. Hum Mol Genet 8, 
397-407. 
Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial 
NN, Moskowitz MA, & Korsmeyer SJ (2005). Cyclophilin D is a component of 
mitochondrial permeability transition and mediates neuronal cell death after focal 
cerebral ischemia. Proc Natl Acad Sci U S A 102, 12005-12010. 
Schmidt EF & Strittmatter SM (2007). The CRMP family of proteins and their role 
in Sema3A signaling. Adv Exp Med Biol 600, 1-11. 
Secondo A, Staiano RI, Scorziello A, Sirabella R, Boscia F, Adornetto A, 
Valsecchi V, Molinaro P, Canzoniero LM, Di Renzo G, & Annunziato L (2007). 
BHK cells transfected with NCX3 are more resistant to hypoxia followed by 
reoxygenation than those transfected with NCX1 and NCX2: Possible 
relationship with mitochondrial membrane potential. Cell Calcium 42, 521-535. 
Shannon K, Hersch S, Lovecky D, & Tarapata K. Huntington's Disease: A Family 
Guide.  2009.  Huntington's Disease Society of America.  
Ref Type: Pamphlet 
Shirasaki DI, Greiner ER, Al-Ramahi I, Gray M, Boontheung P, Geschwind DH, 
Botas J, Coppola G, Horvath S, Loo JA, & Yang XW (2012). Network 
organization of the huntingtin proteomic interactome in mammalian brain. Neuron 
75, 41-57. 
 168 
Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, & Reddy PH 
(2011). Abnormal mitochondrial dynamics, mitochondrial loss and mutant 
huntingtin oligomers in Huntington's disease: implications for selective neuronal 
damage. Hum Mol Genet. 
Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao 
P, & Reddy PH (2012). Mutant huntingtin's interaction with mitochondrial protein 
Drp1 impairs mitochondrial biogenesis and causes defective axonal transport 
and synaptic degeneration in Huntington's disease. Hum Mol Genet 21, 406-420. 
Slee EA, Harte MT, Kluck RM, Wolf BB, Casiano CA, Newmeyer DD, Wang HG, 
Reed JC, Nicholson DW, Alnemri ES, Green DR, & Martin SJ (1999). Ordering 
the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-
2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J Cell Biol 144, 281-
292. 
Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, 
Bissada N, Wetzel R, Leavitt BR, & Hayden MR (2005). Absence of behavioral 
abnormalities and neurodegeneration in vivo despite widespread neuronal 
huntingtin inclusions. Proc Natl Acad Sci U S A 102, 11402-11407. 
Slow EJ, van RJ, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada 
N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, & 
Hayden MR (2003). Selective striatal neuronal loss in a YAC128 mouse model of 
Huntington disease. Hum Mol Genet 12, 1555-1567. 
Smith DJ, Ng H, Kluck RM, & Nagley P (2008). The mitochondrial gateway to cell 
death. IUBMB Life 60, 383-389. 
Smith GL, Elliott EE, Kettlewell S, Currie S, & Quinn FR (2006). Na(+)/Ca(2+) 
exchanger expression and function in a rabbit model of myocardial infarction. J 
Cardiovasc Electrophysiol 17 Suppl 1, S57-S63. 
Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, 
Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, 
Bossy B, Perkins G, & Bossy-Wetzel E (2011). Mutant huntingtin binds the 
mitochondrial fission GTPase dynamin-related protein-1 and increases its 
enzymatic activity. Nat Med 17, 377-382. 
Spandou E, Soubasi V, Papoutsopoulou S, Augoustides-Savvopoulou P, Loizidis 
T, Pazaiti A, Karkavelas G, & Guiba-Tziampiri O (2007). Neuroprotective effect of 
 169 
long-term MgSO4 administration after cerebral hypoxia-ischemia in newborn rats 
is related to the severity of brain damage. Reprod Sci 14, 667-677. 
Spector AA (1975). Fatty acid binding to plasma albumin. J Lipid Res 16, 165-
179. 
Stack EC, Kubilus JK, Smith K, Cormier K, Del Signore SJ, Guelin E, Ryu H, 
Hersch SM, & Ferrante RJ (2005). Chronology of behavioral symptoms and 
neuropathological sequela in R6/2 Huntington's disease transgenic mice. J Comp 
Neurol 490, 354-370. 
Stanika RI, Pivovarova NB, Brantner CA, Watts CA, Winters CA, & Andrews SB 
(2009). Coupling diverse routes of calcium entry to mitochondrial dysfunction and 
glutamate excitotoxicity. Proc Natl Acad Sci U S A 106, 9854-9859. 
Steinberg GK, Saleh J, DeLaPaz R, Kunis D, & Zarnegar SR (1989). 
Pretreatment with the NMDA antagonist dextrorphan reduces cerebral injury 
following transient focal ischemia in rabbits. Brain Res 497, 382-386. 
Sugars KL & Rubinsztein DC (2003). Transcriptional abnormalities in Huntington 
disease. Trends Genet 19, 233-238. 
Sun Y, Savanenin A, Reddy PH, & Liu YF (2001). Polyglutamine-expanded 
huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-
synaptic density 95. J Biol Chem 276, 24713-24718. 
Swayne LA, Chen L, Hameed S, Barr W, Charlesworth E, Colicos MA, Zamponi 
GW, & Braun JE (2005). Crosstalk between huntingtin and syntaxin 1A regulates 
N-type calcium channels. Mol Cell Neurosci 30, 339-351. 
Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, 
Hayden MR, & Bezprozvanny I (2005). Disturbed Ca2+ signaling and apoptosis 
of medium spiny neurons in Huntington's disease. Proc Natl Acad Sci U S A 102, 
2602-2607. 
Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, & 
Bezprozvanny I (2003). Huntingtin and huntingtin-associated protein 1 influence 
neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor 
type 1. Neuron 39, 227-239. 
 170 
Tanveer A, Virji S, Andreeva L, Totty NF, Hsuan JJ, Ward JM, & Crompton M 
(1996). Involvement of cyclophilin D in the activation of a mitochondrial pore by 
Ca2+ and oxidant stress. Eur J Biochem 238, 166-172. 
Thayer SA & Miller RJ (1990). Regulation of the intracellular free calcium 
concentration in single rat dorsal root ganglion neurones in vitro. J Physiol 425, 
85-115. 
Thor H, Hartzell P, & Orrenius S (1984). Potentiation of oxidative cell injury in 
hepatocytes which have accumulated Ca2+. J Biol Chem 259, 6612-6615. 
Thurneysen T, Nicoll DA, Philipson KD, & Porzig H (2002a). 
Immunohistochemical detection of the sodium-calcium exchanger in rat 
hippocampus cultures using subtype-specific antibodies. Ann N Y Acad Sci 976, 
367-375. 
Thurneysen T, Nicoll DA, Philipson KD, & Porzig H (2002b). Sodium/calcium 
exchanger subtypes NCX1, NCX2 and NCX3 show cell-specific expression in rat 
hippocampus cultures. Brain Res Mol Brain Res 107, 145-156. 
Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, 
Hansen KB, Yuan H, Myers SJ, & Dingledine R (2010). Glutamate Receptor Ion 
Channels: Structure, Regulation, and Function. Pharmacol Rev 62, 405-496. 
Trettel F, Rigamonti D, Hilditch-Maguire P, Wheeler VC, Sharp AH, Persichetti F, 
Cattaneo E, & MacDonald ME (2000). Dominant phenotypes produced by the HD 
mutation in STHdh(Q111) striatal cells. Hum Mol Genet 9, 2799-2809. 
Trottier Y, Devys D, Imbert G, Saudou F, An I, Lutz Y, Weber C, Agid Y, Hirsch 
EC, & Mandel JL (1995). Cellular localization of the Huntington's disease protein 
and discrimination of the normal and mutated form. Nat Genet 10, 104-110. 
Trushina E, Dyer RB, Badger JD, Ure D, Eide L, Tran DD, Vrieze BT, Legendre-
Guillemin V, McPherson PS, Mandavilli BS, Van HB, Zeitlin S, McNiven M, 
Aebersold R, Hayden M, Parisi JE, Seeberg E, Dragatsis I, Doyle K, Bender A, 
Chacko C, & McMurray CT (2004). Mutant huntingtin impairs axonal trafficking in 
mammalian neurons in vivo and in vitro. Mol Cell Biol 24, 8195-8209. 
 171 
Tymianski M, Charlton MP, Carlen PL, & Tator CH (1993a). Secondary Ca2+ 
overload indicates early neuronal injury which precedes staining with viability 
indicators. Brain Res 607, 319-323. 
Tymianski M, Charlton MP, Carlen PL, & Tator CH (1993b). Source specificity of 
early calcium neurotoxicity in cultured embryonic spinal neurons. J Neurosci 13, 
2085-2104. 
Velier J, Kim M, Schwarz C, Kim TW, Sapp E, Chase K, Aronin N, & DiFiglia M 
(1998). Wild-type and mutant huntingtins function in vesicle trafficking in the 
secretory and endocytic pathways. Exp Neurol 152, 34-40. 
von HS, Schmitt I, Nguyen HP, Holzmann C, Schmidt T, Walther T, Bader M, 
Pabst R, Kobbe P, Krotova J, Stiller D, Kask A, Vaarmann A, Rathke-Hartlieb S, 
Schulz JB, Grasshoff U, Bauer I, Vieira-Saecker AM, Paul M, Jones L, 
Lindenberg KS, Landwehrmeyer B, Bauer A, Li XJ, & Riess O (2003). Transgenic 
rat model of Huntington's disease. Hum Mol Genet 12, 617-624. 
Vonsattel JP & DiFiglia M (1998). Huntington disease. J Neuropathol Exp Neurol 
57, 369-384. 
Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, & Richardson EP, Jr. 
(1985). Neuropathological classification of Huntington's disease. J Neuropathol 
Exp Neurol 44, 559-577. 
Walker FO & Raymond LA (2004). Targeting energy metabolism in Huntington's 
disease. Lancet 364, 312-313. 
Wang GJ & Thayer SA (1996). Sequestration of glutamate-induced Ca2+ loads 
by mitochondria in cultured rat hippocampal neurons. J Neurophysiol 76, 1611-
1621. 
Wang LH & Strittmatter SM (1997). Brain CRMP forms heterotetramers similar to 
liver dihydropyrimidinase. J Neurochem 69, 2261-2269. 
Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, Hayden AR, 
Kanazawa I, Ross CJ, & Hayden MR (2011). HTT haplotypes contribute to 
differences in Huntington disease prevalence between Europe and East Asia. 
Eur J Hum Genet 19, 561-566. 
 172 
Waterhouse NJ, Finucane DM, Green DR, Elce JS, Kumar S, Alnemri ES, 
Litwack G, Khanna K, Lavin MF, & Watters DJ (1998). Calpain activation is 
upstream of caspases in radiation-induced apoptosis. Cell Death Differ 5, 1051-
1061. 
Wellington CL, Ellerby LM, Gutekunst CA, Rogers D, Warby S, Graham RK, 
Loubser O, van Raamsdonk J, Singaraja R, Yang YZ, Gafni J, Bredesen D, 
Hersch SM, Leavitt BR, Roy S, Nicholson DW, & Hayden MR (2002). Caspase 
cleavage of mutant huntingtin precedes neurodegeneration in Huntington's 
disease. J Neurosci 22, 7862-7872. 
Wellington CL, Singaraja R, Ellerby L, Savill J, Roy S, Leavitt B, Cattaneo E, 
Hackam A, Sharp A, Thornberry N, Nicholson DW, Bredesen DE, & Hayden MR 
(2000). Inhibiting caspase cleavage of huntingtin reduces toxicity and aggregate 
formation in neuronal and nonneuronal cells. J Biol Chem 275, 19831-19838. 
Wheeler VC, Auerbach W, White JK, Srinidhi J, Auerbach A, Ryan A, Duyao MP, 
Vrbanac V, Weaver M, Gusella JF, Joyner AL, & MacDonald ME (1999). Length-
dependent gametic CAG repeat instability in the Huntington's disease knock-in 
mouse. Hum Mol Genet 8, 115-122. 
Wheeler VC, White JK, Gutekunst CA, Vrbanac V, Weaver M, Li XJ, Li SH, Yi H, 
Vonsattel JP, Gusella JF, Hersch S, Auerbach W, Joyner AL, & MacDonald ME 
(2000). Long glutamine tracts cause nuclear localization of a novel form of 
huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in 
mice. Hum Mol Genet 9, 503-513. 
White RJ & Reynolds IJ (1995). Mitochondria and Na+/Ca2+ exchange buffer 
glutamate-induced calcium loads in cultured cortical neurons. J Neurosci 15, 
1318-1328. 
Wieckowski MR, Brdiczka D, & Wojtczak L (2000). Long-chain fatty acids 
promote opening of the reconstituted mitochondrial permeability transition pore. 
FEBS Lett 484, 61-64. 
Wilson SM, Xiong W, Wang Y, Ping X, Head JD, Brittain JM, Gagare PD, 
Ramachandran PV, Jin X, & Khanna R (2012). Prevention of posttraumatic axon 
sprouting by blocking collapsin response mediator protein 2-mediated neurite 
outgrowth and tubulin polymerization. Neuroscience 210, 451-466. 
 173 
Yu SP & Choi DW (1997). Na(+)-Ca2+ exchange currents in cortical neurons: 
concomitant forward and reverse operation and effect of glutamate. Eur J 
Neurosci 9, 1273-1281. 
Yu ZX, Li SH, Evans J, Pillarisetti A, Li H, & Li XJ (2003). Mutant huntingtin 
causes context-dependent neurodegeneration in mice with Huntington's disease. 
J Neurosci 23, 2193-2202. 
Yu-Taeger L, Petrasch-Parwez E, Osmand AP, Redensek A, Metzger S, 
Clemens LE, Park L, Howland D, Calaminus C, Gu X, Pichler B, Yang XW, Riess 
O, & Nguyen HP (2012). A novel BACHD transgenic rat exhibits characteristic 
neuropathological features of Huntington disease. J Neurosci 32, 15426-15438. 
Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden 
MR, & Raymond LA (2002). Increased sensitivity to N-methyl-D-aspartate 
receptor-mediated excitotoxicity in a mouse model of Huntington's disease. 
Neuron 33, 849-860. 
Zhang H, Li Q, Graham RK, Slow E, Hayden MR, & Bezprozvanny I (2008). Full 
length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of 
striatal neurons in the YAC mouse model of Huntington's disease. Neurobiol Dis 
31, 80-88. 
Zhou M & Baudry M (2006). Developmental changes in NMDA neurotoxicity 
reflect developmental changes in subunit composition of NMDA receptors. J 
Neurosci 26, 2956-2963. 
Zoratti M & Szabo I (1995). The mitochondrial permeability transition. Biochim 
Biophys Acta 1241, 139-176. 
Zuccato C & Cattaneo E (2007). Role of brain-derived neurotrophic factor in 
Huntington's disease. Prog Neurobiol 81, 294-330. 
Zuccato C & Cattaneo E (2009). Brain-derived neurotrophic factor in 
neurodegenerative diseases. Nat Rev Neurol 5, 311-322. 
Zuccato C, Ciammola A, Rigamonti D, Leavitt BR, Goffredo D, Conti L, 
MacDonald ME, Friedlander RM, Silani V, Hayden MR, Timmusk T, Sipione S, & 
Cattaneo E (2001). Loss of huntingtin-mediated BDNF gene transcription in 
Huntington's disease. Science 293, 493-498. 
 174 
Zuccato C, Valenza M, & Cattaneo E (2010). Molecular mechanisms and 
potential therapeutical targets in Huntington's disease. Physiol Rev 90, 905-981. 
 
 
  
 
CURRICULUM VITAE 
 
Jessica J. Pellman 
 
Education  
 
Aug 2009 – Aug 2016         
Ph.D. in Toxicology 
Department of Pharmacology and Toxicology  
Indiana University, Indianapolis, IN  
  
Aug 2005 – May 2009        
B.S. in Pharmaceutical Sciences with College and Departmental Honors  
Major: Pharmacology and Toxicology, Minor: Chemistry  
The University of Toledo College of Pharmacy, Toledo, OH  
 
Experience  
 
Aug 2012 – July 2015 
Graduate Research with Dr. Nickolay Brustovetsky 
Regulation of neuronal calcium homeostasis in Huntington’s Disease 
Department of Pharmacology and Toxicology 
Indiana University School of Medicine 
Indianapolis, IN  
 
Jan – Mar 2010, May 2010 – July 2012  
Laboratory Rotation, Graduate Research  
with Drs. Gerry Oxford and Joyce Hurley  
TRP channel toxicology  
Department of Pharmacology and Toxicology 
Indiana University School of Medicine 
Indianapolis, IN  
 
March 2010 – May 2010  
Laboratory Rotation with Dr. Zachary Rodd  
Ethanol self-administration in alcohol-preferring rats  
Department of Psychiatry 
Indiana University School of Medicine 
Indianapolis, IN  
 
 
  
 
Oct 2009 – Dec 2009  
Laboratory Rotation with Dr. William Sullivan Jr.  
DNA damage repair in Toxoplasma gondii  
Department of Pharmacology and Toxicology 
 Indiana University School of Medicine 
Indianapolis, IN  
 
May 2009 – July 2009  
Toxicology Intern  
Drinking Water Treatment Unit Certification 
NSF International  
Ann Arbor, MI  
 
Jan 2007 – May 2009  
Undergraduate Research with Dr. William S. Messer Jr.  
Honors thesis: Pharmacology of novel muscarinic antagonists in vitro  
Department of Pharmacology and Toxicology 
The University of Toledo College of Pharmacy 
Toledo, OH  
 
Publications 
 
Hamilton J, Pellman JJ, Brustovetsky T, Harris RA, Brustovetsky N. 
(2016) Oxidative metabolism and Ca2+ handling in isolated brain 
mitochondria and striatal neurons from R6/2 mice, a model of Huntington’s 
disease. Hum Mol Genet. (ePub ahead of Print). 
 
Pellman JJ, Hamilton J, Brustovetsky T, Brustovetsky N. (2015) Ca2+ 
handling in isolated brain mitochondria and cultured neurons derived from 
the YAC128 mouse model of Huntington’s Disease. J Neurochem. 
134(4):652-67. 
 
Hamilton J, Pellman JJ, Brustovetsky T, Harris RA, Brustovetsky N. 
(2015) Oxidative metabolism in YAC128 mouse model of Huntington’s 
Disease. Hum Mol Genet. 24(17):4862-78.  
 
Kunkler PE, Zhang LJ, Pellman JJ, Oxford GS, Hurley JH. (2015). 
Sensitization of the trigeminovascular system after environmental irritant 
exposure. Cephalalgia. 35(13):1192-201. 
 
  
 
Brustovetsky T, Pellman JJ, Yang XF, Khanna R, Brustovetsky N. (2014). 
Collapsin response mediator protein 2 (CRMP2) interacts with N-methyl-
D-aspartate (NMDA) receptor and Na+/Ca2+ exchanger and regulates their 
functional activity. J. Biol. Chem. 289(11):7470-7482. 
 
Kunkler PE, Ballard CJ, Pellman JJ, Zhang LJ, Oxford GS, Hurley JH 
(2014). Intraganglionic signaling as a novel nasal-meningeal pathway for 
TRPA1-dependent trigeminovascular activation by inhaled environmental 
irritants. PLoS One. 9(7): e103086. 
 
Wilson SM, Schmutzler BS, Brittain JM, Dustrude ET, Ripsch MS, 
Pellman JJ, Yeum T-S, Hurley JH, Hingtgen CM, White FA,  Khanna R. 
(2012). Inhibition of transmitter release and attenuation of anti-retroviral-
associated and tibial nerve injury-related painful peripheral neuropathy by 
novel synthetic Ca2+ channel peptides. J Biol Chem. 287(42):35065-
35077. 
 
Maheshwari A, Rao P, Larke L, Pellman JJ, Harmeyer B, Messer W. 
Development of M1 muscarinic receptor agonists for the treatment of 
cognitive deficits. (Submitted). 
 
Presentations and Accepted Abstracts 
 
Hamilton J, Pellman JJ, Brustovetsky T, Brustovetsky N. Respiratory 
activity and calcium uptake capacity in brain mitochondria from R6/2 mice, 
a model of Huntington’s disease. Accepted Abstract. 2015 Neuroscience 
Meeting. Chicago, IL: Society for Neuroscience, 2015. 
 
Pellman JJ, Brustovetsky T, Brustovetsky N. Calcium uptake capacity 
and induction of the permeability  transition pore in brain mitochondria 
from YAC128 mice. Presentation No.795.21. 2014 Neuroscience Meeting, 
Washington, DC; Society for Neuroscience, 2014. 
 
Pellman JJ, Hamilton J, Brustovetsky T, Brustovetsky N. Calcium uptake 
capacity and  induction of the permeability transition pore in brain 
mitochondria from YAC128 mice. 2014 Gil Symposium, Bloomington, IN, 
2014 
 
 
  
 
Pellman JJ, Hamilton J, Brustovetsky T, Brustovetsky N. Calcium uptake 
capacity and induction of the permeability transition pore in brain 
mitochondria from YAC128 mice. Indianpolis Chapter of the Society for 
Neuroscience, Indianapolis, IN, 2014. 
 
Brustovetsky T, Pellman JJ, Khanna R, Brustovetsky N. CBD3 peptide, a 
fragment of CRMP2, protects against glutamate-induced Ca dysregulation 
by attenuating both NMDAR and Na/Ca exchanger activities. 
Nanosymposium, Presenting Author. Program No. 601.11. 2013 
Neuroscience Meeting, San Diego, CA; Society for Neuroscience, 2013. 
 
Pellman JJ, Brustovetsky T, Yang X-F, Khanna R, Brustovetsky N. 
Collapsin response mediator protein 2 interacts with NMDA receptor and 
Na+/Ca2+ exchanger and regulates their functional activity. Indianpolis 
Chapter of the Society for Neuroscience, Indianapolis, IN, 2013. 
 
Pellman JJ, Brustovetsky T, Yang X-F, Khanna R, Brustovetsky N. 
Collapsin response mediator protein 2 interacts with NMDA receptor and 
Na+/Ca2+ exchanger and regulates their functional activity. 2013 Gill 
Symposium, Bloomington, IN, 2013. 
 
Pellman JJ, Kunkler PE, Hurley JH, Oxford GS. Function and expression 
of TRPA1 channels in response to environmental irritant exposure in vitro. 
Accepted Abstract. Program No. 784.04. 2012 Neuroscience Meeting 
Planner. New Orleans, LA: Society for Neuroscience, 2012.  
 
Pellman JJ, Kunkler PE, Hurley JH, Oxford GS. Function and expression 
of TRPA1 channels in response to environmental irritant exposure in vitro. 
Poster Presentation. 51st Society of Toxicology Annual Meeting, San 
Francisco, CA, 2012.  
 
Pellman JJ, Messer W. Development of M5 muscarinic acetylcholine 
receptor antagonists. 23rd  National Conference on Undergraduate 
Research, La Crosse, WI, 2009. 
 
Jennings JJ, Messer W. Development of M5 muscarinic acetylcholine 
receptor antagonists. 22nd National Conference on Undergraduate 
Research. Salisbury, MD, 2008.  
 
 
  
 
Awards 
  
IUSM Graduate Student Travel Grant 
Indiana University School of Medicine, 2015 
Paradise Travel Award, Department of Pharmacology and Toxicology  
 Indiana University School of Medicine, 2013 
Graduate Student Travel Award 
Society of Toxicology, 2012  
College Honors 
The University of Toledo College of Pharmacy, 2009 
Departmental Honors, Department of Pharmacology and Toxicology, 
 The University of Toledo College of Pharmacy, 2009 
Undergraduate Summer Research Award 
The University of Toledo College of Pharmacy, 2007  
Levis Leadership UT, Fellow and Facilitator 
The University of Toledo, 2005-09 
 
Professional Organizations  
 
Society of Toxicology, July 2011-Present  
 Specialty Sections: Neurotoxicology, Women in Toxicology  
Ohio Valley Society of Toxicology, Aug 2011-Present  
Society for Neuroscience, April 2012-Present 
American Association for the Advancement of Science, Mar 2012-Present  
 
Leadership and Service 
 
Central Indiana Science Outreach (CINSO) 
Board and Founding Member, Sept 2014-Present 
Indiana State Museum 1816 Advisory  
Board Member, Feb 2015-Present 
 Pharmacology and Toxicology  
Student Journal Club Coordinator, Aug 2012-Aug 2014 
 Trained two Ph.D. rotation students and one M.S. student 
 Fall 2012, Winter 2013, Spring 2014 
 Indiana BioMedical Gateway Program 
  Recruitment of new graduate students, Jan 2010-Feb 2013 
 
